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HEAd ANd NECk CANCER
 Each year, more than 500.000 cases of head and neck cancer (HNC) occur 
worldwide1. More than half of these are oral cavity cancers, while the rest comprises 
pharyngeal and laryngeal cancers (Figure 1). The vast majority (~90%)2 of HNC 
diagnoses are squamous cell carcinomas, originating from the epithelium. HNC can 
be divided into three clinical stages: early, locoregionally advanced and metastatic, 
of which more than 50% belongs to the second category3. Metastases are seen in the 
lymph nodes of the neck, and are often the first sign of the disease. Morbidity rates 
are close to 25% but are highly dependent on staging. Early detection exponentially 
increases the chance of curing. Alcohol consumption, tobacco smoking and human 
papillomavirus infection are the most important risk factors (alcohol and tobacco 
accounting for 75% of HNCs)4-6. 
Figure 1 Schematic overview of the head and neck area.
RAdIATION THERAPy FOR HEAd ANd NECk CANCER
 Treatment of HNC varies according to stage and location, but often surgery is 
used to resect the tumor, followed by radiation- and/or chemotherapy7, 8. Radiation 
therapy (RT) used in cancer treatment is based on its ionizing properties. Atoms, 
which are components of the molecules that form tissues, can be ionized by 
radiation, i.e. electrons are removed of these atoms, resulting in the breakage 
of chemical bonds and the molecule falling apart. This leads to damage to cell 
components including DNA,  either directly or indirectly when water molecules in 
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the cell are ionized and form highly reactive free radicals (reactive oxygen species), 
that immediately react with any biomolecule in its surrounding. Damage to the 
DNA can acutely lead to cell death of tumor cells, or cause genomic instability 
transmitted through many generations via the progeny of surviving cells, which also 
ultimately leads to cell death9. Furthermore, radiation leads to vascular damage, 
creating a hypoxic, hypovascular and hypocellular environment with a compromised 
regenerative capacity. 
RAdIATION dAMAGE
 Although radiation is targeted at the tumor, it is inevitable that normal 
surrounding tissue will also be affected. In general, rapidly dividing tissues, such as 
lymphoid organs, bone marrow and intestines, are highly radiosensitive, whereas 
slowly dividing tissues as brain and spinal cord have a low radiosensitivity10.
 In the head and neck region, relatively many different tissues are situated in close 
proximity of each other, responding differently to RT. RT can induce infection of 
oral mucosa (i.e.  mucositis), while taste loss is caused by damaged taste buds and 
hyposalivation is due to salivary gland damage. Mucositis and taste loss are acute 
effects that can arise during RT, and are reversible11, 12. After RT, these complications 
will prolapse. Late effects are often irreversible and include hyposalivation, 
trismus (limited jaw opening due to increased muscle rigidity), radiation caries 
and osteoradionecrosis (ORN; RT-induced bone death)13. Salivary gland damage, 
leading to hyposalivation, is the most prominent side effect of RT in the head and 
neck region, while the risk of developing radiation caries and ORN poses a life-long 
threat14. This thesis focuses on RT- induced salivary gland and bone damage.
Salivary glands
 Salivary glands are slowly dividing, highly differentiated tissues that have 
an unexpected high radiosensitivity10. Radiation affects salivary flow rate and 
composition, and thus salivary gland function, both acute and chronically.
Anatomy and morphology
 Major and minor salivary glands together are responsible for the production 
of saliva, which has many different functions ranging from the lubrication of the 
throat and mouth, initiating digestion to maintaining oral health15. Minor salivary 
glands can be found in the lower lip, tongue, palate, cheeks and pharynx. The major 
salivary glands consist of the parotid-, submandibular-, and sublingual glands. The 
latter two are situated in the floor of the mouth, while the parotid gland is located 
in front of the ear and extends to the lower borders of the jawbones (Figure 1). 
The submandibular glands produce approximately 65% of saliva in an unstimulated 
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state, while upon stimulation the parotid glands are the main contributors of saliva 
secretion. The production of saliva takes place in the serous and mucous acinar cells 
of the glands. Parotid glands mainly have serous acinar cells, and produce a serous, 
more watery, secretion, while sublingual glands consist predominantly of mucous 
acinar cells and the submandibular glands contain a mixture of these two. Besides 
acinar cells, salivary glands contain ducts that modify the ionic composition of the 
acinar secretions as it is transported to the oral cavity, and myoepithelial cells which 
are wrapped around acinar cells and regulate secretion from acinar cells into ducts 
by contracting upon nervous stimulation (Figure 2).
Figure 2 Schematic overview of the salivary gland. Arrows depict direction of salivary flow.
Radiation damage 
 Early radiation damage is thought to target the plasma membrane of acinar 
cells, since water excretion is severely inhibited directly after irradiation while cell 
number remains intact. Takagi et al showed irreversible radiation-induced damage 
to water channels in acinar cells and a significnant loss of plasma membrane-bound 
aquaporin 516. Based on various experiments, Coppes et al distinguished four 
phases of radiation-induced damage to the submandibular glands of rats17. Phase 
1 (0-10 days) is the acute phase in which water excretion is quickly impaired with 
no cell loss visible. In phase 2 (10-60 days), the compromised acinar cells disappear, 
with no compensation of cells. There are no major changes observed in terms of 
cell number and salivary flow in phase 3 (60-120 days). Phase 4 represents the 
expression of late radiation damage with a lack of functional acinar cells, caused 
by the killing of progenitor- and stem cells and replacement by connective tissue 
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(i.e. fibrosis). Generation of acinar cells does take place, however flow rate is still 
deteriorated, suggesting that the new cells cannot function properly due to damage 
of ducts, blood vessels and nerves. 
 In HNC patients, radiation damage to the salivary glands leads to chronic 
hyposalivation, which is subjectively experienced by patients as a dry mouth and 
called xerostomia. Xerostomia is the most common complication of radiation 
therapy for head and neck cancer18. Patients have trouble with speech, mastication, 
swallowing and suffer from impairment of taste and disturbance of sleep patterns, 
which greatly affects quality of life13, 19, 20. In addition, xerostomia may result in 
compromised protection of teeth resulting in progressive dental decay.
Bone
 Radiation can lead to necrosis of bone, so called osteoradionecrosis (ORN). In the 
head and neck area, the mandible is prone to develop ORN since it is often in the 
radiation field and has a relatively poor blood supply21. 
Anatomy and morphology
 The mandible is the largest and strongest bone of the face and consists mainly 
of cortical, or dense, bone of which the majority is composed of inorganic 
hydroxyapatite and organic collagen. Only a small part consists of cells, i.e 
osteoblasts, osteocytes and osteoclasts. Osteoblasts and osteoclasts play an 
important role in bone remodeling (Figure 3), in which old bone is continuously 
resorbed and new bone formed, allowing the bone to adapt to mechanical load and 
strain. Osteoclasts derive from a monocyte stem cell lineage and resorb bone upon 
activation. In the reversal phase that takes place after resorption, mononuclear 
cells appear on the bone surface and provide signals for osteoblast differentiation 
and migration. Subsequently, osteoblasts that derive from osteoprogenitor cells 
produce osteoid, which is primarily composed of collagen type 1 and eventually 
becomes mineralized. Osteoblasts then become surrounded with the bone matrix 
they have produced and differentiate into osteocytes, the mature bone cells that 
are responsible for matrix maintenance and regulate the bone’s response to stress 
and mechanical load22. In normal homeostasis, bone resorption and formation are 
balanced, but a number of clinical diseases can cause an imbalance resulting bone 
loss or excessive bone formation23.
Radiation damage
 Radiation induces damage to small arteries leading to a reduced circulation, 
which influences the viability of osteogenic cells24. Whether radiation also directly 
targets osteogenic cells remains a matter of debate.  Subsequently the bone has 
a reduced ability to heal, which especially poses a risk when the jaw is infected. 
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Figure 3 Schematic representation of bone remodeling and the bone cells involved.
 ORN can occur spontaneously after irradiation, but the risk is highly increased 
when an insult is inflicted on previously irradiated bone, such as subsequent surgery 
or biopsy, tooth extractions or denture irritations25. Especially when patients suffer 
from xerostomia, the oral environment is more prone to develop dental caries that 
can lead to infection and consequently ORN. Even years after radiation, the risk to 
develop ORN remains high in previously irradiated bone.
PREVENTION ANd TREATMENT OF RAdIATION dAMAGE
 Efforts have been made to prevent or treat radiation damage to the head and 
neck area, since the complications greatly affect quality of life. Obviously, prevention 
is the ultimate goal, since radiation damage is for the most part irreversible. Salivary 
gland damage is the most prominent complication of RT and the prevention of 
salivary gland damage and ORN are in close association since xerostomia is an 
underlying cause of ORN and dental decay. 
Prevention
 To reduce the risk for ORN and dental decay, teeth at risk will be removed before 
radiation therapy26. Minimizing the radiation dose delivered to salivary glands 
and bone is important in sparing their function. In the last decades, advances in 
the delivery of radiotherapy have been made to target the tumor tissue more 
efficiently. Fractionated radiation significantly reduces damage to adjacent tissues. 
Three-dimensional conformal RT (3D-CRT) uses highly collimated beams to target 
the tumor and minimize the treatment field and thus normal tissue damage. A 
greater repair-potential is achieved when using intensity modulated radiation 
therapy (IMRT), where radiation doses vary in intensity, resulting in parts of the 
tissue receiving lower exposure27-29. Especially the parotid glands can be spared to 
some extent using these techniques. Sparing submandibular glands remains more 
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challenging, since they are often located closer to the tumor30.
 Another way of preventing radiation induced normal tissue damage is by using 
agents that protect cells from radiation damage. The only cytoprotectant approved 
by the US Food and Drug Administration (FDA) is amifostine, which acts as a selective 
free radical scavenger for normal tissue. However, clinical trials on its effectiveness 
are conflicting and concern remains about its toxicity as serious adverse events such 
as hypotension and gastrointestinal disturbances have been reported13, 31, 32.
 Surgical transfer of salivary glands to the submental place outside the radiation 
field33, 34 is an option that is not used frequently. In some patients, it is impossible 
to shield the submental place because of the proximity of the tumor. Furthermore, 
salivary gland transfer is only useful in patients that need postoperative RT, which is 
not always predictable13.
Treatment
 In the treatment of xerostomia and ORN, maintaining a strict oral hygiene is 
important to avoid oral infections and dental problems. To mimic saliva function, 
salivary replacements are available. They offer temporary relief of symptoms, but 
do not have the antibacterial and immunological properties of saliva and some 
patients prefer regular water intake14.
 Saliva secretion can be increased by sialogogues, which enhance any residual 
secretory function. Pilocarpine is the only sialogogue approved by the FDA. It is a 
cholinergic agonist that acts parasympathicomimetically, thereby stimulating the 
unaffected acinar cells to secrete saliva13. However, due to its general mechanism 
of action, caution should be taken with respect to its administration, especially in 
patients with cardiovascular disease, glaucoma or uncontrolled asthma35.
 For ORN, treatment options depend on the stage of the disease; early stage can 
be treated with local wound care and antibiotic therapy, whereas late stage patients 
need radical resection and reconstruction26, 36.
 Despite these prevention and treatment modalities, patients experience no 
full recovery from xerostomia and once bone or dental fragments are affected, 
full healing is not feasible anymore. The need for other therapies is therefore 
evident. Preclinical studies have investigated the possibility of gene transfer and 
stem cell therapy to restore salivary gland function37, 38, but clinical studies have 
not been performed yet, and these therapies are therefore still far from clinical 
implementation.
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HyPERBARIC OXyGEN THERAPy
 Hyperbaric oxygen therapy (HBOT) is used as an adjunctive treatment for the 
management of ORN, or when tooth extraction has to take place in a previously 
irradiated region. Patients breathe 100% oxygen under elevated pressure (typically 
2.4 atmospheres absolute) in specially built pressure chambers. One session lasts 
approximately two hours, and 20-40 daily sessions are carried out, depending on 
the indication.
History
 The use of hyperbaric therapy dates back to 1662, when the British physician 
Henshaw built the first hyperbaric chamber. He used reduced pressure for the 
treatment of chronic illnesses and increased pressure for more acute illnesses. By 
the late nineteenth century, chambers were widely used for a variety of conditions. 
These early chambers used compressed air instead of oxygen, because of the reports 
of oxygen toxicity. In spite of this, Drager explored the use of pressurized oxygen in 
the treatment of decompression sickness, which was tested by the US Military and 
put into practice in the 1930s. Beneficial effects on a number of other diseases, 
investigated in the 1950s and 1960s, led to the widespread use of hyperbaric oxygen 
therapy. In 1976, the ‘Committee on Hyperbaric Oxygen Therapy’ was founded 
by the Undersea and Hyperbaric Medical Society (UHMS) to oversee the ethical 
practice of hyperbaric medicine39. This committee is currently the international 
authority on HBOT. The list of accepted indications includes delayed radiation injury 
(see table below).
        *Undersea and Hyperbaric Medical Society
Mechanism of action
 All living cells need oxygen to function and the oxygen demand of the tissue 
will rise when wound healing and regeneration needs to take place in response to 
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injury. Normally, oxygen is transported by the blood in two forms: by the reversible 
binding to hemoglobin proteins of red blood cells (98%), and dissolved in plasma 
(2%). Under normal circumstances, hemoglobin is saturated for 97%. The elevated 
pressure combined with pure oxygen breathing used in HBOT, results in an increase 
of the amount of oxygen dissolved in plasma39. The oxygen can diffuse further into 
tissues, and can reach obstructed places where red blood cells cannot pass (Figure 
4). In irradiated tissue, this leads to a better oxygenation of hypoxic areas40. Oxygen 
is involved in numerous processes regarding wound healing and regeneration, such 
as microbial killing, cytokine release, apoptosis and angiogenesis41-43.  Therefore it 
is expected that HBOT may have an effect on these processes. However, the precise 
effects and mechanism of action of HBOT remain poorly understood. Angiogenesis 
is the most studied process, and it is generally accepted to be positively influenced 
by HBOT39, 44-48. 
Figure 4 Mechanism of hyperbaric oxygen therapy (HBOT). A radiation-induced occlusion (damaged 
blood vessel) prevents red blood cells from passing (upper picture), resulting in hypoxic tissue (blue). 
Due to the administration of hyperbaric oxygen (lower picture), oxygen is dissolved in much higher 
amounts in the plasma, allowing diffusion into hypoxic areas resulting in much higher tissue oxygen 
tensions.
 The effect of HBOT on radiation-induced hyposalivation has been studied 
clinically49-54. Moderately positive effects have been reported, but evidence remains 
scarce. Studies on the clinical use of HBOT to prevent or treat ORN are more 
prevalent20, 36, 52-70, but there is no general consensus about the beneficial effects of 
the therapy.
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Effects on tumor tissue
 Patients that are treated with HBOT to repair or prevent radiation-induced tissue 
damage have a history of cancer. This has raised concerns about the promoting 
effects that HBOT might have on (residual) tumor tissue. If HBOT promotes 
angiogenesis in tumors, it could stimulate growth and recurrence of cancer71-73. 
On the other hand, hypoxic tumors are known to be more aggressive in terms of 
invasive growth, metastasis and therapy resistance than well-oxygenized tumors74, 
75. In this case, if HBOT is able to oxygenize the tumor, it might positively influence 
the prognosis.
REGENERATING AGENTS
 ReGeneraTing Agents (RGTAs) are clinically used in the management of non-healing 
wounds, although conclusive evidence of its beneficial effect needs to be obtained. 
RGTAs are designed to mimic heparan sulfates, which are normally localized in the 
extracellular matrix (ECM), bound at heparan sulfate binding sites that are present 
on macromolecules of the ECM, such as collagen, fibronectin and laminin. Heparan 
sulfates in their turn, can bind growth factors and cytokines, preventing them from 
being degraded, thereby maintaining normal tissue homeostasis. In the case of 
injury, however, the heparan sulfates are degraded by heparanases. This allows 
other proteases to degrade parts of the ECM and leads to a loss of growth factors 
and cytokines, which are essential for repair processes. RGTAs are engineered in 
such a way that they can bind at heparan sulfate binding sites and are able to bind 
growth factors. The difference with natural heparan sulfate is that RGTAs cannot be 
degraded by heparanases. In this way, growth factors and cytokines will be available 
in the injured site and can fulfill their action needed to repair the tissue76. 
 Several animal studies have shown positive effects of RGTAs on tissue repair in 
bone77, muscle78, 79, skin80, 81 and mucosa82, 83. Clinical studies are mostly small pilot 
studies and case reports, regarding various diseases 84-88 that advocate randomized 
controlled trials to be performed. Effects of RGTAs on radiation-induced damage 
have not been studied extensively, except for a study in which radiation-induced 
mucositis was prevented by RGTA in rats82.
AIM & OUTLINE
 The current thesis aims to give more insight in the prevention of radiation-
induced damage to the tissues of the head and neck, including bone and salivary 
glands, by hyperbaric oxygen therapy, and to a lesser extent, by RGTAs. For this 
purpose, a mouse model was used, in order to be able to assess morphological, 
cellular and molecular changes in the tissues, since these parameters have not been 
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investigated extensively and will help to better understand working mechanisms. 
Effects of HBOT on irradiated tumor tissue are also addressed.
 Chapter 2 gives an overview of the existing literature regarding hyperbaric oxygen 
therapy in the irradiated head and neck region.
 Chapter 3 describes the hyperbaric oxygen chamber that was specially built 
to enable research with small laboratory animals, in our case mice. Hyperbaric 
chambers used for the treatment of humans are not suitable for experimental 
animal research and chambers for animal use are not abundantly available.
 In Chapter 4, irradiated mandibular bone is characterized by means of microCT 
and histology, and the effect of HBOT on these parameters is studied.
 In Chapter 5, the effects of HBOT on irradiated soft head and neck tissues were 
studied, focusing on the salivary glands. Salivary flow rate was measured, as well as 
proliferation, apoptosis and blood vessel density, up to 24 weeks after irradiation. 
 Chapter 6 focusses on RGTA, and its potential to influence irradiated salivary 
gland function and morphology, by investigating saliva production and composition 
and assessing the amount of functional acinar cells by histology.
 Chapter 7 provides a more profound insight on the molecular pathways that 
are affected by HBOT in irradiated submandibular glands. Microarray analysis was 
used to detect differences in gene expression that lead to activation or inhibition of 
different molecular processes within the tissue.
 The effects of HBOT on irradiated and non-irradiated tumor tissue are addressed 
in chapter 8. For this purpose, an orthotopic floor-of-mouth mouse model of head 
and neck squamous cell carcinoma was used. Tumor growth, vascular permeability, 
hypoxia and metastasis could be investigated using in vivo optical imaging 
techniques, in combination with histological methods and PCR.
 Chapter 9 provides a general discussion on the results obtained in this thesis and 
offers suggestions for further research.
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ABSTRACT
Purpose: Radiotherapy is generally used in the treatment of malignant tumors 
in the head and neck region. It causes a hypoxic, hypocellular, and hypovascular 
environment that leads to injury to surrounding normal tissue, both acute and 
chronic, ranging from xerostomia to osteoradionecrosis. These side effects are 
debilitating and greatly influence quality of life in these patients. Hyperbaric oxygen 
(HBO) therapy is clinically used to prevent or treat these side effects by enhancing 
oxygen pressure and thereby regeneration. Although this therapy is widely applied, 
its mechanism of action is still poorly understood, and controversy exists in the 
literature about its clinical use. This review therefore aims to analyze the existing 
experimental and clinical research on this topic.
Methods: A systematic search was performed in PubMed for experimental and 
clinical studies conducted regarding the use of HBO therapy in previously irradiated 
tissue, in the period from January 1990 to June 2009.
Results: Experimental research is scarce, and clinical studies are especially lacking 
in terms of randomized controlled studies. Although discussions on the subject are 
ongoing, most studies suggest a beneficial role for HBO in previously irradiated 
tissue.
Conclusion: Further research, both experimental and clinical, is necessary to unravel 
the working mechanism of HBO therapy and validate its clinical use.
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INTROdUCTION
 Malignant tumors in the head and neck region are generally treated by surgery in 
combination with chemotherapy and/or radiotherapy. Besides its direct influence 
on the malignant tumor, radiotherapy results in injury to surrounding normal tissue 
that appears either acutely or as a late effect. Late effects can be observed months 
to years after radiotherapy. Radiation causes mitotic cell death by the formation of 
free radicals that irreversibly disturb deoxyribonucleic acid replication. Furthermore, 
radiation induces stasis and occlusion of small blood vessels, resulting in hypoxia 
and hypovascularity. This hypoxic environment profoundly reduces the potential of 
cells to regenerate and survive. The occlusion of vessels also inhibits the infiltration 
of osteoprogenitor cells and endothelial progenitor cells, further compromising the 
regenerative capacity. The overall result is a hypoxic, hypovascular, and hypocellular 
environment comparable to that of a chronic, nonhealing wound1.
Osteoradionecrosis
 An early side effect of radiotherapy in the head and neck region is xerostomia. 
The mucus that is secreted by salivary glands thickens because of a change in 
composition. Patients with xerostomia have a dry mouth, which results in difficulties 
with eating and speech. Repair of salivary gland tissue is problematic, and provided 
that it occurs, will take months to years2. Xerostomia causes an environment that is 
more prone to develop dental caries, which in turn can lead to periapical infection 
and, ultimately, necrosis of the underlying bone, so-called osteoradionecrosis 
(ORN)3. ORN can occur spontaneously after radiation, when the dose exceeds 50 to 
60 Gy4, but the risk is increased when the previously irradiated region undergoes 
trauma (eg, tooth removal). ORN has a profound influence on the quality of life (QoL) 
of patients and leads to major difficulties with regard to reconstructive surgery. 
Reuther et al5 reported the incidence of ORN to be 8.2% in a group of 830 head and 
neck tumor patients who received radiotherapy. ORN affects the mandible more 
often than the maxilla and, in fact, more than any other bone in the body, probably 
because of the poor blood supply in the mandible6. The risk of ORN developing after 
radiotherapy is highest during the first 3 to 24 months, but it persists throughout 
the patient’s life and even increases over time for trauma-induced ORN7.
Hyperbaric Oxygen Therapy
 The delivery of oxygen is an essential process when considering (bone) tissue 
repair. Inadequate vascularity of bone reduces osteogenesis and thus bone 
mass. Most osteogenic factors stimulate angiogenesis, and when angiogenesis 
is inhibited during the repair of bone fractures, fibrous tissue is formed instead 
of bone8. Oxygen stimulates collagen synthesis, matrix deposition, angiogenesis, 
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epithelialization, and the eradication of bacteria9. The use of hyperbaric oxygen 
(HBO) therapy in improving wound healing is based on this principle. In HBO 
therapy patients will breathe 100% oxygen at increased pressure (2-3 atmospheres 
absolute). In the short term, this causes an increase in the tissue’s internal oxygen 
pressure, leading to vasoconstriction, enhanced oxygen delivery, edema reduction, 
phagocytose activation, and an anti-inflammatory effect. The long-term effects 
are neovascularization, osteogenesis, and a stimulation of collagen production by 
fibroblasts, all of which promote wound healing9.
 It is estimated that in Europe approximately 500 patients are treated with 
HBO for radiotherapy-induced injury every year10. Most of these patients have 
had malignancies in the head and neck region and are being treated for some 
form of ORN. HBO can also be used prophylactically, for example, when a tooth 
extraction is performed in a previously irradiated region. Cellular, biochemical, 
and physiologic mechanisms of HBO are still not completely understood. Clinical 
studies regarding the effectiveness of HBO, especially with regard to prophylactic 
use, show contradictory outcomes, and the lack of randomized, controlled, double-
blind trials further hampers assessment of the efficacy of this treatment. Therefore 
no consensus exists regarding both the mechanism of action and the effectiveness 
of HBO in the prevention and treatment of ORN. Subsequently, several theories on 
the pathophysiology of ORN have arisen.
 Al-Nawas et al11 propose that the essence of the development of ORN is the direct 
effect of radiation on osteoclasts, which occurs before vascular alterations. According 
to this theory, the suppression of bone turnover via increased osteoclast function 
is the most important factor in ORN, and consequently, the use of HBO therapy 
will not be valuable. Another theory focuses on radiation-induced fibrosis12. This 
theory states that the activation and dysregulation of fibroblastic activity, leading 
to atrophic tissue, are the key events in the progression of ORN within previously 
irradiated bone. The use of pentoxifylline together with tocopherol (vitamin E) 
is suggested to prevent ORN, because these 2 drugs act synergistically as potent 
antifibrotic agents, thereby possibly reducing the negative effect of radiation on 
tissues.
 This review takes an in-depth look into the existing experimental and clinical 
literature on the effect of HBO in irradiated bone, with special focus on the head 
and neck region. Furthermore, we aim to present a guideline for the direction of 
future research on HBO that is needed to validate the use of this therapy.
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MATERIALS ANd METHOdS
 A systematic search of the literature was performed by use of the PubMed 
database with the following key words, as well as combinations of these terms: 
hyperbaric oxygen, irradiation, radiation, radiotherapy, maxillofacial, craniofacial, 
head and neck, bone, mandible, soft tissue, salivary glands, and mucosa. Only 
articles written in English within the time period from January 1990 to June 2009 
were included. Experimental and clinical studies were included, whereas case 
reports were excluded. References of the articles found were checked regarding 
importance and obtained when useful.
RESULTS
Working mechanism of HBO
 Experimental studies regarding the working mechanism of HBO in general were 
evaluated to give a brief overview of the existing knowledge. In vitro9, 13-15 and in 
vivo16-20 studies were included, and the results of these studies will be reviewed in 
the “Discussion” section.
Experimental research
 The next step was to identify experimental studies that consider the effect of HBO 
on irradiated bone tissue. Five studies were found that focused on the cancellous 
bone of the hind legs of rabbits or mice, either with or without placement of 
implants21-25. Eight studies were carried out in the head and neck region, 7 of 
which combined irradiation and HBO therapy with distraction osteogenesis (DO) 
in rabbit mandibles26-32. Williamson33 studied the effect of HBO on irradiated tissue 
regeneration in the mandible of the rat, when given 1 week after the completion of 
radiotherapy.
Clinical research
 Twenty clinical studies were found that were conducted to study the effect of 
HBO therapy on previously irradiated head and neck tissue34-53. The studies varied 
widely in protocols and conclusions, of which the most important parameters are 
listed in Table 1 (see next page). The term “surgery” in this table comprises implant 
placements as well as tooth extractions, with perioperative or postoperative HBO 
therapy. Furthermore, the HBO use was either prophylactic, to prevent radiation- 
induced injuries, or therapeutic, when these injuries already existed.
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dISCUSSION
 HBO has been used since the late 1950s to treat a variety of conditions, such 
as syphilis, multiple sclerosis, myocardial infarction, gangrene, and decompression 
sickness54. ORN—a late irradiation complication— could, in theory, benefit from 
HBO use, either prophylactically or therapeutically. However, conflicting opinions 
about the efficacy exist, hence this review on experimental and clinical studies 
reported in the literature.
Marx, the founder of the so-called 3H model (hypoxia, hypocellularity, 
hypovascularity) of the pathogenesis of ORN, and colleagues55 conducted a classical 
study regarding the effect of HBO on the prevention of ORN. They compared the 
effect of HBO in irradiated mandibles that required dental extraction with that in 
a control group and found a decrease in the incidence of ORN from 29.9% in the 
control group to 5.4% in the HBO group. These findings paved the way for more 
studies to come and, concurrently, the clinical use of HBO in irradiated head and 
neck tissue.
Working mechanism of HBO
 The exact working mechanism of HBO is not completely understood. With regard 
to bone tissue, radiotherapy decreases bone-forming capacity by decreasing the 
numbers of osteocytes and osteoblasts, increases bone resorption by increasing 
the number of osteoclasts, and decreases the capillary density56. Multiple in vitro 
studies therefore focused on the effects of HBO on osteoblasts, the bone-forming 
cells. Wong et al14 found an inhibition in the growth of osteoblasts. In the study of 
Wu et al15, proliferation of osteoblasts was either stimulated or reduced, depending 
on the type of culture medium. The mineralization was stimulated in both types of 
mediums, and it was thus suggested that HBO results in differentiation of osteoblasts 
to an osteogenic phenotype, rather than increasing cellular proliferation. These 
conclusions were supported by Tuncay et al13. They compared
hypoxic (10% O2) and hyperoxic (90% O2) conditions in osteoblast-enriched cultures 
from fetal rat calvarias and showed that hyperoxia suppressed cellular proliferation 
whereas alkaline phosphatase activity and collagen synthesis (both markers 
for bone forming) were increased. Effects of hypoxia were opposing, and when 
hypoxic cells were switched to a hyperoxic environment, their metabolic activities 
were abruptly reversed. This suggests a triggering role for oxygen tension in bone 
remodeling. Tompach et al9 concentrated on the effect of HBO on endothelial cells 
and fibroblasts and found an increase in proliferation for both cell types.
 In vivo experiments with HBO supported the findings of the in vitro studies. 
Levin et al19 showed an enhancement of fibroblastic, osteoblastic, osteoclastic, 
and angioblastic activities in the femoral heads of rats, and Jan et al18 found a 
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significantly higher boneforming capacity in critical-sized defects in rabbits’ parietal 
bones. The regenerate of the HBO-treated group in this latter study also showed 
a higher capillary density than the control group, at both 6 weeks’ and 12 weeks’ 
follow-up. Some studies shed light on how the increase in angiogenesis due to HBO 
can be explained. Two studies conclude that HBO mobilizes endothelial progenitor 
cells through induction of bone marrow nitric oxide17, 20. Fok et al16 found HBO to 
increase vascular endothelial growth factor, one of the primary growth factors 
responsible for neovascularization during wound healing.
 The finding that HBO promotes/stimulates angiogenesis led to some concern 
regarding its use in cancer patients. Tumors are dependent on blood supply to grow; 
therefore, increased angiogenesis may promote (recurrent) tumor growth. However, 
in a thorough systematic review, Feldmeier et al57 concluded that there is no reason 
to presume that a history of malignancy must be considered a contraindication for 
HBO therapy.
Experimental research
HBO and Cancellous Bone
 Cortical bone, of which the craniofacial bones are predominantly composed, 
differs from cancellous bone in composition as well as repair mechanism. Cortical 
healing is slower than cancellous healing58, 59, so it is likely that radiation has a more 
profound effect in the former. On the other hand, cancellous bone is highly cellular 
and usually has a higher rate of metabolic activity than cortical bone60, which can 
increase the negative effect of radiotherapy. Therefore it is important to distinguish 
these 2 bone types in research and be careful when applying results of studies 
undertaken in cancellous bone to bone of the head and neck region and vice versa.
 Two studies that emerged from our literature search investigated the effect of 
HBO in irradiated hind legs of rabbits and mice, respectively, and reported various 
results22, 25. No significant effect of irradiation or HBO on bone mineral density 
was found in the study of Johnsson et al22, probably because of high variations in 
bone-forming capacity between animals and a limited number of animals. They 
could only report a tendency toward improved bone formation after HBO therapy 
in nonirradiated tissue. Wang et al25 found that HBO significantly reduces the 
retardation of bone growth induced by irradiation but only at radiation doses of 
10 and 20 Gy. At a higher dose (30 Gy), the damage from irradiation could not be 
alleviated by the use of HBO. It must be noted that in this study and, actually, in all 
aforementioned in vivo experimental studies, the radiation dose and fractionation 
may not replicate the radiation pathology in humans, because tissue response is 
species specific61.
 In 3 studies implants were placed in irradiated hind legs of rats or rabbits, and 
2Hyperbaric oxygen therapy and radiation injury: a review of the literature
31
the effect of HBO on the tissue reaction around these implants was investigated21, 
23, 24. Results varied from slightly improved trabecular bone formation and improved 
implant-bone contact21 to improved bone formation and maturation23 and an 
increase in the biomechanical force necessary to unscrew titanium implants24.
HBO in Head and Neck Region
 Literature regarding HBO therapy in previously irradiated head and neck tissue 
in animals proved to be scarce. Only 1 study was exclusively designed to determine 
whether HBO is effective in reducing the long-term side effects of therapeutic 
irradiation treatment on the rat mandible33. In this study HBO therapy was given 
to rats 1 week after completion of radiotherapy. The follow-up period was up to 36 
weeks to obtain a clear view on the late effects of irradiation (and HBO). Furthermore, 
not only bone was investigated, but also salivary glands were taken into account. 
A dysfunction of these glands can cause xerostomia, a very debilitating side effect 
of irradiation. The results of this study indicate an HBO-influenced reduction in the 
acute inflammatory damage caused by radiotherapy. This leads to an increase in the 
preservation of specialized tissues, which can explain a reduction in the long-term 
complications of radiotherapy.
 In the studies of Muhonen et al27-32, all animals were subjected to DO. This technique 
is clinically used in the treatment of various deficiencies of the maxillofacial skeleton. 
An osteotomy is performed in hypoplastic bone, after which the bone segments are 
slowly driven apart by a distraction device. Thus the growth of new bone tissue 
between the bone segments is stimulated, resulting in lengthening of the distracted 
bone. The force that is generated during DO causes severe damage to irradiated 
bone and delays its regeneration. The authors, therefore, investigated whether the 
use of HBO can help to successfully perform DO in irradiated bone of the head and 
neck region. Three of the studies investigated the osteoblastic activity in the bone 
of the mandible27-29, whereas another 3 studies focused on the temporomandibular 
joint30-32, of which one was specially focused on the condylar cartilage32. Different 
methods were used to measure osteoblastic activity, including fluoride [18F] 
positron emission tomography, morphometry, and immunohistochemistry. Two of 
the studies carried out in the temporomandibular joint concluded that HBO did 
not have a positive effect or, at best, a scant limitation to the radiation-induced 
damage30, 32. However, the study that used positron emission tomography to measure 
osteoblastic activity found an increase in this activity in high-dosage radiotherapy, 
albeit to a lesser extent than in lower-dosage radiotherapy, and thus concluded 
HBO to be beneficial31. The 3 other studies focusing on the mandible resulted in 
more positive conclusions regarding the effect of HBO27-29. In general, all reported 
a higher osteoblastic activity because of HBO, although this activity never reached 
the level of nonirradiated bone. 
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 One study did not find a direct effect of HBO on the osteogenic rate but 
hypothesized that HBO might improve bone healing because of a lengthening of the 
period of high osteoblastic activity, rather than an increase of the activity itself29. 
Remarkably, in the control mandibles (without DO), the osteoblastic activity did not 
differ between all groups. Neither irradiation nor HBO had an effect on the basic 
osteogenic rate, which could be expected. It has to be noted that all of the studies 
were done by the same research group. Clark et al26 performed a similar study but 
were unable to show a significant difference in percentage of bone fill and bone 
mineral density of irradiated bone with or without HBO therapy. A general remark on 
the previously mentioned studies is that the long-term effects were not considered, 
because the animals were sacrificed 4 weeks after the DO was completed.
 In the experimental studies mentioned, HBO had either no effect or a positive 
effect on the irradiated tissue, whereas no negative effects were reported. There is 
no general consensus on the mechanism of action and the efficacy of HBO.
Clinical research
 Reports on clinical research regarding the effect of HBO on previously irradiated 
tissue are more abundant than experimental studies. Twenty clinical studies were 
found that met our criteria. Different strategies were used to investigate the effect 
of HBO (Table 1). Thirteen studies were retrospective, and the findings should 
therefore be viewed with some caution. As Hess62 stated, results of retrospective 
studies are, at best, hypothesis generating. Indeed, conclusions are carefully 
described, ranging from “HBO seems to be an efficacious treatment modality 
for many radiation- induced late side effects37” to “this paper supports existing 
literature on the potential benefit of HBO as a prophylactic agent and adjunctive 
treatment of ORN39”.
 Another serious limitation is that 60% (12) of the studies lack a control group. This 
is because of the retrospective nature of these studies and ethical considerations. 
Because HBO therapy has become a common recommendation for most patients 
with radiation-induced late side effects, it is considered unethical to withhold them 
from this therapy53, 63. In contrast, Annane et al35 terminated their prospective 
clinical trial because of potentially worse outcomes in the HBO-treated group and 
concluded that HBO should not be recommended to treat patients with overt 
mandibular ORN. However, a discussion arose regarding the thoroughness of this 
study. Laden64 states that, because of the termination, at least 75% of the treatment 
group did not receive the protocol minimum of 30 treatments. The study is “under-
powered,” and; therefore, Laden is surprised by the unequivocal statement made by 
Annane et al. Rogers65 shares the same concern, by wondering whether a single trial 
with 30 patients in each group can decide policy. In his opinion, this study highlights 
the need for robust randomized trials, rather than concluding that the use of HBO 
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should cease in this field. van Merkesteyn and Bakker66 criticize the study protocol 
by stating that twice-daily HBO treatment is in contrast to the majority of reports in 
the literature, in which once-daily treatment is used.
 Some studies used QoL questionnaires to evaluate the effect of HBO37, 44, 48, 50. 
Despite the fact that these questionnaires are validated, the subjective character of 
these data plays a major role. Bui et al37 used QoL scores in a retrospective study, 
relying on the patient’s ability to recall symptoms they experienced. However, results 
were compared with notes of the HBO physician who prospectively documented 
the progress of major symptoms, and they correlated with the patients’ response 
in 98% of cases. This is probably because late radiation side effects are severe and 
therefore easily remembered. In a prospective study, difficulties with QoL scores can 
also arise, as is seen in the study of Teguh et al50. They found a difference in baseline 
value for the European Organization for Research and Treatment of Cancer (EORTC) 
Head and Neck Cancer Module (H&N35) QoL questionnaire dry mouth questions. 
The patients in the non-HBO group had higher scores (subjective dryer mouth) than 
the HBO group before treatment was started. It is discussed that a possible reason 
could be that some of the patients who knew they were not scheduled for HBO 
argued that they must have a dry mouth to some extent because the purpose of 
the study was to investigate potential successful treatment of xerostomia with HBO 
therapy. Teguh et al concluded that a placebo effect could not be totally disproved. 
Another bias in research that uses QoL scores, according to Schoen et al48, is that 
the HBO treatment is an extra burden and, especially if small effects are achieved, 
this could negatively influence QoL results in these patients. However, this indicates 
that the effect of HBO is not worth the effort according to the patients, rather than 
being a bias.
 It must be noted that some of the studies have a rather small sample size, 
diminishing the power of these studies. Furthermore, in 60% (12) of the studies, 
no statistical analysis was conducted. Conclusions in these studies are based on the 
comparison of percentages.
 In general, 75% (15) of the studies mention a positive effect of HBO therapy 
on the prevention or treatment of ORN, as well as on the survival rate of implant 
placement in previously irradiated head and neck tissue. As outlined previously, 
findings must be read with caution, and in some of the studies, conclusions are 
merely suggestions rather than statements. It is remarkable that, although almost all 
studies suggested the use of an extensive randomized controlled trial to investigate 
the efficacy of HBO, until now, no such trial has been executed. This is probably 
because of the difficulties that arise when planning such an elaborate investigation, 
ethical issues included. The only authors who present skepticism about this idea are 
Schoen et al48. They state that their small randomized trial shows that a very large 
population is needed to detect a clinically significant benefit of HBO treatment and 
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even doubt whether such a large randomized controlled trial will actually prove 
beneficial. 
 Despite the lack of randomized controlled trials, the literature suggests a positive 
role for HBO in the treatment and prevention of ORN. However, opposing views 
on this subject exist. Several review articles advocate the use of HBO67-69, whereas 
others build a case against it60, 70, 71. Arguments against the use of HBO mainly focus 
on the scant evidence for the necessity of HBO treatment and on the high costs of 
the therapy.
 This review aims to give an overview of experimental and clinical studies regarding 
the effect of HBO therapy on previously irradiated head and neck tissue in the last 
2 decades. Experimental research is scarce, and the power of clinical research is 
limited because of the lack of randomized controlled trials. HBO is used clinically, 
which is remarkable considering the existing opposing views on its efficacy and 
value. It is therefore concluded that more research, both clinical and experimental, 
is necessary before solid conclusions can be drawn. In experimental studies the 
mechanism of action of HBO should be further unraveled, the results of which can 
possibly be implemented in clinical research to generate an accurate protocol for 
the prevention and treatment of radiation- induced late side effects in the head and 
neck region.
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ABSTRACT
Facilities for hyperbaric oxygen therapy that are suitable for animal experimental 
research are scarce. In this paper, the authors introduce a hyperbaric oxygen 
chamber that was developed specifically for animal experimental purposes. The 
hyperbaric oxygen chamber was designed to meet a number of criteria regarding 
safety and ease of use. The hyperbaric oxygen chamber conforms to 97/23/EC 
(Pressure Equipment Directive), Conformity Assessment Module G Product Group 
1. It provides easy access, and can be run in manual mode, semi-automatic mode 
and full-automatic mode. Sensors for pressure level, oxygen level, temperature, 
humidity and carbon dioxide level allow full control. This state-of-theart hyperbaric 
oxygen chamber for animal experimental purposes permits the investigation of 
the biological mechanisms through which hyperbaric oxygen therapy acts at a 
fundamental level.
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INTROdUCTION
 Patients who are treated for head and neck cancer often undergo a combination 
of tumour resection and radiotherapy. Tumour resection often involves surgical 
removal of parts of the surrounding normal tissues, such as jaw bone, tongue and 
floor of the mouth as well. This may result in large tissue defects, which need to be 
corrected by means of reconstructive surgery. Concurrent radiotherapy may result 
in decreased regenerative capacity of these normal tissues. As a result, wound 
healing after reconstructive surgery is compromised, which can have negative 
consequences for the patient’s quality of life.
 Hyperbaric oxygen therapy (HBOT) is considered to be able to partly or 
completely reduce radiation-induced tissue damage by stimulating cell proliferation, 
neovascularisation, and oxygenation in the irradiated tissues. Thus, HBOT improves 
the success rate of reconstructive surgery in previously irradiated tissues. Although 
HBOT has been clinically applied for several years, the exact biological mechanisms 
through which HBOT acts are not completely understood. The scientific literature 
shows that there is need for further pre-clinical research on this topic1.
 Animal studies that focus on investigating the effects of HBOT on irradiated tissues 
of the head and neck area are desired but HBOT facilities that are suitable for animal 
experimental research are scarce. Clinical HBOT facilities are often not suitable for 
various reasons. In this paper, the authors introduce a hyperbaric oxygen chamber 
that was developed specifically for animal experimental purposes.
CHARACTERISTICS OF THE HyPERBARIC OXyGEN CHAMBER
 The hyperbaric oxygen chamber (HBO Test Vessel P1460) (Fig. 1) has been 
developed in collaboration with a company with extensive expertise in the field of 
hyperbaric technology (Hytech BV, Raamsdonksveer, the Netherlands, http://www.
hyperbaric-technology.com). The hyperbaric oxygen chamber was designed to meet 
a number of criteria regarding safety and ease of use. The HBO chamber conforms 
to 97/23/ EC (Pressure Equipment Directive), Conformity Assessment Module G 
Product Group 1. It has been certified by TÜV (TÜV Industrie Service GmbH, TÜV 
SÜD Gruppe, Dampf- und Drucktechnik, München, Germany). The laboratory in the 
Erasmus Laboratory Animal Science Centre, where the HBO chamber is located, has 
been modified to meet the requirements for safe installation of hyperbaric oxygen 
chambers. The HBO chamber is connected to the central oxygen supply system of 
the laboratory, which provides pressurized pure oxygen so separate oxygen bottles 
are not needed to supply the HBO chamber with oxygen. This eliminates the risk of 
running out of oxygen during hyperbaric oxygen treatment because of the limited 
volume of an oxygen bottle. There is no need to replace depleted oxygen bottles 
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Figure 1 The hyperbaric oxygen chamber 
is large enough to accommodate the most 
commonly used experimental animals. (a) 
In the open position, the platform on which 
the animals are placed is easily accessible. (b) 
Compartmentalized cages are used to treat up 
to 24 mice simultaneously. (c) In the closed 
position, a safety pin and valve prevent the 
chamber from opening whilst pressurized. High-
pressure proof acrylic windows and two bright 
LED lights allow a clear view into the chamber.
with full ones, which saves time and minimizes the chances of operator errors whilst 
changing the oxygen bottles.
 The cylindrical HBO chamber is 70 cm in diameter and 115 cm long. The HBO 
chamber has a volume of 420 l and weighs 600 kg. Inside the chamber there is a 
level, rectangular platform, on which animal cages can be placed, measuring 95 
cm in length and 47.5 cm in width. Despite its weight, the roll-out unit and hand 
grip allow the HBO chamber to open and close smoothly. A safety pin is integrated 
to prevent the HBO chamber from opening whilst under pressure. The maximum 
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working pressure for this vessel is 5 bar (equivalent to approximately 5 atmosphere 
absolute, whereas the normal air pressure at sea level is 1 atmosphere absolute). A 
safety valve is present which gradually reduces the pressure in case it exceeds 5 bar.
 By installing the HBO chamber on a storage trolley suitable for its dimensions and 
weight, the HBO chamber is mobile and can be easily transported if necessary. All 
the materials used are suitable for exposure to pure oxygen and high pressure. The 
materials used should be able to withstand corrosion and should not be flammable 
in contact with pure oxygen. The maximum working pressure of 5 bar is equivalent 
to the weight of a column of water at approximately 50 m depth, therefore the 
materials used should be able to withstand such high pressure.
 When the connector is plugged into a single-phase 230 V AC electric socket, all 
electrical devices on the HBO chamber are supplied with electricity. These electronic 
devices can be controlled from the control box and include a water machine (for 
circulating cool or hot water into the heating/cooling system), two LED lights (5 
W each) inside the chamber, a gas/pressure analyser, a temperature analyser, a 
ventilator, a heating/cooling system, an alarm buzzer, and a data recorder (Fig. 2).
Figure 2 (a) A control box allows the operator to control the parameters inside the chamber. (b) The 
control box integrates switches, screens, and a data recorder, to control, visualize and record the 
various parameters.
 The HBO chamber was designed to fit the most commonly used small laboratory 
animals, ranging from mice to rabbits. It is large enough to accommodate multiple 
animals simultaneously (the total number depending on the size of the animals 
used). There is easy access to the HBO chamber for placing the animals in the vessel, 
and the inner surfaces are easy to clean after use. A clear view into the vessel is 
provided by high-pressure proof acrylic windows, whilst the two LED lights provide 
sufficient light to be able to monitor the behaviour of the animals during treatment.
 Human subjects who undergo hyperbaric oxygen therapy are usually placed in a 
chamber that is pressurized with normal air, whilst the pure oxygen is administered 
through oxygen masks. Animal subjects often do not tolerate such oxygen masks, 
so the HBO chamber is designed as a chamber in which the complete volume of 
air inside the vessel is replaced by pure oxygen. In this case, no oxygen masks are 
necessary.
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 Sensors are able to measure the oxygen concentration, the carbon dioxide 
concentration, the pressure, the temperature and the humidity inside the HBO 
chamber. A data recorder with thin-film transistor (TFT) screen is integrated to store 
the data on internal hard disk, compact flash memory card, or external USB device.
 The system can run in three different modes: manual, semi-automatic, and fully 
automatic. When operating in manual mode, the operator controls the pressure 
level and oxygen level by adjusting the oxygen valves and purge flow meter by hand. 
The fully automatic mode relieves the operator from continually having to adjust 
the valves, by executing a program with pre-set values for pressure build-up time 
and desired oxygen level. The HBO chamber allows the operator to store up to ten 
pre-set programs. The semi-automatic mode can be used when the user needs to 
adjust the pressure and oxygen level manually at first, and let the automatic system 
take over to maintain the manually achieved oxygen and pressure levels.
 The integrated climate control system helps to maintain a constant temperature 
in order to minimize temperature-related stress in the animals, as the temperature 
will fluctuate as a result of changes in pressure. A purge flow meter enables the 
operator to control the refresh rate of pure oxygen. This is important, as living 
creatures exhale carbon dioxide during their treatment inside the HBO chamber. By 
adjusting the purge flow meter, it is possible to maintain an oxygen concentration 
level of 100%.
dISCUSSION
 Animal experimental studies allow the study of various parameters in a statistically 
relevant number of subjects, but facilities to study the effects of HBOT in animal 
models are often not available. Clinically used HBO chambers are often not suitable 
for use with animals for logistical reasons (e.g. no animal experimental work can 
be done during the time that the HBO chamber is in use by human patients), for 
ethical reasons (e.g. patients may reject the idea that the same facilities for human 
subjects are also used for animal experiments), or for practical reasons (e.g. the 
oxygen masks that are used for oxygen administration are suitable for human 
subjects but are not tolerated by animal subjects).
 HBO chambers specifically suitable for animal experimental purposes are scarce. 
To the authors’ knowledge, only Rech et al2 have recently published a similar technical 
note on a hyperbaric oxygen chamber for animal use. Such an HBO chamber needs 
to comply with strict safety regulations, because high pressure and pure oxygen are 
involved. Such devices should only be manufactured by companies with extensive 
expertise in hyperbaric technology. The financial costs of developing such a device 
are high. The authors’ research group has developed a state-of-the-art, safe and 
easy-to-use HBO chamber specifically for animal experimental purposes. This 
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allows for the investigation of the effects of hyperbaric oxygen therapy on tissue 
repair and regeneration on a fundamental level in the most commonly used small 
animal models.
 Many animal experimental studies involve small animal models, such as mice and 
rats. To be able to keep mice safely in the HBO chamber, compartmentalized cages 
were fabricated to accommodate up to 12 mice per cage simultaneously. These 
cages are also suitable to accommodate rats; the compartments can be enlarged 
by removing the partitions between the compartments. A cage can provide space 
for up to 6 rats simultaneously. In the HBO chamber, there is room for two such 
cages, suitable for up to 24 mice or 12 rats simultaneously. The cages are made of 
corrosion-resisting steel, because of the corrosive nature of pure oxygen. The steel 
plates are punctured, giving a meshed appearance. This allows the oxygen to enter 
every single compartment, and also allows viewing inside the compartments to 
monitor the behaviour of the animals. Such custom-made cages can be fabricated 
for any other suitable small laboratory animal.
 Regarding the effects of HBOT on the regeneration of irradiated head and neck 
tissues, the number of experimental papers is limited1. HBOT has been used clinically 
to treat radiation-induced damage for many years, but there remain opposing views 
on its efficacy3-9. This reflects the need for more in-depth animal experimental 
research on HBOT.
 The authors’ current pre-clinical research focuses on the effects of HBOT on 
radiation-induced oral tissue damage, but HBOT can be used as adjunctive or main 
treatment for various other medical indications. The authors’ HBO chamber can 
be of value to many members of the scientific community who are interested in 
carrying out animal experimental research on hyperbaric oxygen therapy.
 In conclusion, the authors have developed a state-of-the-art hyperbaric oxygen 
chamber specifically for animal experimental purposes. It meets the criteria 
regarding safety regulations and ease of use. This will create new possibilities for 
further in-depth research and strong collaborations in the field of hyperbaric oxygen 
therapy.
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ABSTRACT
Background: Radiation therapy (RT) as part of the treatment of head and neck 
cancers often leads to irradiation of surrounding normal tissue, such as mandibular 
bone. A reduced reparative capacity of the bone can lead to osteoradionecrosis 
(ORN). Hyperbaric oxygen therapy (HBOT) is used to treat ORN, based on its 
potential to raise the oxygen tension in tissues. However, prevention of radiation-
induced damage is of optimal interest. Our purpose was to investigate whether 
HBOT could prevent radiation-induced damage to murine mandibles. 
Methods: Twenty-eight mice were irradiated in the head and neck region with a 
single dose (15 Gy) and half of them were subsequently subjected to HBOT. Another 
14 mice did not receive any treatment and served as controls. Ten and 24 weeks after 
RT, mandibles were harvested and analysed histologically and by microcomputed 
tomography (micro-CT).
Results: Micro-CT analysis showed a reduction in relative bone volume by RT, 
which was partly recovered by HBOT. Trabecular thickness and separation were 
also positively influenced by HBOT. Morphologically, HBOT suppressed osteoclast 
number, indicating decreased resorption, and decreased the amount of lacunae 
devoid of osteocytes, indicating increased bone viability. 
Conclusions: HBOT was able to partly reduce radiation-induced effects on 
microarchitectural parameters, resorption and bone viability in mouse mandibles. 
HBOT could therefore potentially play a role in the prevention of radiation-induced 
damage to human mandibular bone.
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INTROdUCTION
 Radiation therapy (RT) is a standard component in the protocol treatment of head 
and neck cancer. Inevitably, normal surrounding tissues, including maxillofacial 
bones such as the mandible, will also be exposed to RT. Radiation damages small 
arteries, reducing the circulation to the, already relatively poor vascularized 
mandible. This causes an impaired remodeling capacity of the bone, that can lead 
to a reduction in bone mass and bone density, and thus to more vulnerable bone1. 
The impaired reparative capacity of the bone especially poses a risk when trauma, 
such as subsequent surgery, biopsy or tooth extraction and consecutive implant 
placement, is inflicted on the previously irradiated bone. Due to the vascular 
damage, a hypoxic and hypovascular environment exists in which bone is more 
prone to inflammation, which can eventually lead to destruction of bone, so called 
osteoradionecrosis (ORN)2. 
 ORN of the mandible is a serious long term side effect in patients that receive 
radiation as part of the treatment for head and neck cancer. It is a very painful 
condition that can present itself even years after RT and is difficult to treat. Treatment 
regimens depend on the grade of ORN; lower grade can be treated effectively by 
long term oral antibiotic therapy, while for more severe cases, removal of the 
affected bone might be necessary. 
 Hyperbaric oxygen therapy (HBOT) is used as an adjuvant therapy to treat ORN, 
or is used in a preventative manner when minor or major surgery is performed in 
irradiated bone. The rationale is that HBOT, in which patients breathe 100% oxygen 
under elevated pressure, raises the oxygen tension and can thereby positively 
affect the healing process. Although clinical studies report positive effects, a 
general consensus about the effectiveness of the therapy remains to be achieved3, 
4. Experimental studies on the effects of HBOT on the treatment or prevention 
of ORN are especially scarce, while these kind of studies would provide a better 
understanding of the effects and working mechanism of HBOT. Furthermore, the 
potential of HBOT to protect bone from radiation damage before complications 
have arised, has not been investigated thoroughly.
 In this study, we investigated the effects of HBOT, when given directly after RT, 
on irradiated mandibular bone of mice, by means of micro-CT and histology.  We 
were particularly interested in the effect on bone microarchitecture and viability in 
non-traumatised bone, to assess if HBOT is able to prevent radiation-induced bone 
damage.
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MATERIALS ANd METHOdS
Animals
 Female C3H mice (Harlan Netherlands BV, Horst, the Netherlands), 7-9 weeks old 
at the start of experimentation were kept under standard housing conditions with 
free access to food pellets and acidified water. The mice were divided into three 
groups: control, radiation therapy (RT) and radiation therapy followed by hyperbaric 
oxygen therapy (RT+HBOT). At 10 and 24 weeks after RT, 7 mice of each group 
were sacrificed and mandibles were harvested for ex-vivo micro-CT scanning, after 
which they were used for histology. Animals were weighed frequently and given 
soft crushed food pellets to allow sufficient food intake after RT. The experimental 
protocol was approved by the Animal Care Committee of the Erasmus MC, 
Rotterdam, the Netherlands, under the National Experiments on Animals Act and 
adhered to the rules laid down in this national law that serves the implementation 
of “Guidelines on the protection of experimental animals” by the Council of Europe 
(1986), Directive 86/609/EC.
Radiation- and hyperbaric oxygen therapy
 Radiation therapy and hyperbaric oxygen therapy were given as previously 
described5. In short, RT consisted of a single 15 Gy dose administered to the head 
and neck region of anesthetized mice. Mice in the RT+HBOT group received the first 
HBOT session the day after RT. In a HBOT session, mice breathed 100% oxygen at 2.4 
atmospheres absolute during one hour  in a hyperbaric chamber suitable for small 
laboratory animals 6. Twenty consecutive sessions were carried out daily, except at 
saturdays and sundays.
Micro-CT scanning
 Immediately after sacrifice by CO
2
-asphyxiation, at 10 and 24 weeks after RT, 
mandibles were harvested and fixated in 10% buffered formalin. Microcomputed 
tomography (micro-CT) was used to analyze bone parameters. Micro-CT scans 
of the tissue blocks were made with a SkyScan 1076 in vivo microCT scanner 
(SkyScan, Aartselaar, Belgium) and manufacturer’s scanning software. Examination 
consisted of a scout view, selection of region of interest, off-line reconstruction, 
and evaluation. Serial transverse scan images were made at a resolution of 18 
µm. Nrecon 1.3 (SkyScan, Aartselaar, Belgium) and CT Analyser 1.3.2.2 (SkyScan, 
Aartselaar, Belgium) software were used to reconstruct the data for analysis. A 
3-dimensional volume of interest was created by applying interpolation between 
2-dimensional free-hand selections of the mandibular bones. Within the volume of 
interest, the relative bone volume (BV/TV) was determined to quantify new bone 
formation, as well as trabecular number (TbN), trabecular thickness (TbTh) and 
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trabecular separation (TbSp). 
Histology
 After micro-CT scanning, mandibles were decalcified in 10% 
ethylenediaminetetraacetic acid (EDTA) for 12 days, after which they were 
dehydrated  and embedded in paraffin blocks. 5 µm slides were sagitally cut and 
standard hematoxylin eosin (HE) staining was performed. Per slide, the amount 
of empty lacunae and osteocytes were counted in 2-3 fields (20X magnification). 
Empty lacunae were expressed as a percentage of the total count of osteocytes. 
Adipocyte density in bone marrow (number and area of adipocytes per mm2 bone 
marrow) was quantified using Image J version 1.45b (National Institutes of Health, 
Bethesda, USA). Tartrate-resistant acid phosphatase (TRAP) staining was used to 
stain osteoclasts. Slides were first incubated for 20 minutes in 0.2M acetate buffer 
with 50mM L(+) tartaric acid (ICN Biomedicals Inc, Aurora, USA). Then, 0.5 mg/ml 
naphthol AS-MX phosphate (Sigma-Aldrich Corp., St. Louis, USA) and 1.1 mg/ml 
fast red TR salt (Sigma-Aldrich Corp., St. Louis, USA) were added, after which slides 
were incubated for 60 minutes at 37°C, rinsed in distilled water, counterstained with 
hematoxylin and embedded with vectamount. The number of positively stained 
osteoclasts per mm bone marrow perimeter was counted.
Statistical analysis
 All data are expressed as mean values with standard error of the mean (SEM), and 
were analysed using SPSS PASW 21.0 for Windows (SPSS Inc., Chicago, USA). The 
Shapiro-Wilk test was used to test for normality, followed by the Mann-Whitney U 
test for the comparison of non-normally distributed data, while Student’s T-test was 
used for normally distributed data. P<0.05 indicated significant differences.
RESULTS
Micro-CT
 Figure 1 shows bone parameters quantified by micro-CT scanning in the 
mandibles of mice, 10 and 24 weeks after radiation therapy. Figure 1A shows the 
volume of interest, between the red lines, that was selected. At ten weeks post-RT, 
no differences between groups were found in bone volume (Figure 1B), trabecular 
thickness (Figure 1C), trabecular separation (Figure 1D) and trabecular number 
(Figure 1E). However, porosity (Figure 1F) was significantly increased in the RT-
group (36.6 ± 1.1%) compared to controls (31.3 ± 2.0%; p<0.05). HBOT given after 
RT reduced the percentage of porosity towards control levels (30.7 ± 2.0%; p<0.05). 
 Twenty-four weeks after RT, no differences in the percentage of porosity were 
present anymore. However, the effect of RT became evident in the other parameters 
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measured. Relative bone volume (BV/TV) significantly decreased in the RT-group 
(57.2 ± 0.6%) compared to control (63.0 ± 1.1%; p<0.01). When HBOT was given after 
RT, relative bone volume increased towards control levels (62.2 ± 3.0; p<0.05 for RT 
vs. RT+HBOT). The same pattern was seen for the trabecular thickness (control 0.171 
± 0.005 mm; RT 0.145 ± 0.003 mm; RT+HBOT 0.157 ± 0.007 mm; p<0.001 for control 
vs. RT; p<0.05 for RT vs. RT+HBOT). Trabecular separation was inversely affected, 
with a higher separation of trabeculae in RT (0.108 ± 0.002) compared to control 
(0.100 ± 0.002 mm; p<0.05) and oppositely a reduction in trabecular separation due 
to HBOT (0.096 ± 0.008 mm; p<0.05). Trabecular number was increased by RT (3.96 
± 0.06 vs. 3.70 ± 0.04 in controls; p<0.01), whereas the administration of HBOT after 
RT did not influence trabecular number (3.95 ± 0.04) compared to RT.
Figure 1 Micro-CT analysis. Micro-CT analysis was performed in mandibles of mice; the volume 
of interest is indicated between red lines (A). Relative bone volume (B), trabecular thickness (C), 
trabecular separation (d), trabecular number (E) and percentage porosity (F) were calculated, at 10 
and 24 weeks after radiation therapy. RT = radiation therapy, HBOT = hyperbaric oxygen therapy. Lines 
indicate significant differences between  groups.
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Histology
 The amount of empty lacunae, devoid of osteocytes, reflects bone viability and 
has been reported to be increased after RT7, 8. In our study, the percentage of empty 
lacunae increased at 24 weeks after RT (3.69 ± 0.41% vs. 1.26 ± 0.43% in controls; 
p<0.01), while no effect was seen at 10 weeks post-RT (Figure 2A). HBOT had a 
positive effect since a lower percentage of empty lacunae was found at 24 weeks 
post-RT (2.34 ± 0.31%; p<0.05 for RT vs. RT+HBOT).
Adipocyte density (Figure 2B) of bone marrow was increased by RT, at both 10 weeks 
(62.1 ± 14.6 vs. 8.2 ± 4.4 in controls; p<0.05) and 24 weeks post-RT (49.88 ± 13.5 vs. 
13.8 ± 7.2 in controls; p<0.05). HBOT did not have an effect on adipocyte density. 
 The number of bone-resorbing osteoclasts (Figure 2C) was increased by RT at 
both time-points, however not significantly at 24 weeks post-RT (1.68 ± 0.34 vs. 
0.07 ± 0.04 in controls at 10 weeks, p<0.05; 1.48 ± 0.55 vs. 0.66 ± 0.17 in controls at 
24 weeks). HBOT decreased osteoclast number at 24 weeks post-RT compared to RT 
treatment alone (0.38 ± 0.17 in RT+HBOT vs. 1.48 ± 0.55 in RT; p<0.05).
Figure 2 Morphological analysis. Quantification of morphological parameters, with pictures from 
different groups at 24 weeks postRT. The percentage of empty lacunae is shown in A. White arrows 
depict empty lacunae, which are more abundant in the RT-group. Scale bars represent 50 µm. Adipocyte 
density is shown in B, with an increased density in both RT-treated groups. Scale bars represent 100 
µm. C represents the number of osteoclast per mm bone marrow perimeter. Osteoclasts are stained 
red by TRAP staining and are more abundant in the RT-group. Scale bars represent 100 µm. RT = 
radiation therapy, HBOT = hyperbaric oxygen therapy. Lines indicate significant differences between 
groups.
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dISCUSSION
 Radiation therapy, used as a standard component in the protocol treatment of 
head and neck cancer, inevitably exposes surrounding normal tissues to radiation. 
Maxillofacial bones that are in the field of irradiation become more vulnerable to 
fractures and have a decreased regenerative capacity. Reconstructive surgery on 
irradiated bones therefore often gives suboptimal results9,10. Treatments that can 
improve the condition of tissues that suffer from radiation-induced damage are 
desired.
 Hyperbaric oxygen therapy is used in the treatment of osteoradionecrosis, as well 
as necrosis of the bone due to bisphosphonates11. It is also used in a preventative 
manner when dental alveolar surgery and implantology need to be performed 
in previously irradiated mandibular bone. However, its effectiveness remains 
debatable, with an increasing amount of studies reporting a lack of effect and 
advocating the need for randomized controlled trials3, 12-14. Also, the mechanism of 
action is not fully understood4, 15. 
 In the present study, we investigated if HBOT was able to protect the mandibular 
bone from long-term radiation effects. For this purpose, microarchitecture and 
morphology were assessed at 10 and 24 weeks after RT and compared with controls.
 
 Micro-CT analysis is a powerful and non-destructive tool to quantify bone 
properties on a microstructural level. Its advantage over histologic analysis is that 
this technique enables the measurement of various parameters in larger volumes 
of bone, whereas histological assessment of bone microarchitecture relies on the 
extrapolation of measurements performed in a few slides 16. Relative bone volume 
(BV/TV), trabecular number (TbN), trabecular thickness (TbTh) and trabecular 
separation (TbSp) are the most common parameters used to describe bone 
microarchitecture. BV/TV, TbN and TbTh have been shown to decrease in response 
to radiation in animal models, whereas TbSp increases after RT7, 16-18. These changes 
in bone microarchitecture result in reduced strength of the bone, which thus 
becomes more vulnerable to fractures. 
 Our study is in accordance with previous studies and showed a decrease of BV/TV 
and TbTh 24 weeks after radiation therapy, whereas TbSp was increased. Surprisingly, 
TbN was increased due to radiation. Apart from the percentage of porosity, no effect 
was seen at 10 weeks after RT, while other studies showed changes in microstructure 
at the same or earlier time-points7, 16-18.This could be due to the use of different 
animal models with varying RT dose and administration in these studies, making it 
difficult to compare time-points. Most studies are performed in hind limbs, while 
the effects of RT on mandibular bone are less well studied. Damek-Poprawa and 
colleagues7 have established that the onset of osteoradionecrosis is more rapid in 
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the mandibles than in the tibias of rats. A 50 Gy single dose, administered locally to 
the mandible was used in this study, whereas we used a 15 Gy  single dose which 
comprised the head and neck area. These differences could account for the fact that 
in our study, effects on bone microarchitecture were only visible 24 weeks after RT, 
as compared to effects seen on 10 weeks after RT in the study of Damek-Poprawa. 
 In addition to the observed microarchitectural changes, morphological changes 
due to RT were also observed. Adipocyte density in the bone marrow increased 
at both time points studied. The increase of adipocytes in bone marrow as a 
consequence of radiation has been reported19. Mesenchymal stem cells (MSCs) 
in the bone marrow can differentiate into osteoblasts and adipocytes20. Radiation 
probably targets the MSCs and disrupts the balance between MSCs osteoblast- and 
adipocyte differentiation. Adipocytes secrete anti-osteogenic factors and therefore 
decrease bone formation and bone mass21, probably due to an induction of apoptosis 
of bone-forming osteoblasts and increased proliferation and differentiation of 
bone-resorbing osteoclasts22. Osteoclast number was indeed also increased after 
RT in our study, indicating increased bone resorption.
 The number of empty lacunae, which represents loss of osteocytes, increased 
under the influence of RT at 24 weeks post-RT. Osteocytes derive from osteoblasts 
that have become ‘trapped’ in the matrix they have produced themselves. They 
keep contact with each other and with the osteoblasts and osteoclasts that reside 
at the bone surface by cytoplasmic extensions called dendrites, that extend into 
channels in the matrix23. In this way, osteocytes send signals for bone resorption 
and formation to osteoclasts and osteoblasts, respectively, and therefore play an 
essential role in bone maintenance and remodeling24. Dying or dead osteocytes 
have been suggested to stimulate resorption25, 26. Various studies on the effects 
of radiation on bone use the increased amount of empty lacunae as a measure 
for radiation damage7, 8, 27-29 and our results confirm the radiation-induced loss of 
osteocytes. 
 Effects of hyperbaric oxygen on (irradiated) bone have not been studied extensively. 
Experimental animal studies are mainly conducted in either distracted, previously 
irradiated, bone or include the placement of implants. Moderately positive effects 
of HBOT on osteoblastic activity have been reported in irradiated distracted bone 
(reviewed in 4). Implantology is usually performed in the hind legs of rats, mice 
or rabbits, which differ from the predominantly cortical bones of the head and 
neck region, since they mainly consist of cancellous bone. Small improvements in 
bone formation, implant-bone contact and force needed to unscrew implants due 
to HBOT were reported4. Williamson and colleagues subjected rats to RT followed 
by HBOT and investigated bone 36 weeks after RT30. They counted the number of 
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lacunae filled with osteocytes and reported a positive effect (i.e. higher number of 
filled lacunae) in the group treated with RT and HBOT compared with the group that 
was irradiated. Our findings, at 24 weeks after RT, correspond with these results, as 
HBOT was also able to positively influence osteocyte count and thus the viability of 
mandibular bone. In addition, we found positive effects of HBOT on microstructural 
parameters that were negatively influenced by RT, and a suppression of osteoclasts.
 The effects of HBOT on osteogenic cells, i.e. bone-forming osteoblasts and bone-
resorbing osteoclasts, have been studied in vitro. Positive effects of HBOT on 
proliferation and/or differentiation of osteoblasts have been described31, 32, while 
Wong and colleagues found no effect of HBOT on normal or irradiated osteoblasts33. 
Osteoclast formation has been shown to be suppressed due to HBOT34. In our in vivo 
study, osteoclast number was decreased by HBOT, at 24 weeks after RT, indicating 
a reduction of bone resorption. Together with the decreased number of empty 
lacunae, this may have led to the increased relative bone volume seen by micro-CT 
analysis. 
 The clinical relevance of our results remains to be elucidated. It is to be defined 
if the single radiation dose of 15 Gy (biologically equivalent to a cumulative dose 
of 32 Gy) that was used in our experimental model leads to the same degree of 
bone damage as the fractionated radiation dosing schemes that are clinically used. 
Furthermore, it is clinically important to investigate whether the observed HBOT 
induced changes cause stronger bone and an improved regenerative capacity when 
trauma is inflicted. Further experimental investigation followed by randomized 
clinical trials are therefore desired.
CONCLUSION
 Radiation irreversibly damages bone and other specialized tissues. Therefore, 
the prevention of radiation-induced damage to bone would be preferable to the 
treatment of complications. Our results showed that HBOT was able to positively 
influence microarchitectural parameters of irradiated mandibular bone of mice, 
suppress osteoclast number and increase bone viability. This could indicate that 
HBOT has potential to be used as a prevention modality for radiation-induced bone 
damage. Further research will be necessary to evaluate whether the observed 
microstructural and morphological changes of irradiated bone can indeed cause 
stronger bone, less vulnerable to microfractures or other trauma which can lead to 
ORN. 
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ABSTRACT
Objectives: Hyperbaric oxygen therapy (HBOT) is used clinically in irradiation-
induced injury to healthy tissues, but the effectiveness and working mechanism 
remain unclear. This study examined the effects of HBOT on irradiated salivary 
glands and tongue in a mouse model.
Materials and methods: Mice were irradiated with a single dose (15 Gy) in the head 
and neck region and subjected to HBOT, either before or after irradiation. During 
the course of the treatments, salivary flow rates were measured and at different 
time points after radiation (2, 6, 10 and 24 weeks), salivary glands and tongue were 
harvested and (immuno) histochemically analysed.
Results: Proliferation and blood vessel density in salivary glands were enhanced 
by HBOT in the medium term (10 weeks after irradiation), while salivary flow rates 
were not influenced. In the long term, irradiation-induced proliferation in the 
muscle tissue of the tongue was decreased by HBOT.
Conclusion: Hyperbaric oxygen therapy (HBOT) appears to stimulate regeneration 
or protection of salivary gland tissue following radiation therapy. Possible 
implications of the effect of HBOT on muscle tissue of the tongue for the prevention 
of dysphagia and trismus are discussed. This study provides insights on the cellular 
changes after HBOT and encourages further research on this topic to achieve a 
better implementation of the therapy in humans.
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INTROdUCTION
 Head and neck cancer is most commonly treated by radiotherapy (RT), alone 
or in combination with chemotherapy or surgery. RT causes not only injury to the 
malignant tumour, but also to surrounding healthy tissues. The salivary glands 
and tongue are often in the radiation field and suffer from the adverse effects of 
RT. Acute effects include mucositis and hyposalivation, of which the latter often 
persists into a chronic stage called xerostomia1. Patients with xerostomia have 
difficulties with speech, mastication, swallowing and suffer from impairment of 
their taste and sleep patterns2-4. Therefore, the quality of life of these patients is 
significantly reduced5. To date, no prevention modality or treatment exists that 
offers protection or full recovery from xerostomia. Prevention strategies currently 
used for xerostomia include the surgical transfer of major salivary glands outside 
the radiation field, intensity modulated radiotherapy to spare salivary glands and 
the use of cytoprotectants such as amifostine1, 6. However, these interventions are 
not applicable to all patients and, in the case of amifostine, there is still controversy 
regarding possible tumour protection and toxic side effects7. 
 Current treatments of xerostomia rely on the stimulation of the residual secretory 
capacity of salivary glands via sialogogues, or, if this is insufficient, the use of saliva 
substitutes1. However, these have to be taken for the rest of the patients’ lives, 
with their associated side effects, as the therapeutic effect directly ceases when 
the administration is stopped. Therefore, the need for a therapy that stimulates 
salivation is evident.
 Other debilitating consequences of RT in the head and neck region include 
dysphagia (swallowing problems) and trismus (an inability to normally open 
the mouth due to muscle rigidity)8, 9. Damage of the tongue can be a factor in 
the development of RT-induced dysphagia10. Dysphagia can result in aspiration 
pneumonia and permanent or long-term feeding tube dependence, whereas 
patients with trismus often suffer from malnutrition, difficulty in speaking and 
compromised oral hygiene. 
 Hyperbaric oxygen therapy (HBOT) has been used to treat radiation injuries since 
the early 1970s11. Patients breathe 100% oxygen at elevated pressure, typically 2–3 
atmospheres absolute (ATA). The increased pressure, combined with pure oxygen 
breathing, will increase the portion of oxygen that is carried in solution. This leads 
to a 10-fold increase in the oxygen tension in tissues12. As the oxygen is in solution, it 
can also reach obstructed areas where red blood cells cannot pass and it can diffuse 
further into poorly vascularised regions. Hyperoxia has been shown experimentally 
to increase angiogenesis by elevating vascular endothelial growth factor (VEGF) 
levels13 and to facilitate the deposition of collagen fibres around newly formed 
blood vessels14, 15. In this way, HBOT may be able to overcome the progressive loss of 
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the microvasculature resulting in chronic tissue hypoxia that is present in radiation-
induced damage.
 However, experimental as well as clinical evidence on the effects and possible 
risks of HBOT is still scarce, and in addition, its working mechanism not completely 
understood16, 17. In this study, the effects of HBOT, given before or after irradiation, 
on salivary glands and tongue were studied. In order to do this, we used a mouse 
model in which the animals were followed for up to 24 weeks after RT to the head 
and neck region to assess the effects on chronic radiation damage.
MATERIALS ANd METHOdS
Animals
 Female C3H mice, 7–9 weeks old at the time of experimentation, were purchased 
from Harlan (Harlan Netherlands BV, Horst, the Netherlands) and were kept under 
standard housing conditions with free access to food pellets and acidified water. They 
were allowed to acclimatise for at least one week before experimentation started. 
The study comprised two consecutive experiments. For the 10-week experiment, 
84 mice were divided into four groups: HBOT only (HBOT, n = 21), RT only (RT, n = 
21), RT followed by HBOT (RT+HBOT, n = 21) and HBOT followed by RT (HBOT+RT, n = 
21). At 2, 6 and 10 weeks, seven mice from each experimental group were sacrificed 
by CO2 asphyxiation. Five additional animals served as non-treatment controls. For 
the 24-week experiment, 21 mice were evenly assigned to three groups (HBOT, RT 
and RT+HBOT) and sacrificed at 24 weeks. Furthermore, seven mice did not receive 
any treatment and were sacrificed after 24 weeks. Schematic representation of the 
study design is shown in Figure 1. To assure sufficient food intake, animals were 
weighed frequently and all irradiated animals were given crushed food pellets 
mixed with water. The experimental protocol was approved by the Animal Care 
Committee of the Erasmus MC, Rotterdam, the Netherlands, under the national 
Experiments on Animals Act and adhered to the rules laid down in this national law 
that serves the implementation of ‘Guidelines on the protection of experimental 
animals’ by the Council of Europe (1986), Directive 86/609/EC.
Radiotherapy
 Mice were anesthetised intraperitoneally (i.p.) with a mixture of ketamine and 
xylazine (120 mg kg-1 and 6 mg kg-1 body weight, respectively). The head and neck 
region was locally irradiated with a single dose of 15 Gy by a 250 kV orthovoltage 
irradiator (Philips RT250, Philips Medical Systems, Brussels, Belgium) using a Cu 
filter and a dose rate of 1.9 Gy min-1. The rest of the body was shielded by a 0.5 cm 
lead plate.
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Figure 1 Study design. Mice received either RT, HBOT, or a combination and were sacrificed at 
2, 6, 10 or 24 weeks (n = 7 for each group and timepoint) whereafter tissues were harvested for 
immunohistological analyses. Salivary flow rates were measured the day before sacrifice, and every 
other week in the 24-week experiment and controls. HBOT consisted of 20 sessions divided over a 
4-week time period, and RT consisted of a single dose of 15 Gy to the head and neck area. HBOT, 
hyperbaric oxygen therapy; RT, radiotherapy.
Hyperbaric oxygen therapy
 The hyperbaric oxygen chamber used in this study was custom-built for small 
laboratory animals (Hytech BV, Raamsdonksveer, the Netherlands)18. HBOT 
consisted of 20 daily sessions, given over a 4-week time period. Each session started 
with a compression phase of 30 min, during which the pressure in the chamber was 
elevated to 2.4 atmospheres absolute (ATA) and the oxygen level to 100%. These 
parameters were kept constant during the isopression phase, which lasted 1 h. 
Finally, decompression to 1 ATA took another 15 min. All sessions were carried out 
in the morning. For group RT+HBOT, the HBOT started the day after RT; for group 
HBOT+RT, RT was given the day after completion of HBOT.
Saliva collection
 Whole saliva was collected the day before animals were sacrificed (10-week 
experiment) or every other week starting at 10 weeks (24-week experiments). In 24-
week control mice, saliva was collected at the same time points used in the 10- and 
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24-week experiments. Mice were injected i.p. with pilocarpine (2 µg g-1 bodyweight, 
Sigma-Aldrich BV, Zwijndrecht, the Netherlands). Animals were manually fixed and 
saliva was collected for 10 min, starting 2 min after pilocarpine injection. Saliva was 
pipetted directly from the mouth and collected in preweighed Eppendorf tubes. 
Saliva volume was determined gravimetrically, assuming a density of 1 g ml-1 of 
saliva19, and flow rates (µl min-1) were calculated.
Histology and immunohistochemistry
 Immediately after sacrifice, parotid glands, submandibular glands and tongue 
were excised and stored in 10% buffered formalin for 24–36 h. All tissues were then 
dehydrated, embedded in paraffin blocks, and 5-µm slides were cut. A standard 
haematoxylin–eosin staining was carried out to address overall morphology, 
whereas the periodic acid–Schiff (PAS) staining was used to identify functionally 
active acinar cells in the salivary glands. In short, slides were rehydrated, quenched 
in 0.5% periodic acid solution for 5 min, followed by 15 min in Schiff’s reagent, 
before dehydration and embedding with Permount® (Fisher Scientific, Pittsburgh, 
PA, USA). For immunohistochemistry, sections were probed with primary antibodies 
against Ki67 (Novus Biologicals Ltd., Cambridge, UK), cleaved caspase-3 (Cell 
Signaling Technology Inc., Danvers, MA, USA) and CD-31 (Abcam, Cambridge, UK) to 
assess proliferation, apoptosis and blood vessel density, respectively. Biotinylated 
goat antirabbit IgG (Dako, Carpinteria, CA, USA) was used as secondary antibody. 
Detection of the antibody complex was performed with streptavidin–peroxidase 
(R&D Systems, Oxon, UK) and 3,3′-diaminobenzidine (Dako). Haematoxylin served 
as counterstain.
Quantification
 Slides were scanned using a slide scanner (Hamamatsu Photonics K.K., 
Hamamatsu, Japan). For both submandibular and parotid glands, Ki67-positive cells 
or CD31-positive blood vessels were counted in a representative field (magnification 
10x). For the tongue, Ki67-positive cells were counted in three fields per slide 
(magnification 10x), taken from dorsal, medial and ventral parts. Caspase-3-positive 
cells were counted in sections of the whole submandibular gland and expressed as 
the number of positive cells per mm2 gland tissue.
Statistical analysis
 All data are expressed as mean values with standard deviation (s.d.) and were 
analysed using SPSS PASW 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Univariate 
tests with post hoc Bonferroni correction were used to identify statistical differences 
(P < 0.05) between groups within the same time point. T tests were used to compare 
individual groups with non-treated controls.
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RESULTS
Effects of HBOT in the short/medium term
 To investigate the effects of HBOT on head and neck tissues in the short and 
medium term after RT, salivary glands and tongue of locally irradiated mice were 
analysed at 2, 6 and 10 weeks after RT.
Salivary glands 
 Salivary flow rate was reduced by half at 6 and 10 weeks (P < 0.001) after RT and 
was not positively influenced by HBOT (Figure 2a). Overall morphology of irradiated 
submandibular glands is depicted in Figure 2b for the different time points. At 10-
week post-RT, some enlarged nuclei were present and the tissue showed some 
signs of disorganisation, but no gross changes in the tissues were visible. HBOT 
treatments did not influence morphology (data not shown).
Figure 2 Short-/medium-term effects of RT and HBOT on salivary flow rates and overall morphology 
of submandibular glands. (a) Salivary flow rates following pilocarpine injection expressed as μl min_1 
(mean + s.d.). Within each time point, groups with different symbols (#, $ or o) are statistically different 
from each other. (b) H&E stainings of submandibular gland tissue of RT group at different time points. 
At 10 weeks after RT (right panel), slight disorganisation of acinar cells with some enlarged nuclei is 
visible. Scale bar 200 μm. HBOT, hyperbaric oxygen therapy; RT, radiotherapy.
 Proliferation, as measured by the number of Ki67-positive cells (Figure 3a), 
decreased after RT compared with non-treated controls in both submandibular- 
and parotid glands (submandibular gland: P < 0.01 at 6 weeks and P < 0.05 at 10 
weeks; parotid gland P < 0.01 at 6 and 10 weeks). HBOT given after RT increased 
proliferation compared with RT alone for the submandibular gland at 10 weeks (P < 
)a(
)b(
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0.001) and for the parotid gland at 6 and 10 weeks (P < 0.001). HBOT given before 
RT increased proliferation compared with RT alone in both glands at 6 and 10 weeks 
after RT (submandibular gland: P < 0.05 at 6 weeks and P < 0.001 at 10 weeks; 
parotid gland: P = 0.001 at 6 and 10 weeks). The proliferation levels of HBOT-treated 
irradiated groups were comparable to nontreated control levels.
 In the submandibular gland, blood vessel density (Figure 3b) decreased after 
RT (P < 0.001). When HBOT was given after RT, blood vessel density was higher 
compared with RT alone at 10 weeks (threefold, P < 0.001). The effect of HBOT 
on blood vessel density on this time point was even higher when HBOT was given 
before RT (fivefold, P < 0.001). The same pattern was seen in the parotid gland, with 
the largest effect of HBOT on blood vessel density when it was given before RT (P < 
0.01).
 Staining for cleaved caspase-3 showed no significant effects of HBOT on the 
degree of apoptosis in irradiated submandibular glands (Figure 3c). Only at 10-week 
post- RT, HBOT given before RT showed significantly more apoptosis compared with 
when it was given after RT (P < 0.05).
Tongue
 No differences in proliferation of the basal layer of the tongue were seen (data 
not shown). In the muscle tissue, the level of proliferation (Figure 3d) decreased 
after RT (P < 0.01 at 2 and 6 weeks, P < 0.001 at 10 weeks). However, when HBOT 
was applied before or after RT, at 10 weeks after RT, proliferation values were higher 
(P < 0.01 for HBOT+RT) and were comparable to the non-treated groups.
Figure 3 (next page) Immunohistochemical analysis of the short-/medium-term effects of RT and HBOT. 
(a) Quantification of proliferating (Ki67-positive) cells in submandibular and parotid glands (mean + 
s.d.) and Ki67 immunostaining of submandibular gland tissue from different groups at 10 weeks (scale 
bar 200 μm). (b) Quantification of CD31-positive blood vessels in submandibular and parotid glands 
(mean + s.d.) and CD31 immunostaining of submandibular gland tissue from different groups at 10 
weeks (scale bar 100 μm). (c) Quantification of apoptotic (caspase-3-positive) cells in submandibular 
gland (mean + s.d.) and immunostaining of caspase-3-positive cells (scale bar left panel 100 μm, right 
panel 50 μm ). (d) Quantification of proliferating (Ki67-positive) cells in the muscle tissue of the tongue 
(mean + s.d.) and Ki67 immunostaining in this tissue from different groups at 10 weeks (scale bar 100 
μm). Within each time point of each graph, groups with different symbols (#, $ or o) are statistically 
different from each other. HBOT, hyperbaric oxygen therapy; RT, radiotherapy.
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Effects of HBOT in the long term
 In order to investigate whether the observed HBOTinduced short-/medium-term 
changes in the irradiated tissues could ultimately lead to better functionality, a 
subset of conditions were also analysed at 24-week post-RT.
Salivary glands
 Salivary flow rates decreased after RT, as was also seen in the 10-week experiment, 
and showed no sign of improvement during the time frame of our study, which 
confirms the chronicity of hyposalivation. HBOT given directly after RT did not 
increase salivary flow rates, and the administration of HBOT alone resulted in salivary 
flow rates comparable to controls (Figure 4a). HE and PAS stainings clearly showed 
the effect of radiation on the submandibular gland at 24-week post-RT (Figure 4b). 
The tissue was notably disorganised, with many enlarged nuclei, inflammatory cells 
and a striking decrease in acinar cells. The administration of HBOT did not influence 
overall morphology as seen in HE and PAS stainings (data not shown).
Figure 4 Long-term effects of RT and HBOT on salivary flow rates and overall morphology of the 
submandibular gland. (a) Salivary flow rates following pilocarpine injection expressed as μl min_1 
(mean + s.d.). Within each time point, groups with different symbols (# or $) are statistically different 
from each other. (b) Haematoxylin eosin (top panels) and periodic acid–Schiff stainings (bottom 
panels) of control (left panels) and RT-treated (right panels) submandibular gland tissue. Scale bars 
200 μm. HBOT; hyperbaric oxygen therapy, RT, radiotherapy.
)a(
)b(
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 Radiotherapy (RT) caused no difference in proliferation rate 24-week post-RT 
when compared with controls in both salivary glands (Figure 5a,b). HBOT did not 
affect proliferation rates of irradiated tissue, but remarkably, in the non-irradiated 
submandibular gland, proliferation was significantly reduced after HBOT compared 
with all other groups (P < 0.001, Figure 5a). Blood vessel density was increased when 
HBOT was given after RT in the parotid gland compared with non-irradiated tissues 
(P ≤ 0.001, Figure 5b). Apoptosis was only measured in submandibular glands and 
showed to be decreased in all groups compared with control (P = 0.01 for HBOT, P = 
0.001 for RT and P = 0.000 for RT+HBOT, Figure 5a).
Tongue
 As in the short-/medium-term experiment, no differences were seen in 
proliferation rates of the basal layer of the tongue mucosa (data not shown). The 
muscle tissue showed a significant five times increase in the amount of proliferating 
cells when irradiated tissue was compared with control tissue (P < 0.001, Figure 5c). 
HBOT significantly decreased this number (P < 0.01), whereas on healthy tissue, 
HBOT did not have an effect.
Figure 5 Immunohistochemical analysis of long-term effects of RT and HBOT. (a) Quantification of 
proliferation (left), blood vessel density (middle) and apoptosis (right) in submandibular gland tissue. 
(b) Quantification of proliferation (left) and blood vessel density (right) in parotid gland tissue. (c) 
Quantification of proliferation in tongue tissue. Within each graph, groups with different symbols (#, 
$ or o) are statistically different from each other. HBOT, hyperbaric oxygen therapy; RT, radiotherapy.
)a(
)b( )c(
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dISCUSSION
 Hyperbaric oxygen therapy (HBOT) is used to treat radiation-induced damage, 
based on the principle that increased oxygen tension in the damaged tissues will 
facilitate repair and regeneration. Still, controversy exists about the efficacy and 
exact working mechanism of this therapy17. Our study therefore focused on the 
ability of HBOT to prevent radiation-induced damage to head and neck tissues, 
namely salivary glands and tongue.
 Clinical studies have investigated the ability of HBOT to treat or prevent radiation-
induced damage to salivary glands by measuring salivary flow rates and/or patient-
scored xerostomia20-22. Despite the fact that some of these studies report a positive 
influence of HBOT on xerostomia complaints17, we do not find an effect of HBOT on 
salivary flow rate in our mouse model. However, most clinical studies only measured 
patient-scored xerostomia and did not objectively determine salivary flow rates. 
When both parameters are investigated, there is often no correlation between the 
two20. Possibly, other factors such as saliva composition contribute more to the dry 
mouth feeling than salivary flow rate.
 To our knowledge, there is only one animal study in which the effect of HBOT 
on irradiated salivary glands was investigated23. This study examined overall gland 
morphology, without measuring salivary flow rates. In our study, salivary flow rates 
declined after RT and were not stimulated by HBOT given either before or after RT. 
The decrease in salivary flow rate preceded histological changes as flow rate dropped 
already with more than 50% at 6-week post-RT, whereas morphological changes 
were most dominantly present at 24-week post-RT. This dissociation between 
structural and functional changes after irradiation has been shown before24-27 and 
supports the theory that the acute drop in salivary flow results from damage to the 
membrane of acinar cells, whereas at later stages, acinar cell number decreases 
due to DNA damage.
 More profound effects of HBOT were seen when the salivary gland tissue was 
investigated immunohistochemically. Proliferation markedly increased by HBOT 
given before or after RT, in both the submandibular gland and the parotid gland. 
Increased proliferation in response to HBOT has been observed in other tissues15, 28-30. 
In these studies often only short-term effects are addressed, whereas we show that 
in slowly dividing submandibular gland tissue, proliferation was elevated by HBOT 
at 10-week post-RT to levels comparable to non-treated controls. Proliferation was 
dominantly seen in the acinar cells, which are differentiated cells that have retained 
the ability to replicate. No increased proliferation was observed in the intercalated 
ducts where the stem cells reside31. This suggests an effect of HBOT on normal 
homeostasis mechanisms, which eventually could lead to improved regeneration of 
the salivary gland after RT. 
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 Blood vessel density in irradiated salivary glands was higher after HBOT at 10-
week post-RT, which suggests a protective effect of HBOT on radiation-induced 
blood vessel loss, or a stimulatory effect on angiogenesis in the medium term. The 
angiogenic potential of HBOT has been proposed before13-15, 30, 32, 33.
 Remarkably, in the muscle tissue of the tongue, proliferation was increased at 
24 weeks in the RT group, whereas RT+HBOT proliferation levels were significantly 
lower. This long-term effect has not been reported before, and the consequences 
could have interesting implications. As has been shown in other tissues34, 35, higher 
proliferation rates may be the result of an increased rigidity in the extracellular 
matrix, a well-known phenomenon associated with radiation injury. The lower 
proliferation levels observed after HBOT could indicate that tissue rigidity is reduced 
and that HBOT thus might have a positive effect on side effects of radiation injury 
such as trismus or dysphagia. Some clinical studies indeed mention positive effects 
of HBOT on swallowing21, 36, but further research will be needed to elucidate this 
possible mechanism of action.
 The use of HBOT either before or directly after RT gave comparable patterns 
of response regarding proliferation in the short-/medium-term experiment. The 
stronger effect of HBOT given before RT on blood vessel density could be due to 
the fact that angiogenesis is already triggered in the healthy tissue before radiation 
exerts its effects. Apoptosis was higher when HBOT was given before RT compared 
with when it was given after RT at 10 weeks. Different studies describe the effect of 
HBOT on apoptosis in various tissues; both induction and attenuation of apoptosis 
in the short term have been reported, while the long-term effect is often not 
considered37-39. As salivary flow rates were not affected by HBOT either given before 
or after RT, this study is not conclusive on the preferable timing of HBOT. On the 
basis of our results in the short/medium term, and the fact that HBOT application 
after RT approaches the clinical situation more closely, only the HBOT after RT group 
was used in the long-term experiment. Also, caution should be taken when giving 
HBOT before RT in patients, as the effects of HBOT on tumour tissue are not yet fully 
known. Some studies claim that HBOT does not promote growth or recurrence of 
tumours40, 41, whereas tumour growth after HBOT has also been reported42.
 Hyperbaric oxygen therapy (HBOT) did affect irradiated salivary gland tissue at 
the cellular level, in terms of proliferation and blood vessel density. However, in our 
model, these changes did not result in an increased salivary flow rate. The radiation 
dose of 15 Gy used in our mouse model has been used in various animal studies 
and has proven to cause significant gland impairment43-47. Clinically, fractionated 
radiation schemes are used with fractions of maximal 2 Gy day-1 with a cumulative 
dose of 24–26 Gy48, while most animal studies use single-dose radiation for practical 
and ethical reasons. The single dose of 15 Gy used in our study is biologically 
equivalent to a clinically relevant scheme of 16 fractions of 2 Gy; however, Coppes 
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et al49 showed higher radiosensitivity of the submandibular gland for the late effects 
after fractionated irradiation compared with single-dose irradiation. Possibly, our 
radiation dose was too high for the translation of the cellular effects of HBOT into 
functional differences.
 In the current experimental study, it appeared that HBOT stimulates the viability 
of radiation-injured tissues, by an enhanced protection and/or a stimulation of the 
regeneration process. A better understanding of the cellular changes that take place 
after HBOT in different tissues may contribute to an improved implementation of 
the therapy in humans.
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ABSTRACT
Background: This study focuses on the potential of ReGeneraTing Agent OTR4120 
(RGTA-OTR4120) to treat radiation-induced damage of salivary glands. RGTAs are 
biopolymers designed to mimic the effects of heparan sulphate, thereby stimulation 
tissue repair and regeneration.
Methods: C3H mice were irradiated with a single dose of 15 Gy in the head and 
neck region. RGTA-OTR4120 was injected 24 h after radiotherapy, followed by 
weekly injections. At 2, 6 and 10 weeks after radiotherapy, salivary flow rates were 
measured and animals were sacrificed to obtain parotid and submandibular glands 
for histology. Periodic acid Schiff stain was performed to visualize mucins that are 
produced by acinar cells. Amylase and total protein content were measured in 
saliva samples.
Results: Salivary flow rates were increased at 2 weeks, but not at 6 and 10 weeks 
after radiotherapy with RGTAOTR4120 administration, compared to irradiated 
controls. Two and 10 weeks after radiotherapy, the mucin production activity of 
acinar cells was increased under influence of RGTA administration. RGTA-OTR4120 
did not influence amylase or total protein secretion.
Conclusion: RGTA-OTR4120 administration has a positive effect on salivary flow 
rates in irradiated mice on the short term. The effect was absent 10 weeks after 
radiotherapy, while at that time point, mucin producing activity of acinar cells was 
elevated by RGTA-OTR4120 administration. Given these results and the advantages 
of RGTA use in irradiated patients, further investigation on the potential of this drug 
to treat radiation-induced salivary gland damage, alone or in combination with 
other drugs, such as amifostine, is suggested.
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INTROdUCTION
 Radiotherapy is an important treatment modality for patients with head and 
neck tumours. It uses high energy radiation to kill cancer cells by damaging their 
DNA, either directly or indirectly by the creation of free radicals. Unfortunately, 
healthy tissues surrounding the tumour are also affected. In the head and neck 
region, salivary glands are prone to experience such unwanted side-effects. In 
recent years, administration forms of radiotherapy have been improved in order 
to minimize damage to surrounding tissues, examples of which are intensity 
modulated radiation radiotherapy, hyperfractionated radiotherapy and accelerated 
fractionated radiotherapy1. However, because of the close proximity of the salivary 
glands to the treatment field, patients still suffer from significant side-effects. Due 
to radiation, the composition and amount of saliva changes, which often leads to 
xerostomia, a situation in which patients subjectively complain about a dry mouth2. 
This has negative effects on the quality of life of patients as they suffer from trouble 
with speech, mastication, swallowing, an impairment of taste and disturbed sleep 
patterns3-5. The problems tend to be life-long, with little or no improvement despite 
current treatments, which include the stimulation of the residual secretory capacity 
of the glands by sialogogues and the administration of salivary replacements2. 
However, these treatment modalities have considerable side-effects and, at 
maximum, may only partly improve patient’s salivary condition. 
 Consequently, the need for therapies that can prevent or treat the damage to 
salivary glands caused by radiotherapy is apparent. Amifostine is the only currently 
available preventive therapy and is based on the free radical scavenging properties 
of the drug. Side-effects include hypotension, vomiting and allergic reactions6, 
further indicating the necessity for new therapies. 
 This study focuses on the potential of ReGeneraTing Agent OTR4120 (RGTA-
OTR4120) to treat radiation-induced damage of the salivary glands. RGTAs are 
biopolymers engineered to mimic heparan sulphate, stimulating tissue repair 
and regeneration7. Heparan sulphate is present in the extracellular matrix (ECM) 
and binds heparan-binding growth factors (HBGFs). These factors, which include 
fibroblast growth factors-1 and -2 and vascular endothelial growth factor (VEGF), are 
important in tissue regeneration8. However, in injury, heparan sulphate is degraded 
and loses its ability to bind growth factors. RGTAs can take over the task of heparan 
sulphate, enhancing the bioavailability of HBGFs and promoting tissue repair. This 
has been shown in various experimental models including bone9, muscle10, 11, skin12, 
13 and mucosa14, 15. 
 We examined the effects of weekly RGTA-OTR4120 administration on salivary 
flow rate, saliva composition and salivary gland histology in mice irradiated in the 
head and neck region, for up to 10 weeks following radiotherapy.
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MATERIALS ANd METHOdS
Animals
 Fifty-two female C3H mice, 7–9 weeks old at the time of experimentation, were 
purchased from Harlan (Harlan Netherlands BV, Horst, The Netherlands) and were 
kept under standard housing conditions with free access to food pellets and acidified 
water. They were allowed to acclimatize for at least 1 week before experimentation 
started. Mice were randomly divided into the following groups: (A) control (n = 
7), (B) radiotherapy only (n = 21) and (C) radiotherapy with RGTA administration 
(n = 21). At 2, 6 and 10 weeks after radiotherapy, mice were sacrificed by CO2-
asphyxiation (n = 7 for each time point). Animals were weighed frequently, and after 
irradiation, food pellets were crushed and mixed with water daily to allow sufficient 
food intake. A normal control-group of three mice was used to measure the effect 
of weekly administration of RGTA alone on the salivary flow rate of healthy (non-
irradiated) mice after 2, 6 and 10 weeks of treatment. The experimental protocol was 
approved by the Animal Experiments Committee under the national Experiments 
on Animals Act and adhered to the rules laid down in this national law that serves 
the implementation of ‘Guidelines on the protection of experimental animals’ by 
the Council of Europe (1986), Directive 86 ⁄ 609 ⁄ EC.
Irradiation
 The mice were anesthetized intraperitoneally (i.p.) with a mixture of ketamine 
and xylazine (120 and 6 kg⁄g body weight, respectively). The head and neck region 
was locally irradiated with a single dose of 15 Gy by a 250 kV orthovoltage irradiator 
(Philips RT250) using a Cu filter and a dose rate of 1.9 Gy⁄min. The rest of the body 
was shielded by a 0.5 cm lead plate.
RGTA administration
 The heparan mimetic RGTA-OTR4120 was obtained from the Tissue Repair 
Laboratory (OTR3, Paris, France) and prepared as previously described (12). RGTA-
OTR4120, with a concentration of 0.1 mg⁄ml in sterile physiological salt solution 
(B. BraunMelsungen AG, Germany), was administered i.p. (1 kg⁄g body weight) 
24 h after radiotherapy, followed by weekly injections during the course of the 
experiment.
Saliva collection
 Whole saliva was collected before animals were sacrificed. Mice were injected i.p. 
with pilocarpine (2 kg⁄g body weight). Animals were manually fixed and saliva was 
collected for 10 min, starting 2 min after pilocarpine injection. Saliva waspipetted 
directly from the mouth and collected in pre-weighed Eppendorf tubes. Saliva 
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volume was determined gravimetrically, assuming a density of 1 g⁄ml of saliva16, 
and flow rates (µl⁄min⁄100 g body weight) were calculated.
Biochemical analysis
 After collection, saliva samples were diluted 10 times and 100 times with 
demineralised water for total protein and amylase measurements, respectively. 
Samples were then stored at 80˚C until analysis. Total protein and amylase activity 
were measured using a Roche Modular P800 and two different assays that were 
executed fully automatically (Roche Diagnostics, Mannheim, Germany). In the total 
protein assay, samples were preincubated in an alkaline solution containing EDTA, 
which denatures protein. Benzethonium chloride, which reacts with protein, was 
then added to produce a turbidity that was read at 505 nm. Values were expressed as 
g⁄l. The principle of the assay for amylase activity is that the a-amylase in the sample 
cleaves 4,6-ethylidene-(G7)- 1,4-notrophenyl-(G1)-a,D-maltoheptaoside and the 
degradation products are subsequently hydrolyzed to p-nitrophenol (PNP) with the 
aid of a-glucosidase. The colour intensity of PNP is measured photometrically and is 
directly proportional to the a-amylase activity expressed as U⁄l.
Histology
 Immediately after sacrifice, parotid and submandibular glands were excised and 
stored in 10% buffered formalin for 36 h. Tissues were then dehydrated, embedded 
in paraffin blocks and 5 µm slides were cut. One slide per animal was used for 
Periodic Acid Schiff (PAS) staining, which detects mucins. In short, slides were 
rehydrated, quenched in 0.5% periodic acid solution for 5 min, followed by 15 min 
in Schiff’s reagent, before dehydration and embedding with Permount. Slides were 
scanned and the entire glands were then analyzed with Celld Imaging Software for 
Life Science Microscopy (Olympus Life Science Europe GmbH, Hamburg, Germany). 
For the first slide, the purple PAS staining was manually selected and automatically 
assigned an accompanying Red Green Blue-value that was subsequently used for all 
slides. The total area that contained this RGB-value (which represents positive PAS 
staining) was calculated by the program. In this way acinar staining was expressed 
as a percentage of the total acinar area.
Statistical analysis
 Data are expressed as mean values ± standard error of the mean (SEM), and were 
analyzed using SPSS PASW RGTA-effects on irradiated murine salivary glands 17.0 
for Windows (SPSS Inc., Chicago, IL, USA). The Student’s t-test was used to identify 
significant differences (P < 0.05).
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RESULTS
Salivary flow rate
 A single dose of 15 Gy irradiation of the head and neck region caused a decrease 
in salivary flow rate compared to controls, which is statistically significant at 6 and 
10 weeks after radiotherapy (Fig. 1; P < 0.05 at 6 weeks, P < 0.01 at 10 weeks). The 
administration of RGTA-OTR4120 to irradiated mice caused an increased flow rate 
at 2 weeks compared to the radiation only group (P < 0.01). This increased flow rate 
was comparable to that of the non-irradiated control. Furthermore, no drug-alone 
effect on salivary flow rates was seen when RGTA-OTR4120 was administrated to 
healthy controls (data not shown).
Figure 1 Salivary flow rates expressed as µl⁄min⁄100 g body weight (mean ± SEM). RT, radiotherapy. 
*Statistical difference of P < 0.05; #statistical difference of P < 0.01.
Histology
 The PAS staining was used to identify mucins which are produced in acinar cells. 
Figure 2 shows examples of this staining in the submandibular gland. Control tissue 
(Fig. 2A and B) is compared with tissue that has been irradiated 10 weeks earlier, 
with (Fig. 2E and F) or without (Fig. 2C and D) the weekly administration of RGTA-
OTR4120. The amount of staining, expressed as the percentage of PAS-positive area, 
was quantified (Fig. 3A and B for submandibular- and parotid gland, respectively). 
Radiotherapy caused a significant decrease of this percentage at all time-points (P 
< 0.05 at 2 and 6 weeks, P < 0.01 at 10 weeks). At 2 and 10 weeks after radiation, 
RGTA-OTR4120 administration increased the percentage of functionally active 
acinar cells significantly, towards a value comparable to non-irradiated controls (P < 
0.01).
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Figure 2 PAS staining in submandibular tissue. (A, B) Control; (C, D) 10 weeks after 15 Gy single dose 
irradiation; (E, F) 10 weeks after 15 Gy single dose irradiation with weekly administration of RGTA-
OTR4120 (i.p., 1 µg⁄g body weight). A, C and E give an overview (scale bar 200 µm). Enlargements 
are shown in B, D and F (scale bar 50 µm). Control (A, B) and RGTA-treated (E, F) groups gave a strong 
purple staining of mucins, while in the radiated group (C, D) this staining was almost absent.
Biochemical analysis
 Amylase and total protein secretion are expressed in Fig. 4A and B, respectively. 
The amount of amylase and total protein which was measured in saliva samples was 
multiplied by the salivary flow rate to generate the actual secretion. Both amylase 
and total protein secretion decreased in response to radiation. For amylase, this 
decrease was significant at 10 weeks after irradiation (P < 0.01), and for total protein 
at all time-points (P < 0.01 at 2 and 10 weeks, P < 0.05 at 6 weeks). RGTA-OTR4120 
did not induce any significant differences.
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dISCUSSION
 Radiotherapy in the head and neck region causes damage to healthy surrounding 
tissue, of which especially the salivary glands are at risk. Damage to these glands 
can result in chronic hyposalivation, a condition that greatly affects quality of life 
with no treatment currently available. In this study we investigated the effects of 
RGTA-OTR4120, a heparan mimetic, on radiation-induced salivary gland dysfunction 
in a mouse model. Mice were irradiated by a single dose of 15 Gy in the head and 
neck region, a dose biologically equivalent to the clinically relevant fractionation 
dose of 16 Gy x 2 Gy17, 18, used in various animal studies19-23 and proven to cause 
significant gland impairment24-26. Chronic radiation damage to salivary glands in 
rodents is fully developed within 60–90 days after therapy25, 27. Our endpoints of 
2, 6 and 10 weeks after radiotherapy, therefore, give insight on the progress of the 
effects of RGTA-OTR4120 up until the chronic phase of radiation injury. 
 For histology we used the two major salivary glands, the parotid and submandibular 
gland, and determined the presence of mucins, that are produced by acinar cells, by 
using the PAS staining. Parotid glands produce the majority of saliva in the stimulated 
Figure 3 Percentage of PAS positive area of the 
total acinar area in the submandibular gland 
(A) and the parotid gland (B) (mean ± SEM). RT, 
radiotherapy. * Statistical difference of P<0.05; # 
statistical difference of P<0.01.
Figure 4 Amylase (A) and total protein (B) secretion 
(mean ± SEM). RT, radiotherapy. * Statistical 
difference of P<0.05; # statistical difference of 
P<0.01.
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state, whereas submandibular glands produce more than two-thirds of the saliva in 
the unstimulated state1, 28. Both glands showed a similar response to radiotherapy 
and to the administration of RGTA-OTR4120 as determined by the PAS staining. This 
is in line with the study of Konings et al29, that described a similar course of damage 
development for parotid and submandibular glands, consisting of an acute phase 
where water excretion is impaired while there is no cell loss and amylase secretion 
is not affected, followed by a reduction in acinar cells and amylase secretion, and 
finally the period of late radiation damage which is marked by a lack of functional 
acinar cells and a further drop in amylase secretion. 
 The reduction in the mucin production by acinar cells after radiotherapy was 
somewhat more prominent in the parotid gland, but both the pattern of radiation 
damage and the scale of the effect following RGTA-OTR4120 administration were the 
same for both glands. The fact that the parotid gland seems to be more vulnerable 
to irradiation is not surprising since parotid glands consist of mainly serous cells, 
which have generally been found to be more radiosensitive than mucous cells30, 31, 
whereas the submandibular gland consists of both serous and mucous cells. Animal 
experiments in which the whole head is irradiated confirm the higher sensitivity 
of the parotid gland27, 32. However, after more localized irradiation to salivary 
glands, this effect was not observed in various other studies33-35. Also, Coppes et 
al17 concluded that, for the late effects, the submandibular gland may even be more 
radiosensitive than the parotid gland when fractionated irradiation is used. Taken 
together, both glands should be carefully considered when examining radiation-
induced damage.
 Salivary flow rates were reduced after radiotherapy, which is in accordance 
with various other studies, reviewed by Grundmann et al1. The magnitude of 
the reduction was less than is seen in other studies, which can be explained by 
differences in saliva collection, type of saliva stimulant and dose17, 20, 24, 36, 37. Still, at 
6 and 10 weeks after radiotherapy there was a significant reduction in salivary flow 
rate. The positive effect of RGTA-OTR4120 administration on salivary flow rate faded 
in time and at 6 and 10 weeks, no significant effect was detectable. This suggests a 
temporary effect of RGTA-OTR4120 administration. Strikingly, the mucin production 
of acinar cells was significantly higher in the RGTA-treated group compared to 
irradiated controls at 10 weeks after radiotherapy. This indicates a positive effect 
of RGTA-OTR4120 administration on the number of saliva-producing acinar cells, 
which was not reflected in the salivary flow rate. In that case, not all acinar cells 
contribute equally to salivary production. This dissociation between structural 
changes observed after radiotherapy and functional changes in salivary output has 
been described earlier36, 38, 39. Furthermore, the loss of cells can affect the function 
of surrounding cells. Factors that are secreted in the process of activating a cell 
death program could create an adverse environment40. 
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 To assess the quality of the saliva we measured amylase and total protein content. 
Amylase is an enzyme that has multiple functions. Besides its enzymatic activity, it 
coats oral tissues, binds to streptococci and is involved in the selective clearance 
and adherence of microorganisms41. Amylase activity is found to be reduced after 
radiotherapy31, 41, 42, a finding that is confirmed by our results. The administration 
of RGTA-OTR4120 did not have a stimulatory effect on amylase activity. Total 
protein content was also not altered significantly by RGTA-OTR4120 administration. 
The increase in activity of acinar cells 2 and 10 weeks after radiotherapy did not 
lead to an increase in the secretion of either amylase or total protein secretion. 
A possible explanation could be that the acinar cells cannot function properly, 
due to intracellular damage or to an unfavourable environment (e.g. damage to 
ducts, blood vessels) 33. Studies that measure salivary flow rate, as well as amylase 
and total protein after irradiation are scarce. Sumita et al43 concluded that bone 
marrow-derived cells can rescue salivary gland function in mice after head and 
neck irradiation. Salivary flow rate is indeed protected, but there was no difference 
in total protein concentration. Coppes et al33 focused on the use of adrenergic 
and muscarinic receptor agonists and found positive effects on saliva quality and 
quantity. However, they stated in their discussion that the concentration necessary 
to exert the effect cannot be used clinically.
 Growth factors have also been the subject of research in several studies that aim 
to protect tissues from radiation-induced damage21, 36, 44, 45. The way to deliver the 
potentially radioprotectant growth factors locally to the site of radiation damage 
forms an obstacle. The local delivery is important in order to avoid protection of 
cancer cells and because growth factors have a very short in vivo half-life45. The 
advantage of the use of RGTAs is that they are only bound at the site of injury, even 
when administered systemically, because they will bind to free heparan sulphate 
binding sites that are only available at sites of tissue damage where proteases have 
degraded the existing heparan sulphates. Additionally, they have a long in vivo half-
life and cannot be degraded by heparanases7, 15, 46. Mangoni et al14 stated that RGTA 
administration is most effective in protecting radiation-induced mucositis in rats 
when administered after the completion of radiotherapy.
 To our knowledge the effect of RGTA administration on radiation-induced damage 
on the long term has not been studied yet. The results of studies in other fields 
of tissue repair and regeneration, and the fairly simple administration, with little 
or no side effects known, make RGTAs plausible candidates as radioprotectants. 
Our study showed a short term protective effect of RGTA administration on salivary 
gland dysfunction, while results on the longer term are mixed, making it necessary 
to further investigate the action of RGTA administration in irradiated tissues.
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ABSTRACT
A side effect of radiation therapy in the head and neck region is injury to 
surrounding healthy tissues such as irreversible impaired function of the salivary 
glands. Hyperbaric oxygen therapy (HBOT) is clinically used to treat radiation-
induced damage but its mechanism of action is largely unknown. In this study, we 
investigated the molecular pathways that are affected by HBOT in mouse salivary 
glands two weeks after radiation therapy by microarray analysis. Interestingly, 
HBOT led to significant attenuation of the radiation-induced expression of a set of 
genes and upstream regulators that are involved in processes such as fibrosis and 
tissue regeneration. Our data suggest that the TGFβ-pathway, which is involved in 
radiation-induced fibrosis and chronic loss of function after radiation therapy, is 
affected by HBOT. On the longer term, HBOT reduced the expression of the fibrosis-
associated factor α-smooth muscle actin in irradiated salivary glands. This study 
highlights the potential of HBOT to inhibit the TGFβ-pathway in irradiated salivary 
glands and to restrain consequential radiation induced tissue injury.
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INTROdUCTION
 Treatment of head and neck cancer routinely involves radiation therapy (RT), 
which not only affects tumor tissue, but also the surrounding healthy tissues. 
Because of their position, salivary glands are often in the radiation portal. 
Radiation-induced damage to salivary glands is irreversible and results in chronic 
hyposalivation and a change in saliva composition, leading to a subjective feeling of 
a dry mouth called xerostomia which greatly affects quality of life. Despite salivary 
gland sparing techniques such as intensity modulated radiation therapy (IMRT), the 
surgical transfer of major salivary glands outside the radiation field and the use of 
cytoprotectants, xerostomia remains a significant problem after radiotherapeutic 
treatment of malignancies in the head and neck area1.
 Unlike other slowly dividing tissues, salivary glands respond acutely to radiation 
treatment. Whereas acinar cell number remains unaltered, salivary flow rates drop 
dramatically at early time points after RT (~0–10 d). It has been proposed that this 
is due to radiation-induceddamage to the plasma membranes, since no cell loss 
is visible yet2, 3. In the chronic stage of radiation damage (~120–240 d), a lack of 
functional acinar cells and replacement by connective tissue and fibrosis causes the 
diminished salivary flow4. In this phase, some generation of acinar cells does take 
place, but it is suggested that the new cells cannot function properly due to damage 
of ducts, blood vessels and nerves5.
 Hyperbaric oxygen therapy (HBOT), in which patients breathe 100% oxygen under 
elevated pressure, has been used for almost 40 years to treat radiation injuries. 
Increased oxygen concentration in combination with elevated pressure raises tissue 
oxygen tension up to ten times. As oxygen under pressure is dissolved in plasma, it 
can reach otherwise hypoxic areas with obstructed blood flow, like radiation-injured 
tissues. In the case of the prevention or treatment of xerostomia, some clinical trials 
report positive effects of HBOT6-8, mostly measured by quality of life questionnaires. 
Experimental evidence on the beneficial effects of HBOT on irradiated salivary 
glands is however scarce9. In a previous study we showed an increased blood vessel 
density in irradiated mouse salivary glands in response to HBOT10. In other tissues 
and cells, it has been shown that vascular endothelial growth factor (VEGF) levels 
can rise in response to HBOT11, 12, and angiogenesis can be promoted13, 14. Besides 
influencing angiogenesis, oxygen also is involved in other key processes associated 
with wound healing, such as modulating cytokine release, accelerating microbial 
oxidative killing, modulating leukocyte activation and adhesion, and reducing 
apoptosis15. The effects of HBOT on gene expression have been analyzed in vitro 
in neurons, osteoblasts and endothelial cells, maximally 24 h after a single HBO 
treatment16-18. In all three cell types, an upregulation of the oxidative stress response 
was reported. In an in vivo model of rat ischemic brain, genes of the neurotrophin 
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system and inflammatory immune response were affected after five consecutive 
HBO treatments19. In patients with nonhealing wounds, an upregulation of genes 
involved in extracellular matrix remodelling and angiogenesis was reported after 
HBOT19, 20.
 Thus far, the effects of HBOT on gene  expression in irradiated tissues have not been 
studied in an in vivo model. In this study, we explore the molecular pathways that 
are influenced by HBOT in irradiated salivary glands of mice by means of microarray 
analysis. By understanding basic HBOT mechanisms, the clinical implementation of 
HBOT for accepted indications can be improved.
MATERIALS ANd METHOdS
Animals
 Female C3H mice, 7–9 wks old, were treated with radiotherapy (RT) and/
or hyperbaric oxygen therapy (HBOT) as described before10. The experimental 
protocol was approved by the Animal Care Committee of Erasmus MC, Rotterdam, 
the Netherlands (protocol IDs 133-08-09 and 133-11-04), under the national 
Experiments on Animals Act and adhered to the rules laid down in this national law 
that serves the implementation of the guidelines on the protection of experimental 
animals from the Council of Europe (1986), Directive 86/609/EEC21.
Radiation Therapy (RT)
 Radiation therapy was performed as described previously10. In short, mice were 
anesthetized intraperitoneally with a mixture of ketamine and xylazine (120 mg/kg 
and 6 mg/kg body weight, respectively) and irradiated locally in the head and neck 
area with a single dose of 15 Gy by a 250 kV orthovoltage irradiator (Philips RT250) 
using a Cu filter and a dose rate of 1.9 Gy/min (Philips Medical Systems, Brussels, 
Belgium). The rest of the body was shielded by a 0.5-cm lead plate.
Hyperbaric Oxygen Therapy
 Hyperbaric oxygen therapy was performed in a custom-built hyperbaric 
oxygen chamber for small laboratory animals (Hytech BV, Raamsdonksveer, the 
Netherlands)22. HBOT was given once a day for five consecutive days a week, with a 
maximum of 20 sessions. Each session consisted of compression to 2.4 atmospheres 
absolute (ATA) and 100% oxygen during 30 min, isopression for 60 min, in which 
pressure and oxygen levels were kept constant and decompression to 1 ATA during 
15 min. For animals that were treated with RT, HBOT started the day after.
RNA Isolation
 Mice were euthanized by CO2- asphyxiation and submandibular salivary glands 
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were removed, snap frozen in liquid nitrogen and stored at –80°C until total RNA 
isolation was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions.
Microarray Analysis
 Microarray analysis was performed on RNA samples of submandibular glands 
of untreated mice (control), mice treated with 10 sessions of HBOT (HBOT), mice 
treated with RT at 2 wks after RT (RT) and mice treated with RT and HBOT at 2 
wks after RT (RT + HBOT; n = 4 for each group). Assessment of total RNA quality 
and purity was performed with the RNA 6000 Nano assay on the Agilent 2100 
bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). cDNA was synthesized from 
total RNA using the IVT Express Labeling kit (Affymetrix, Santa Clara, CA, USA). 
Subsequent biotin- labelled cRNA synthesis, purification and fragmentation were 
performed according to the manufacturer’s recommendations. A total of 12.5 
μg fragmented biotinylated cRNA was subsequently hybridized onto Affymetrix 
Mouse Genome 430 2.0 Array chips. Image analysis was performed using GeneChip 
Operating Software with the Affymetrix GeneChip Scanner 3000 according to 
the manufacturer’s protocol. Microarray Suite software (Affymetrix) was used to 
generate .dat and .cel files. To examine the quality of the various arrays, several R 
packages (including affyQCreport23) were run starting from the .cel files. All created 
plots, including the percentage of present calls, RNA degradation, NUSE and RLE 
indicated a high quality of all samples and an overall comparability. Raw intensity 
values of all samples were normalized by RMA normalization (Robust Multichip 
Analysis) (background correction and quantile normalization) using Partek version 
6.4 (Partek Inc., St. Louis, MO, USA).
 The normalized datafile was transposed and imported into OmniViz version 
6.0.1 (BioWisdom Ltd., Cambridge, UK) for further analysis. For each probe set, the 
geometric mean of the hybridization intensity of all samples was calculated. The 
level of expression of each probe set was determined relative to this geometric 
mean and log2-transformed. The geometric mean of the hybridization signal 
of all samples was used to ascribe equal weight to gene expression levels with 
similar relative distances to the geometric mean. Differentially expressed genes 
were identified using statistical analysis of microarrays (SAM). Cutoff values for 
significantly expressed genes were a false discovery rate (FDR) of 0.1 or less and a 
fold change of ≥1.5.
Functional Annotation
 Functional annotation of the statistical analysis of microarrays results was done 
using Ingenuity Pathway Analysis (Ingenuity, Mountain View, CA, USA). The results 
are shown for biological processes, which are significantly (P < 0.05) enriched after 
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multiple testing.
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
 Total RNA from submandibular glands of four animals per experimental group 
was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA, USA). The resulting cDNA was amplified in 40 cycles (enzyme 
activation at 95°C for 20 s, denaturation at 95°C for 3 s, annealing/ extension at 
60°C for 30 s) with a Bio-Rad CFX 96 Real-Time Detection System (software version 
Bio-Rad CFX Manager 2.0) using Fast SYBR Green Master Mix (Applied Biosystems, 
Life Technologies Europe BV, Bleiswijk, the Netherlands) and primers for: α smooth 
muscle actin (α-Sma), B-cell translocation gene 2 (Btg2), Cd83 antigen (Cd83), 
connective tissue growth factor (Ctgf/Ccn2), cysteine rich protein 61 (Cyr61/Ccn1), 
early growth response 1 and 2 (Egr1 and Egr2), glyceraldehyde-3- phosphate 
dehydrogenase (Gapdh), serpin peptidase inhibitor, calde E, member 1 (Serpine1/
Pai1), SRY-box containing gene 2 (Sox2), transferring receptor (Tfrc), transforming 
growth factor β 1 (Tgfβ1) and thrombospondin 1 (Thbs1). For primer sequences 
see Supplementary Table S1). Each PCR reaction was performed in duplicate and 
the average threshold cycle (Ct) value was used for relative quantification of gene 
expression compared with the housekeeping gene Gapdh, with the comparative Ct 
method (ΔΔCT).
(Immuno-)Histochemistry
 Immediately after euthanization, submandibular glands were excised and stored 
in 10% buffered formalin for 24 to 36 h. Tissues were then dehydrated, embedded 
in paraffin blocks and 5-μm slides were cut. Standard hematoxylin and eosin (H&E) 
and picrosirius red stainings were performed to visualize fibrosis and collagen 
content. For the detection of TGFβ1, Serpine1 and α-SMA, sections blocked with 
5% nonfat milk powder and then probed with a primary antibody against TGFβ1 
(1:50, Santa Cruz Biotechnology Inc, Dallas, USA), Serpine1 or α-SMA (1:100, 
Novus Biologicals Ltd., Cambridge, UK) overnight at 4°C. Biotinylated goat anti-
rabbit IgG (Dako, Carpinteria, CA, USA) was used as secondary antibody (30 min 
at room temperature). Detection of the antibody complex was performed with 
streptavidin–peroxidase (R&D Systems, Oxon, UK) and 3,3′- diaminobenzidine 
(Dako). Hematoxylin served as counterstain.
Quantification
 Slides stained for α-SMA were scanned using a slide scanner (Hamamatsu 
Photonics KK, Japan). A representative 10× magnified picture was taken for each 
gland and α-SMA staining was analysed by Celld (Olympus Life Science Europe 
GmbH) to detect the percentage of α-SMA positive staining.
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Statistical Analysis
 All data are expressed as mean values with standard deviation (SD), and were 
analyzed using SPSS PASW 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Univariate 
tests with post hoc Bonferroni correction were used to identify statistical differences 
(P < 0.05) between groups.
RESULTS
Gene Expression Analysis of Submandibular Glands
 To investigate the effect of hyperbaric oxygen therapy on molecular pathways 
in irradiated and nonirradiated salivary glands, gene expression analysis was 
performed on submandibular salivary glands of control mice, irradiated mice two 
weeks after radiotherapy (RT), mice treated with daily hyperbaric oxygen therapy for 
two weeks (HBOT) and irradiated mice treated with hyperbaric oxygen therapy for 
two weeks (RT + HBOT) (n = 4/group). Principal component analysis (PCA) indicates 
a clear clustering of groups, with samples of both irradiated groups closest to each 
other (Figure 1A).
Figure 1 Summary of microarray data by PCA and Venn diagrams. (A) PCA-mapped scatter plot. The 
global gene expression profiles of the submandibular glands for different treatment groups and 
control analyzed by PCA. The figure represents the first three principal components of microarray 
analysis data (PC1, PC2 and PC3) in x, y and z axes, respectively. (B) Venn diagram that represents the 
number of differentially expressed Affymetrix probe sets in RT versus control (red circle), HBOT versus 
control (green circle) and RT + HBOT versus RT (black circle), with the number overlapping probe sets 
inside the circles.
Differentially expressed probe sets were identified in salivary glands of all 
experimental groups using statistical analysis of microarrays (SAM, ≥ 1.5-fold 
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change, FDR 0.1). Treatment with RT or HBOT resulted in a change in expression 
levels of 613 probe sets and 872 probe sets, respectively. Treatment of irradiated 
glands with HBOT led to the identification of 124 differentially expressed probe 
sets, of which 84 were unique to this group (Figure 1B), indicating that HBOT has 
a different effect on irradiated and healthy glands. The lists of significantly up- and 
downregulated genes of the different groups are shown in Supplementary Tables 
S2–S5. These sets of up- and downregulated genes were used for further functional 
annotation of pathways and functional categorization using Ingenuity Pathway 
Analysis (IPA). The canonical pathways that were affected by RT were anticipated for 
on the basis of existing knowledge and included the P53 and ATM signaling, NRF2-
mediated oxidative response and the acute phase response. Table 1 shows cellular 
and physiological functions that are most significantly influenced by RT, HBOT or RT 
+ HBOT.
Table 1  Cellular and physiological functions.a
aCellular and physiological functions that are affected by RT, HBOT  and RT+HBOT, divided into 
categories. z Scores of <2 (inhibition) or >2 (activation) are considered statistically significant..
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 Irradiated salivary glands of the groups with and without HBOT showed clear 
differential expression of genes that enhance survival, cell proliferation and 
differentiation of connective tissue cells. Strikingly, apoptosis was reduced and cell 
survival enhanced. HBOT resulted in a change in a remarkable number of functions 
associated with the immune response and inflammation in the salivary glands of 
nonirradiated mice. No such strong immunological response of HBOT was detected 
in the irradiated tissue. 
 To elaborate on the influence of HBOT on irradiated tissues, the expression levels 
of the differentially expressed genes of the RT + HBOT versus the RT group were 
analysed by treescape and revealed a group of genes that was upregulated after RT, 
but significantly downregulated if HBOT was applied after RT (Figure 2). This group 
consisted mostly of immediate early response genes like Fos, Jun and members of 
the Egr and Ier family, indicating that HBOT can prevent or inhibit the radiation- 
induced expression of these genes.
Figure 2 Differentially expressed probe 
sets between the RT– and RT + HBOT 
group. OmniViz treescape showing the 
hierarchical clustering of differentially 
expressed Affymetrix probe sets between 
the submandibular glands of the RT 
and RT + HBOT group (middle groups). 
Expression of these probe sets for the 
control and HBOT-group is shown on the 
outside. Red indicates upregulated probe 
sets compared with the geometric mean 
and blue indicates downregulated probe 
sets compared with the geometric mean. 
The color intensity correlates with the 
degree of change. Rectangle shows probe 
sets that are upregulated in the RT group, 
while downregulated in the RT + HBOT 
group. Genes within this rectangle are 
summarized.
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By using the Ingenuity software, activation or inhibition of upstream regulators 
was predicted on the basis of upand downregulated genes in the dataset. In this 
way, regulatory cascades and biological activities occurring in the tissue were 
determined. Table 2 shows the list of RT-activated regulators that were significantly 
inhibited after HBOT treatment, a considerable amount of which are cytokines and 
growth factors known to play roles in radiation-induced processes such as fibrosis, 
apoptosis, tissue regeneration and inflammation.
Table 2 Upstream regulators.a
aUpstream regulators that were predicted to be activated by RT, and inhibited when HBOT was applied 
after RT, on the basis of the microarray data of the submandibular glands. z Scores of <2 (inhibition) or 
>2 (activation) are considered significant.
qPCR Validation
 On the basis of their expression profiles and putative roles in tissue repair, nine 
genes of interest were selected for qPCR-validation (Table 3). The first group consisted 
of genes that are linked to fibrosis and that were significantly downregulated by 
HBOT in irradiated salivary glands while upregulated by RT alone: Egr1, Egr2 and 
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Cyr61. Ctgf was included because of its direct link to fibrosis and the fact that it was 
less upregulated in irradiated glands after HBOT treatment as well.
Table 3 Genes of interest.a
aGenes of interest that were selected for qPCR validation with fold changes from the microarray.
 
 On the basis of their differential expression patterns, Btg2 (antiproliferative 
capacities), Sox2 (stem cell maintenance), Tfrc (control of cell proliferation and 
growth) and Thbs1 (negative regulation of regeneration and angiogenesis) were 
selected because of their putative roles in regeneration. In addition, Cd83 was 
included in the qPCR analysis as it is involved in the immune response and was 
affected considerably by HBOT according to the microarray analysis. By qPCR, 
differential expression was confirmed for all selected genes, although for Egr2 and 
Thbs1, the differences were not statistically significant (Figure 3).
7Chapter 7
102
Figure 3 qPCR validation of genes of interest. qPCR validation of microarray results for the expression 
of genes of interest at 2 wks after RT in the submandibular glands. y Axis shows mean fold change 
relative to controls. Lines above bars represent statistically significant differences (*P < 0.05, **P < 
0.01, ***P < 0.001).
TGFβ-Pathway
 Because of its known role in (radiation- induced) fibrosis, we further analysed 
the TGFβ-pathway in our dataset using IPA. The TGFβ1 regulator pathway was 
predicted to be activated in the RT group and to be inhibited if HBOT was applied 
after RT (see Table 2). Figure 4 shows an upregulation of a set of target genes of 
the canonical TGFβ1-pathway in the RT group compared with controls (Figure 4A), 
and an inhibition when HBOT was given to irradiated tissue (Figure 4B). Expression 
analysis of the Tgfβ1 gene and its effector gene Serpine1 by qPCR at 2 wks after 
RT was performed to confirm the inhibitory effect of HBOT on the TGFβ-pathway 
(Figure 4C). Both genes showed lower expression 2 wks after RT if HBOT had been 
applied. Immunohistochemical staining for TGFβ1 and Serpine1 also showed an RT-
induced upregulation that was partly counteracted by HBOT (Figure 4D).
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Figure 4 Influence of HBOT on the TGFβ-pathway. Differential expression of genes involved in the 
TGFβ-pathway in irradiated submandibular glands compared with control (A) and in irradiated glands 
that received HBOT compared with irradiated glands (B), by Ingenuity Pathway Analysis of microarray 
data. Colors show up- (red) and downregulated (green) genes (≥ 1.2-fold change, FDR 0.05). Notice 
the reverse expression of genes when HBOT is applied to irradiated glands. Continued on next page
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Figure 4 Continued qPCR validation (C) and immunohistochemical staining (D) of Tgfβ1 and Serpine1 
at 2 wks after RT. Scale bars left pictures 200 μm, right pictures 50 μm.
 The expression of α-SMA, which is a profibrotic factor expressed by myofibroblasts, 
but also by myoepithelial cells in the salivary gland, showed a similar pattern with 
higher expression in the RT-treated group at 2 and 10 wks after RT (Figure 5A). 
Immunohistochemistry showed a significantly higher expression in RT-treated 
glands at 24 wks after RT compared with irradiated glands that received HBOT 
(Figure 5B). Although expression analysis showed a potential inhibitory effect of 
HBOT on profibrotic markers, we were unable to identify major signs of fibrosis in 
H&E- and picrosirius red–stained tissue, at 2, 10 and 24 wks after RT.
C
d
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Figure 5 Expression of α smooth muscle actin. Relative expression (mean fold change relative to 
controls) of α smooth muscle actin (α-Sma) at 2, 10 and 24 wks after RT in the submandibular glands 
(A). Line above bars represents statistically significant difference (*P < 0.05). Immunohistochemical 
staining of α-SMA in submandibular glands of control and irradiated mice, either with hyperbaric 
oxygen therapy (RT + HBOT) or without (RT). Graph shows the percentage of positive α-SMA staining 
for the different groups (B). Line above bars represents statistically significant difference (**P < 0.01; P 
= 0.053 for RT versus control). Scale bars upper pictures 200 μm, lower pictures 50 μm.
dISCUSSION
 Radiation-induced damage to salivary glands is a serious, irreversible complication 
of RT to the head and neck region. Hyperbaric oxygen therapy is used in the 
treatment of radiation-induced injury to normal tissues in the head and neck region 
while its mechanism of action remains poorly understood. Especially, little is known 
about the molecular pathways that are influenced by HBOT on irradiated salivary 
glands. Therefore, we investigated the effects of radiotherapy and HBOT on gene 
expression in submandibular glands of mice, 2 wks after a single dose of 15 Gy and 
after 10 consecutive HBO treatments.
 As expected, RT resulted in the activation of pathways involved in cell cycle 
and DNA damage repair, such as the p53 pathway, the NRF2-mediated oxidative 
response and the acute phase response signaling. HBOT did not have an effect on 
these pathways. The microarray data predict that RT has an inhibiting effect on 
A
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apoptosis and increases cell survival 2 wks after irradiation. This apoptotic response 
may seem unexpected since it is known that p53 signaling after irradiation leads 
to apoptosis24 and apoptosis of acinar cells after RT of salivary glands has been 
reported25. However, in response to RT, pro- as well as anti-apoptotic and cell survival 
signaling pathways are activated, which occurs in waves. For instance, to allow DNA 
repair to take place after RT-induced damage, specific signaling pathways stimulate 
cell cycle arrest and prevent apoptosis26, 27. The balance between these pathways 
will decide whether more pro- or anti-apoptotic proteins will be expressed27. 
Our microarray data don’t reveal significant effects of HBOT on apoptosis or cell 
survival pathways, which corresponds to our previous histological study in which no 
profound effect of HBOT on apoptosis levels was detected in salivary glands after 
RT10.
 Radiation causes vascular damage and thereby hypoxia28. It is generally assumed 
that HBOT can positively influence angiogenesis (reviewed in 29). In a previous 
study, we showed an increased blood vessel density due to HBOT in irradiated 
submandibular glands of mice at ten weeks after RT10. The microarray performed 
in the present study, at 2 wks after RT, did not show a discernible effect of HBOT on 
gene expression profiles associated with angiogenesis, possibly because the 2-wk 
time point is too early to detect these effects.
 In healthy submandibular glands, HBOT led to a remarkable amount of 
differentially expressed probe sets, even more than RT alone (872 versus 613 
probe sets) indicating that HBOT induces changes in healthy, nonhypoxic tissue. 
In particular biological functions that are associated with the immune system, 
such as the movement, activation and adhesion of different immunological cells, 
were decreased by HBOT. In a wound model, suppressive effects of HBOT on the 
expression of inflammatory genes have been described and are a basis of its use in 
treating chronic (diabetic) wounds30-32.
 Genes that were most upregulated by RT included the early response genes 
Fos, Jun and Egr1. This upregulation has been reported before in mammalian cells 
shortly after RT33, 34 and our in vivo model shows that this upregulation still persists 
2 wks after RT. Interestingly, HBOT significantly downregulated the expression of 
these early response genes, when applied in irradiated salivary glands, indicating 
a counteraction of HBOT on RT-induced mechanisms. Strikingly, the predicted 
activation of the TGFβ1 regulatory pathway by RT appears to be significantly 
attenuated if HBOT is applied. The TGFβ-pathway is strongly associated with 
radiation-induced fibrosis in different organs, and is the subject of investigation 
regarding possible antifibrotic therapies35-38. This pathway regulates the formation 
of extracellular matrix (ECM), and has been shown to be activated by RT39-42. The 
binding of TGFβ to its receptor can lead, via Smad dependent and independent 
pathways, to the expression of target genes such as Ctgf and Serpine1. CTGF 
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stimulates differentiation of fibroblasts to myofibroblasts, which express α-SMA 
and produce (components of the) ECM. Serpine1 is a protease inhibitor which 
suppresses matrix metalloproteases (MMPs) from breaking down ECM and is thus 
matrix preserving43, 44. Excessive matrix formation/preservation leads to fibrosis 
since functional cells are replaced by ECM leading to dysfunction of the tissue37. 
Conditional overexpression of Tgfβ1 has been shown to induce fibrosis in salivary 
glands of mice as seen under pathological conditions45.
 Different genes that were upregulated by RT and downregulated when HBOT 
was applied to irradiated tissue are involved in the TGFβ-pathway. Increased Egr1 
and Egr2 expression have been postulated as key mediators of TGFβ signalling and 
fibrosis and thereby as potential targets for antifibrotic therapy46-49. Cyr61, which is 
a member of the CTGF family, can be regulated by TGFβ and has proinflammatory 
properties50, 51. THBS1 is an activator of latent TGFβ so it can bind to its receptor52. 
All together, our microarray results indicate that the TGFβ-pathway is repressed by 
HBOT in irradiated tissue, which was confirmed by immunohistochemical staining for 
TGFβ1 and Serpine1. Staining for α-SMA in the submandibular glands also showed a 
HBOT-induced decrease at 24 wks after RT; α-SMA is expressed by myofibroblasts, 
but also by myoepithelial cells that are abundant in the salivary glands. Myoepithelial 
cells can differentiate into myofibroblasts by epithelial-to-mesenchymal transition 
(EMT), a process that is induced by TGFβ and is known to contribute to fibrosis53, 54. 
Fibrosis or higher collagen content was not detected in the submandibular glands at 
any of the time points studied, but the higher expression level of α-SMA in the RT-
group could precede fibrosis. Presumably in our model, fibrosis is not yet revealed 
at 24 wks after RT. It has been shown that irradiation-induced lung fibrosis in mice 
can take 30 wks to develop and is highly strain-dependent55.
 An effect of HBOT on TGFβ signalling in vivo has been observed before in 
nonirradiated tumor tissue by Moen et al56. They found reduced Tgfβ expression 
after HBOT and stated that HBOT is able to induce mesenchymal-to-epithelial 
transition (MET), the opposite of EMT. In vitro, TGFβ expression and secretion by 
fibroblasts has been shown to be decreased in response to HBOT 11, 57. A reduction 
of fibrosis by HBOT has been demonstrated in animal models of laminectomy, 
tracheal anastomosis and myocardial infarction58-60, although in a tendon healing 
model, HBOT seemed to enhance fibrosis61.
 Except for TGFβ1, HBOT was predicted to inhibit other regulatory factors, such 
as platelet derived growth factor (PDGF). PDGF has been shown to influence the 
TGFβ-pathway and is implicated to be involved in fibrosis as well62. The suppression 
of TGFβ and PDGF as potential antifibrotic therapies is of interest and has been 
investigated in several studies36, 42. Fibrosis is a complex process involving several 
pathways that are interconnected and the concurrent suppression of more of 
these factors is more likely to have an effect on a biological process. Therefore, 
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multitargeted therapies may be more effective and HBOT could potentially be such 
a therapy.
 We cannot distinguish whether 100% oxygen only or 100% oxygen delivery under 
pressure leads to the reported changes in gene expression. However, HBOT is an 
established therapy in the treatment of radiation-induced injury and the elevated 
pressure has been shown to increase oxygen tension in tissue more than elevated 
oxygen levels only63. Under pressure, oxygen concentrations are increased in the 
plasma, allowing better oxygenation of obstructed tissue areas, since these are not 
reached by the oxygen that is bound to the hemoglobin of the red blood cells29. 
Therefore it is thought that HBOT is more effective in oxygenation and restoration 
of hypoxic tissues.
CONCLUSION
 We showed that HBOT influences a number of pathways and genes in irradiated 
salivary glands. With respect to radiation-induced damage, the TGFβ- pathway is of 
particular interest, since it is directly related to the pathogenesis of fibrosis. On the 
basis of our microarray data, HBOT seems to inhibit the radiation-induced activation 
of this pathway. In our model, at 24 wks after RT, lower levels of the profibrotic 
marker α-SMA were detected in the salivary glands of mice that underwent HBOT, 
indicating that this therapy could possibly affect the process of fibrosis. Therefore it 
is of interest to further investigate the influence of HBOT on the TGFβ-pathway and 
fibrosis, not only for salivary glands, but also for other tissues that are sensitive to 
radiation-induced fibrosis such as lung, kidney, heart and intestine.
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ABSTRACT
Hyperbaric oxygen therapy (HBOT) is used in the treatment of radiation induced tissue 
injury in cancer patients, but its effect on the growth and development of residual 
tumor tissue is unclear. In this study an orthotopic floor of the mouth mouse model 
of head and neck squamous cell carcinoma (HNSCC) was used in combination with 
optical imaging techniques to investigate the response of untreated and irradiated 
tumors to HBOT. HBOT treatment of mice resulted in accelerated growth (~19%) 
of the non-irradiated but not the irradiated tumors, as was assessed by in vivo 
bioluminescence imaging (BLI). Nevertheless HBOT appeared to be beneficial for 
mouse survival time. In vivo optical imaging using the fluorescent blood pool agent 
AngioSense revealed that HBOT leads to enhanced tumor vascular leakiness (~30%) 
while histological blood vessel parameters were not affected. Fluorescent imaging 
with the HypoxiSense probe showed increased tumor hypoxia after irradiation and 
HBOT. Histological tumor characteristics and epithelial-to-mesenchymal transition 
markers were not influenced by HBOT. The development of metastatic lesions in 
the mice could be detected by BLI, revealing that HBOT did not affect the incidence 
of cervical lymph node metastases. In conclusion, the current HNSCC mouse model 
allowed us to detect and monitor effects of HBOT and radiation therapy on tumor 
growth, vascular permeability, hypoxia and metastasis. The combined longitudinal 
imaging of tumor growth and (supra) molecular analysis of tumor characteristics 
highlight the versatility and potential of optical imaging methods in future 
oncological research. 
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INTROdUCTION
 Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer type worldwide and is associated with a poor prognosis. Treatment of 
these cancers often involves surgical resection followed by radiotherapy. Despite 
advances in radiation protocols that minimize the targeted tissue volume, radiation 
treatment often causes considerable damage to the surrounding healthy tissues 
including salivary glands, oral mucosa, vasculature, muscle and bone. Consequently, 
wound healing is impaired and osteoradionecrosis may occur, resulting in higher 
complication rates of reconstructive surgery in HNSCC patients that had been 
treated with radiotherapy. Hyperbaric oxygen therapy (HBOT) is frequently used 
in the management of radiation induced tissue injury, and has shown beneficial 
effects although its working mechanism has not completely been unraveled yet1, 
2. In HBOT, patients inspire 100% oxygen at elevated air pressure, which enhances 
the amount of oxygen that is dissolved in the plasma leading to an increase of the 
oxygen tension in tissues. By creating an oxygen gradient, HBOT is thought to induce 
neovascularization by which the progressive loss of the microvasculature in hypoxic 
irradiated tissue may be overcome and tissue healing is improved3-5.
 The use of HBOT in patients with a history of cancer has often raised concerns 
about the promoting effect this therapy might have on the growth of (residual) 
tumor tissue. Poor oxygenation and abnormal vasculature is a common feature of 
solid tumors and reduces the ability of cells to divide. It was anticipated that by its 
pro-angiogenic effect, HBOT would stimulate cancer growth and recurrence6-8. On 
the other hand, tumor hypoxia is known to be essential for the progression of cancer 
and is related to increased cell survival, induction of angiogenesis, metastasis and 
therapy resistance9, 10. Enhanced oxygenation of tumors by HBOT could therefore 
lead to less aggressive cancer growth and a better prognosis. Based on clinical 
and experimental studies it was recently adopted that there is no evidence that 
HBOT has a cancer promoting effect11, 12. Even more, on certain cancer subtypes like 
gliomas and mammary tumors, an anti-angiogenic and growth-inhibitory effect of 
HBOT was reported13-15 .
 The effect of HBOT on squamous cell carcinoma has been investigated in several 
experimental tumor models and reached controversial results. Inhibition of tumor-
growth and lymph node metastasis was observed in a carcinogen-induced hamster 
cheek pouch model 16. No differences in growth between control and HBOT groups 
were seen in five other studies in which subcutaneously implanted squamous 
carcinoma cell lines in mice were used17-21. However, in a recent study, Paniello 
et al22 reported enhanced growth of HNSCC tumor cells in C3H mice after HBOT. 
These divergent outcomes suggest that the choice of the experimental model, 
regarding cancer cell type, tumor location or HBOT protocol, is critical for the proper 
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determination of tumor responses to HBOT.
 One of the tumor conditions that is relevant to the clinical situation but has 
been scarcely investigated in experimental HBOT studies is the irradiated tumor. 
Radiation not only modifies the cancer cells but also the microenvironment of the 
tumor by affecting angiogenesis and the hypoxic state of the tissue23. Therefore 
previous irradiation might well influence the response of the residual tumor to 
HBOT.
 To get more insight in the consequences and risks of HBOT for cancer patients, 
further investigations with improved tumor models and advanced analytical 
methods are required. In the present study we used bioluminescent imaging (BLI) 
to non-invasively and adequately monitor the growth of a human squamous cell 
carcinoma line (FaDu) in the floor of the mouth of immunodeficient mice. Near 
infrared fluorescence (NIRF) optical imaging was applied to detect and quantify 
the effects of HBOT and irradiation on specific tumor characteristics in vivo. The 
fluorescent blood pool agent AngioSense was used to analyze tumor blood vessel 
quality and the NIRF targeting probe HypoxiSense was applied to study hypoxia in 
the tumors. Furthermore, this orthotopic mouse model allowed us to investigate 
the effects of HBOT on the development of regional and distant metastases, which 
are likewise frequently seen in patients with HNSCC.
MATERIALS ANd METHOdS
Mice
 All animal experiments of this study were approved by the Animal Experiments 
Committee of the Erasmus Medical Center (DEC 2645). The Dutch Experiments on 
Animal Act is established under European guidelines (EU Directive No. 86/609/
EEC regarding the Protection of Animals used for Experimental and Other Scientific 
Purposes). BALB/c nu/nu female mice (Charles River Laboratories), aged 8 to 11 
weeks were kept in filter-top cages with autoclaved pellet food and sterilized water 
without restriction. Mice with tumors in the floor of the mouth were given soft food 
and were monitored daily. Animals were euthanized when they had lost more than 
20% of their initial body weight or had reached day 35 after tumor implantation.
Tumor generation
 The human hypopharyngeal squamous cell carcinoma line FaDu-luc2 was 
kindly received from the laboratory of Prof. C.W. Löwik, PhD (Leiden University 
Medical Center, Leiden, the Netherlands). This cell line had been transfected with 
a luciferase-expressing vector (pCAGGS- Luc-2) allowing the monitoring of the 
tumor growth by bioluminescence imaging (BLI)24. FaDu-luc2 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, Lonza) supplemented with 10% (v/v) 
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fetal bovine serum (Hyclone) and antibiotics (50 units/ml of penicillin and 50 µg/
ml streptomycin) at 37°C in a humidified atmosphere of 5% CO
2 
in air. Orthotopic 
tumors were established by transcervical injection of 1x105 cultured FaDu-luc2 cells, 
suspended in 20µl serum-free DMEM into the floor of the mouth of anesthetized 
(2-4% isoflurane) nude mice. 
Hyperbaric oxygen treatment (HBOT)
 Treatment with hyperbaric oxygen started at day 5 after tumor implantation and 
consisted of daily sessions, until the end of the experiment with a maximum of 
30 sessions. The hyperbaric oxygen chamber used in this study was custom-built 
for small laboratory animals (Hytech BV, Raamsdonksveer, the Netherlands)25. Each 
session started with a compression phase of 15 min, during which the pressure in 
the chamber was elevated to 2.4 atmospheres absolute (ATA) and the oxygen level 
to 100%. After 90 min of isopression, decompression to 1 ATA took place in 15 min.
Radiation therapy (RT)
 Mice were locally irradiated at day 5 after tumor implantation with a single dose 
of 5 Gy using a Gammacell 40 Exactor 137Cs γ-source. For tumor irradiation mice 
were anesthetized by intraperitoneal (i.p.) injection of a mixture of ketamine and 
xylazine (65 mg/kg and 10 mg/kg respectively) and shielded using a Gammacell 40 
Collimator centering the head and neck region in a 3 cm radiation field. 
Bioluminescence imaging (BLI)
 Tumor growth was monitored twice a week by bioluminescence imaging using an 
IVIS Spectrum Imaging System (Xenogen). An aqueous solution of luciferin (Caliper 
Life Sciences) at 150 mg/kg was injected intraperitoneally 10-20 minutes before 
imaging. During imaging animals were anesthetized with 2-4% isoflurane and 
placed in a dorsal position. Using the Living Image software 3.2 (Xenogen) photon 
flux was quantified within a circular region of interest encompassing the head and 
neck region of each mouse. For 3D reconstruction, BLI images were coregistered 
with computed tomography (CT) images.
Fluorescence molecular tomography (FMT) imaging
 One day prior to their endpoint and at least 20 hours after the last HBOT 
session, mice were intravenously injected with 1.3 nmol of the fluorescent 
blood pool imaging agent AngioSense750 (PerkinElmer) and/or 1.3 nmol of the 
carbonic anhydrase IX (CAIX) targeted fluorescent imaging agent HypoxiSense680 
(PerkinElmer) or  MMPSense680, a probe  that is activated after cleavage by matrix 
metalloproteinases (MMPs). For quantitative fluorescence molecular tomography 
imaging (FMT 2500, PerkinElmer), mice were anesthetized (isoflurane, 2-4%) and 
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fixed in a definite position in an animal imaging cassette. The FMT 2500 tomography 
software was used to quantitate fluorochrome concentration distribution of 
AngioSense in a region of interest (ROI) of 750 mm3 in the tumor area (floor of the 
mouth). In vivo imaging sessions were performed 2 h and 24 h post-injection and 
immediately hereafter, the mice were euthanized with an overdose of isoflurane, 
the tumors were dissected and used for ex vivo imaging. For multi-modality imaging, 
image data from FMT were fused with CT using markers in the multimodal mouse 
bed.
Histology
 Mouse tumors were fixed in 10% formalin, embedded in paraffin and 5 µm 
slides were cut. Routine hematoxylin and eosin (H&E) staining was performed and 
assessed by a pathologist. For immunohistochemistry slides were probed with 
primary antibodies against Ki67 (Novus Biologicals Ltd.) and CD-31 (Abcam) to 
assess proliferation and blood vessel density and diameter, respectively. Biotinylated 
goat antirabbit IgG (Dako) was used as secondary antibody. Detection of the 
antibody complex was performed with streptavidin–peroxidase (R&D Systems) and 
3,3′-diaminobenzidine (Dako). Hematoxylin served as counterstain. 
 Slides were scanned using a slide scanner (Hamamatsu Photonics). To measure 
proliferation the percentage of Ki67 positive cells per tumor area was determined by 
using Celld (Olympus Life Science Europe GmbH). Apoptosis levels were determined 
by counting the number of apoptic cells in proliferating tumor areas (20x) in H&E 
stained slides. To determine vascular density, CD31-positive blood vessels were 
counted in 20 representative fields (40x) for each tumor. The vascular diameter of 
30 vessels for each tumor was measured in 63x high power fields. 
Metastasis 
 During the course of the experiment the development of metastases was 
monitored by BLI of the total mouse body. Imaging was performed using unmixed 
emission spectra, allowing signal detection at particular tissue depths, which 
prevented outshining of the signal of the regional metastasis by the primary tumor. 
To establish the incidence of lymph node metastases, 2 superficial cervical lymph 
nodes were resected from each mouse, incubated for 10 minutes in luciferin solution 
(30 µg/ml) and ex vivo BLI was performed. To confirm the metastatic lesions, lymph 
nodes were embedded in paraffin, sectioned and H&E-stained.
Quantitative real-time reverse transcription polymerase chain reaction (qPCR)
 Mouse tumors were dissected, rapidly frozen in liquid nitrogen and stored at 
−80°C. Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse 
transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). The resulting cDNA was 
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amplified in 40 cycles (enzyme activation at 95°C for 20 sec, denaturation at 95°C 
for 3 sec, annealing/extension at 60°C for 30 sec) with a Bio-Rad cycler using Fast 
SYBR Green Master Mix (Applied Biosystems). Specific primers (supplematary table 
S1) were used to amplify cDNA from human vascular endothelial growth factor 
A (VEGF), carbonic anhydrase IX (CAIX), E-cadherin (CDH1), Vimentin (Vim), snail 
family zinc finger 1 (Snail), transforming growth factor beta 1 (TGFβ1) and the 
internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Each PCR 
reaction was performed in duplicate and the average threshold cycle (Ct) value was 
used for relative quantification of gene expression with the comparative Ct method 
(ΔΔCT).
Statistical analysis
 Data are expressed as mean values with standard error of the mean (SEM), and 
were analyzed using SPSS PASW 21.0 for Windows (SPSS Inc., Chicago, USA). The 
Shapiro-Wilk test was used to test for normality, followed by the Mann-Whitney U 
test for the comparison of non-normally distributed data, while Student’s t-test was 
used for normally distributed data. P<0.05 indicated significant differences. Survival 
data was analyzed by the Kaplan-Meier and logrank tests for survival distribution. 
The Fisher’s exact test was used to analyze differences in the incidence of lymph 
node metastasis between groups. 
RESULTS
Effect of HBOT on tumor growth and mouse survival 
 To examine the effect of HBOT on the growth of orthotopic tumors FaDu-
luciferase cells were implanted in the floor of the mouth of nude mice and the 
growth was monitored by bioluminescence imaging until they met criteria for 
euthanasia, mostly due to weight loss. As shown in Figure 1 the increase of the 
bioluminescent (BLI) signal was significantly higher (P=0.023) in the group of mice 
that had undergone daily treatments of HBOT compared with the untreated group 
on day 18 after tumor cell inoculation (Fig. 1A, B). The mean doubling times for 
the BLI signals of the individual tumors were determined and were significantly 
lower in the HBOT group versus the control (2.15 vs 2.47 days, p=0.006) (Fig. 1C). 
In irradiated tumors the increase of the BLI signal was delayed compared to control 
tumors, but no significant effect of HBOT on the tumor growth rate was observed 
here (doubling times 3.46 and 3.65 days) (Fig. 1B, C). 
 The median survival periods for mice in the control, HBOT, RT and RT+HBOT 
groups were 23, 21, 27 and 36 days respectively. There was no significant effect 
of HBOT on the survival of non-irradiated mice, but mice with irradiated tumors 
had an increased survival time if HBOT had been applied (p=0.003) (Fig. 1D). The 
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maximal BLI values measured at the time of euthanasia were higher in the HBOT 
group as compared to the control for both non-irradiated (p=0.020) and irradiated 
tumors (not significant, p=0.176)(Fig. 1E)
Figure 1 In vivo effects of HBOT on tumor growth and survival time in FaDu-luc tumor bearing mice. 
A. Bioluminescence imaging (BLI) of representative mice of the different treatment groups on day 4, 
11 and 18 or 19 after xenografting tumor cells in the floor of the mouth. B. BLI was measured twice 
a week and data points indicate the increase in tumor signals compared to day 4 after xenografting 
tumor cells (9-12 mice per group). Error bars indicate SEM. *p<0.05 C. Mean doubling times of the 
tumors based on the BLI signals measured between day 7 and 18 (ctrl and HBOT) or day 11-22 (RT 
and RT+HBOT). Error bars indicate SEM. **p<0.01. indicate SEM. *p<0.05. d. Mouse survival time 
analysis using the Kaplan-Meier method and comparisons using log rank tests. E. Mean BLI signals of 
the tumors at the endpoint. Error bars RT: radiation therapy, HBOT: hyperbaric oxygen therapy.
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Effect of HBOT on tumor vascularization and vascular permeability
 Vascularization of the tumors was analyzed by investigating the CD31 positive 
blood vessels in tumor sections (Fig. 2A). The mean blood vessel density was 
slightly increased in irradiated tumors (1.2 fold, p=0.014) but no significant effect 
of HBOT was observed (Fig. 2B). The mean tumor blood vessel diameter did not 
differ between the groups (Fig. 2C). Expression of VEGF, a key factor involved in 
angiogenesis, was quantified in the tumors of the different experimental groups by 
qPCR. VEGF mRNA levels were significantly increased in the irradiated tumors (1.3 
fold, p=0.000), but not affected by HBOT (Fig. 2D).
 Tumor blood vessel quality  was analyzed in vivo with FMT using AngioSense750 
as a blood pool marker. AngioSense remains in the vasculature for 0-4 hours and 
therefore the signal detected in the tumor area 2 h after probe injection is a 
measure for the tumor vascular volume. The degree of AngioSense retention in the 
tumor area after 24 h is indicative for vascular leakiness26, 27. In Fig. 2E the site of 
accumulation of AngioSense750 in and around the tumor is shown and coregistered 
with the signal of the probe MMPSense680  which indicates the tumor margins. 
Mean AngioSense concentrations in the tumor areas were determined shortly after 
injection and after 24 h (Fig. 2F), but differences between the groups did not reach 
statistical significance (results not shown). Because variations in tumor size might 
have obscured the differences, the mean ratio between the 24 h and 2 h AngioSense 
signals for each individual mouse was determined. Probe accumulation appeared 
to be higher in the HBOT groups of the non-irradiated (1.3 fold, p=0.042) as well as 
the irradiated animals (1.3 fold, p=0.078), indicating an increase in tumor vascular 
permeability after HBOT (Fig. 2G). 
Effect of HBOT on tumor hypoxia
 Expression of the hypoxia inducible marker carbonic anhydrase IX (CAIX) in the 
tumor was measured by quantitative PCR. A clear increase in CAIX mRNA levels (2.4 
fold, p=0.000) was observed in tumors of irradiated animals but no significant effect 
of HBOT on CAIX expression was detected (Fig. 3A). 
 Tumor hypoxia was further analyzed by FMT using the CAIX targeted fluorescent 
imaging agent HypoxiSense680 as a probe. Because of the low fluorescence levels 
it was not possible to obtain in vivo data regarding the hypoxic state of the tumors. 
Mice were sacrificed 24 h after probe injection and analyzed ex vivo (Fig. 3B). 
HypoxiSense signals were detected in a subset of excised tumors. Strikingly, in none 
of the control tumors but half of the HBOT tumors fluorescence was detectable. 
Stronger HypoxiSense signals were observed in the tumors of the irradiated animals 
with again the highest fluorescent levels in the HBOT group (Fig. 3B, C), indicating 
that tumor hypoxia is increased after HBOT. 
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Figure 2 Effect of HBOT on tumor vasculature A. Representative immunohistochemical CD31 staining 
of blood vessels in FaDu-luc tumors. Scale bar represents 20 µm. B. Quantification of the tumor 
blood vessel density. C. Quantification of the tumor blood vessel diameter. d. Relative expression 
levels of VEGF mRNA in the tumors as determined by qPCR. E. Multimodal FMT/CT imaging of a 
FaDu-luc mouse 24h after i.v. injection of MMPSense680 (shown in green) and the blood pool agent 
AngioSense750 (shown in red) to detect tumor margins and region of tumor vascular leak, respectively. 
F. Representative FMT images of tumor regions in FaDu-luc mice of the different treatment groups, 2h 
and 24h after i.v. injection of AngioSense750. G. Quantification of blood vessel leakage in the tumor 
regions. For each animal the 24h/2h AngioSense signal ratio was determined (n=6). Error bars indicate 
SEM. *p<0.05. RT: radiation therapy, HBOT: hyperbaric oxygen therapy. 
Figure 3 Effect of HBOT on tumor hypoxia A. Relative expression levels of CAIX mRNA in the tumors 
as determined by qPCR. Error bars indicate SEM. **p<0.01. B. Representative ex vivo FMT images of 
dissected FaDu-luc tumors from mice 24 hours after i.v. injection of the hypoxia probe HypoxiSense C. 
Quantification of HypoxiSense signals in individual dissected tumors of the different treatment groups. 
RT: radiation therapy, HBOT: hyperbaric oxygen therapy.
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Effect of HBOT on tumor pathological features and metastasis
 To investigate if HBOT influenced pathological features of the tumor, histologic 
sections of the FaDu-tumors were rated by a pathologist. For all experimental groups, 
the tumors were characterized as poorly to moderately differentiated squamous 
cell carcinoma with moderate infiltrative borders (Fig. 4A, B, C). Perineural growth 
and vascular invasion of tumor cells was evident in several tumor sections but no 
significant differences were observed between the HBOT and the control groups. 
The degree of necrosis (Table 1) was highly variable among the tumors (0-42.2% of 
the tumor area) and was related to tumor size, but no significant effect of HBOT on 
the level of tumor necrosis could be established. Furthermore, immunohistological 
staining of the proliferation marker Ki67 showed no effect of HBOT on cell 
proliferation levels (Table 1). Apoptosis levels were also not significantly different 
between the groups although a trend towards decreased cell death after HBOT was 
observed (Table 1).
Table 1 Proliferation, apoptosis, and necrosis in FaDu tumors.
1Mean values ± SEM
2Median values [range]
RT: radiation therapy, HBOT: hyperbaric oxygen therapy
 To investigate the impact of HBOT on EMT, mRNA expression levels of the 
malignancy markers E-cadherin, Vimentin, Snail and TGFβ were determined in 
tumors of the different experimental groups. Vimentin expression was slightly 
upregulated in the irradiated tumors (1.4 fold, p=0.039) but its levels were not 
significantly influenced by HBOT (Fig. 4E). On the tumor expression of E-cadherin, 
Snail and TGFβ, no significant effects of either RT or HBOT were observed (Fig. 4D, 
F, G).
 The orthotopic tumor model allowed us to identify and monitor the development 
of regional or distant metastases in real time by in vivo BLI using spectral unmixing 
and 3D reconstruction to circumvent outshining of the signals by the strong total 
BLI signals of the primary tumor in the floor of the mouth (Fig. 4H). In the time 
frame of the experiment distant metastases were not detected but cervical lymph 
node metastases developed in the majority of the mice. To confirm and quantify the 
control HBOT RT RT+HBOT
Metastatic 
incidence 
8/12 8/11 9/10 10/11
Metastatic 
percentage
67% 72% 90% 91%
Fisher’s exact 
test vs control
1.000 0.323 0.317
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locoregional metastases, two superficial cervical lymph nodes of each mouse were 
harvested immediately after euthanasia and analyzed by ex vivo BLI and histological 
methods (Fig. 4I, J). As shown in Table 2 the metastatic incidence was 67%, 72%, 
90% and 91% for the control, HBOT, RT and HBO+RT groups respectively. A trend 
towards enhanced metastasis rates after irradiation was observed (p=0.137), but 
there was no effect of HBOT on the incidence and histological stage of the lymph 
node metastases.
Figure 4 Effect of HBOT on tumor malignancy parameters A. H&E staining of a tissue section of a 
representative FaDu-luc tumor dissected from the floor of the mouth. All treatment groups show 
poorly to moderately differentiated squamous cell carcinoma. Scale bar represents 2 mm. B. Detail of A. 
Scale bar represents 20 µm. C. Detail of A. Scale bar represents 100 µm. d-G. Relative expression levels 
of E-cadherin, Vimentin, Snail and TGFβ1 mRNA in the tumors as determined by qPCR. RT: radiation 
therapy, HBOT: hyperbaric oxygen therapy. H. In vivo BLI at an emission wavelength of 560 nm of a 
tumor bearing mouse at day 20 showing lymph node metastases I. Ex vivo imaging of metastasized 
cervical lymph nodes. Photographic (left) and bioluminescent (right) images are shown J. H&E staining 
of a tissue section of a representative metastasized lymph node. Scale bar represent 0.5 mm.
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Table 2 Incidence and rate of lymph node metastasis in mice with FaDu tumors.
dISCUSSION
 In this study tumor responses to HBOT and irradiation were investigated in 
an orthotopic model of head and neck squamous cell carcinoma using optical 
imaging methods. By means of bioluminescence imaging, the growth of a human 
hypopharyngeal carcinoma cell line in the floor of the mouth of mice was accurately 
monitored and revealed a small but significant increase in tumor growth rate (19%) 
under the influence of HBOT. No effect of HBOT however was detected on the growth 
of tumors that had been irradiated before. The difference in response might lie in 
the fact that irradiation, except for killing tumor cells, also  damages endothelial 
cells28, 29, resulting in a tumor microenvironment that is less susceptible to HBOT-
induced, growth promoting stimuli. Although tumors grew faster in HBOT- treated 
mice as compared to controls, the survival time of these animals was not affected. 
Interestingly, the bioluminescent signals of the tumors at the endpoints were higher 
in the HBOT group, indicating that these mice survived higher tumor loads. Also in 
the irradiated groups, in which the survival period was extended by HBOT but the 
tumor growth rate was not affected, a trend towards increased endpoint tumor 
sizes was noticed, suggesting a beneficial effect of HBOT on survival rate. 
 HBOT stimulates vessel development in normal tissue and in wounds3, 5 but its 
effect on tumor vascularization is unclear. Tumors possess disorganized and leaky 
tumor vessels which block adequate tissue perfusion leading to the presence of 
hypoxic regions that are associated with poor prognosis and treatment outcome30, 
31. Normalization of the tumor vasculature is thought to lead to less tumor hypoxia 
and is a goal of anti-angiogenic therapies9, 32. We evaluated the effect of HBOT on 
vascular function and tissue hypoxia in our HNSCC tumor model. Histological analyses 
revealed no significant effect of HBOT on tumor vascular density and diameter. 
Using in vivo optical molecular imaging with the blood pool agent AngioSense the 
effect of HBOT on tumor vascular permeability was investigated and disclosed a 
higher vascular leakiness in tumors of HBOT treated animals. This is the first study 
exploring the effects of HBOT on vascular permeability, revealing that HBOT does 
not lead to normalization of blood vessels and even appears to deteriorate tumor 
control HBOT RT RT+HBOT
Proliferation (% Ki67 
positive tumor cells)1 38.1±1.8 40.0±1.5 43.2±1.7 41.9±1.2
Apoptosis (# cells/mm2) 1 30.6±2.9 24.9±2.4 22.2±3.9 19.0±4.1
Necrosis (% area) 2 2.9 [0-28.0] 6.9 [0.5-27.5] 5.0 [0-42.1] 6.9 [0-31.0]
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vascular quality. 
 To compare the hypoxic states of the tumors using optical imaging, the recently 
developed HypoxiSense probe, which detects the protein CAIX on the tumor cell 
surface, was employed. Due to relatively low fluorescent signals, however, in 
vivo data could not be obtained. In previous studies this fluorescent agent was 
successfully used in subcutaneous xenograft tumors with volumes of 600-700 
mm3 33. In our orthotopic model the tumors in the floor of the mouth did not grow 
beyond 250 mm3 and therefore  signal detection was  probably hampered by optical 
properties such as background absorption and scattering34. Nevertheless, ex vivo, 
hypoxic regions were detected in a subset of tumors and, although the numbers 
were small, the data suggest that irradiated tumors were more hypoxic than non-
irradiated tumors and moreover, that HBOT increased tumor hypoxia as well. It has 
been shown that HBOT increases the oxygen concentration in tumor tissue during 
and shortly after treatment35, 36 but this effect is transient. The drop in oxygen level 
following a HBOT session may lead to the induction of a hypoxic response in the 
tumor tissue, by which CAIX expression could be enhanced. This would correspond 
to previous studies in which exposure to HBOT resulted in increased levels of the 
hypoxia inducible factor HIF-1ɑ in the liver and brain of rats37-39. The data indicate 
that enhanced oxygenation using an intensive HBOT protocol, does not lead to long 
term overall reduction of tumor hypoxia. 
 The presence of cervical lymph node metastasis is an important prognostic 
indicator for patients with HNSCC. The current bioluminescent orthotopic tumor 
model allowed us to monitor the effect of treatment on the development of 
lymph node metastases. Metastatic incidence was increased from approximately 
70% to 90% in the irradiated animals, but was not affected by HBOT. This confirms 
previous experimental results obtained in different cancer and animal models, 
in which stimulation of metastasis by HBOT was not established either16, 40-44. 
Histopathological analysis of tumors taken from mice after the maximal growth 
period also revealed no significant HBOT-induced changes in malignant parameters, 
like differentiation grade and degree of infiltrative and invasive growth. Epithelial-
to-mesenchymal transition (EMT) is a central mechanism of cancer metastasis 
whereby epithelial cells are reprogrammed, resulting in decreased adhesion and 
enhanced migration and invasion45-47. The expression of the hallmark molecules 
of EMT, the epithelial marker E-cadherin, the mesenchymal marker Vimentin, and 
the EMT-inducing factors Snail and TGFβ was not affected by HBOT, indicating that 
there was no switch to more aggressive tumors. Moen et al15 reported induction of 
mesenchymal-to-epithelial transition (MET) by HBOT in a mammary tumor model, 
but thus far there are no indications for similar effects in squamous cell cancer. 
 Altogether, using an orthotopic mouse model for squamous cell carcinoma we 
found the following effects of HBOT on tumor growth and development: HBOT 
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stimulated the growth of non-irradiated tumors, enhanced tumor blood vessel 
leakiness and appeared to increase tumor hypoxia. These are factors known to 
promote aggressive tumor behavior and poorer treatment outcome10, 31. On the other 
hand HBOT was beneficial for animal survival and no effects of HBOT were detected 
on metastatic incidence, histological grade and malignancy markers, suggesting 
that the effects of HBOT on disease outcome are limited. Irradiated tumors differed 
from non-irradiated tumors in that they grew slower but showed more malignant 
features since more metastasis and hypoxia was observed and higher transcript 
levels of VEGF, CAIX, and Vimentin, factors that are negatively associated with 
patient prognosis in cancer, were detected. The response of irradiated tumors to 
HBOT was similar to that of non-irradiated tumors, except that no effect on growth 
rate was observed. Therefore, there might be no increased risk for negative effects 
of HBOT in patients that were previously subjected to radiation therapy. Previous 
experimental studies on the effects of HBOT on tumor behavior thus far revealed 
varying results8, 11. In mammary and glioma tumor models growth-inhibiting, anti-
metastatic and anti-angiogenic effects of HBOT were reported13, 14, 48, but studies 
using squamous cell cancer models in mice did not reveal effects of HBOT on tumor 
growth16-21, except for a recent study of Paniello et al22 who also observed enhanced 
growth of xenografted tumors in mice. Specific tumor characteristics and treatment 
conditions might underlie the different outcomes. The improved animal model 
and in vivo molecular imaging methods used in this study disclosed influences of 
HBOT on the growth rate, blood vessel quality and hypoxic state of squamous cell 
carcinoma and opens up possibilities to further investigate the circumstances and 
conditions in which HBOT can be safely used in cancer patients.
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SUPPLEMENTARy dATA
Table S1 Primers used for qPCR
mRNA Forward (5’-3’) Reverse (5’-3’)
VEGF CGAAACCATGAACTTTCTGCTG TCCATGAACTTCACCACTTCG
CAIX AGGGGTCTCTGACTACACCG GAGGGTGTGGAGCTGCTTAG
CDH1 AATCCCACCACGTACAAGGG GTGTATACAGCCTCCCACGC
Vim AGGAGGAAATGGCTCGTCAC AGAAATCCTGCTCTCCTCGC
Snail CCAGTGCCTCGACCACTATG CTGCTGGAAGGTAAACTCTGG
TGFβ1 CGTGGAGGGGAAATTGAGGG CCGTTGATGTCCACTTGCAG
GAPDH CACCGTCAAGGCTGAGAACG GAGGGATCTCGCTCCTGGAAG
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TREATMENT OF RAdIATION INdUCEd TISSUE dAMAGE
 Normal tissue damage due to radiation treatment of head and neck cancers 
(HNC) remains an important complication that can greatly affect quality of life of 
these patients. Although different radiation techniques have improved the local 
targeting of tumor tissue, it is still inevitable that surrounding normal tissue will 
receive radiation, leading to impaired functionality. In the head and neck region, 
many different tissues lie in close proximity to each other, and are thus susceptible 
to radiation damage. This thesis focusses on radiation damage to salivary glands and 
bone. Damage to salivary glands can lead to chronic hyposalivation and xerostomia, 
which is the most common complication of radiation therapy for head and neck 
cancer. It also creates an oral environment in which bone damage is more prone 
to develop, which increases the risk of developing osteoradionecrosis (ORN). Both 
complications are irreversible and greatly compromise oral functions. In addition, 
reconstructive surgery, often needed in HNC patients, may be complicated.
 Treatment options are scarce and do not provide full recovery, therefore, 
prevention of radiation-induced damage is of optimal interest. We investigated 
the potential of hyperbaric oxygen therapy (HBOT), a therapy that is used in the 
treatment of ORN, and of the heparan sulfate mimetic RGTA, which has shown 
promising results in the treatment of chronic non-healing wounds, to prevent 
radiation damage to salivary glands and bone. The main focus of this thesis is HBOT, 
since this is already clinically used.
 HBOT is mostly used in the treatment of chronic (diabetic) wounds and delayed 
radiation injury, such as ORN. In chapter 2, the literature about HBOT on irradiated 
head and neck bone was surveyed. Experimental as well as clinical studies proved to 
be scarce. Experimental animal studies were mostly done in rodents and monitored 
the effects of HBOT on tissue regeneration after implant placement in hind legs or 
dealt with radiation therapy that was combined with distraction osteogenesis. 
 Most clinical studies were retrospective and therefore lacked controls. HBOT 
is used either as treatment for ORN, or as a prevention modality when surgery 
is needed in previously irradiated bone. None of the studies used HBOT as a 
prevention for bone damage by administering it shortly after radiation therapy. 
Roughly seventy-five percent of these studies report a positive effect of HBOT on 
prevention or treatment of ORN, although most conclusions are merely suggestions. 
Recent publications have questioned the efficacy of HBOT regarding treatment or 
prevention of ORN1-4 and state that HBOT may not offer any appreciable clinical 
benefit, although positive effects, and thus recommendation for HBOT use, are 
also reported5-8. The consensus among virtually all clinical studies is that there is a 
need for large randomized controlled trials, which have not been performed up to 
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now. Schoen and colleagues9 did perform a randomized clinical trial in which HBOT 
could not be shown to enhance implant survival, but they used a rather small study 
population. Another trial of Annane et al10 was prematurely terminated because of 
possible worse outcomes in the HBOT group. However, the study design was heavily 
criticized by others11-14. The formation of a control group when studying effects of 
HBOT on ORN can be difficult. Since HBOT is regarded as a standard treatment for 
ORN, ethical committees can decline to withhold ORN patients from HBOT15, 16.  
ANIMAL MOdELS FOR RAdIATION INdUCEd TISSUE dAMAGE
 More insight into the efficacy and mechanisms of action of HBOT is needed on a 
functional, cellular and molecular level. Animal models provide an important tool for 
this purpose. Radiation damage to salivary glands and bone has been studied using 
different animal models, most commonly mice and rats. Various radiation doses 
and schedules have been used. The 15 Gy local radiation dose used in our model 
has been proven to cause significant salivary gland damage, without compromising 
the general health of the animals17-21. Animal studies regarding radiation damage 
to mandibular bone generally administer much higher doses, targeted at the 
mandible22-25. Also for salivary glands, it is proposed that radiation therapy should 
be targeted locally to the salivary glands in order to exclude indirect radiation 
effects caused by the irradiation of other tissues in the radiation portal26. In our 
model, however, the aim was to simultaneously investigate effects on bone and 
salivary glands and therefore the complete head and neck region was irradiated. 
Clinically, these tissues are often not direct targets of radiation therapy but the 
interplay between radiation effects on multiple head and neck tissues cause the 
side effects which we aim to address. Pilot experiments were performed to assess 
whether bone damage was more feasible with a 25 Gy single dose, compared to 15 
Gy. The 25 Gy dose, however, resulted in severe mucositis, cataracts and significant 
loss of body weight within days after irradiation. Since we were mainly interested in 
the long-term effects, the 15 Gy single dose was chosen. Mice tended to lose some 
body weight in the first week after irradiation, but it never reached critical values. 
In the irradiated area, mice had some hair loss and because of somewhat loosened 
teeth, soft diet was provided in order to maintain sufficient food intake. None of the 
mice had to be prematurely taken out of the experiment because of weight loss or 
other detrimental health effects. 
 In clinical practise, fractionated radiation therapy is used instead of single dose 
radiation. DNA repair of normal tissue is allowed between fractions and tumor cells 
that were in a radio-resistant cell cycle phase during one fraction, might be in a 
more radiosensitive phase during the next fraction, allowing more tumor damage27. 
A single dose of 15 Gy has been reported to be biologically equivalent to a clinically 
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relevant scheme of 16 fractions of 2 Gy28, however, according to Coppes et al. 
higher radio-sensitivity of the submandibular gland for late effects was achieved 
after fractionated irradiation28. The extrapolation of results of animal radiation 
experiments to the human situation should therefore be carefully considered. Since 
mice need to be anesthetized every time they receive radiation, which is not without 
risk and is an invasive procedure for the animals, we used single dose irradiation for 
practical and ethical reasons.
HyPERBARIC CHAMBER FOR ANIMAL EXPERIMENTATION
 To be able to investigate the effects of HBOT in irradiated mice, a hyperbaric 
oxygen chamber was built especially for animal experimental purposes, which is 
described in chapter 3. HBO chambers that are clinically used are not suitable for 
animal experimentation for logistical, ethical and practical reasons. The custom built 
HBO chamber which is placed at the Animal Experimental Center of the Erasmus 
MC meets the strict safety regulations for the use of high pressure and pure oxygen 
and is easy to operate. It allows experimentation with small animal models such as 
mice, rats and rabbits. The most notable difference with chambers used clinically 
is that the whole chamber is flushed with 100% oxygen, rather than supplying the 
oxygen via masks that are used for patients but are not feasible for animals. Apart 
from that, the HBOT protocol in our mice study was designed to closely resemble 
clinically used treatment schedules, with a pressure of 2.4 atmospheres absolute 
and 100% oxygen during daily sessions of one hour.
HBOT ANd IRRAdIATEd MANdIBULAR BONE
 In our study on the prevention of radiation-induced damage to mandibular bone 
(chapter 4), we showed a positive effect of HBOT on microstructural parameters 
such as bone volume and trabecular thickness, which were negatively affected by 
RT. On a histological level, the amount of osteoclasts and of empty lacunae was 
decreased by HBOT, reflecting less bone resorption and an increased bone viability. 
These changes were all apparent on the long term, i.e. 24 weeks after RT.
 The pathophysiology of ORN remains a matter of debate, since different theories 
have been suggested. The so-called 3H-model proposed by Marx has long been the 
most accepted theory, on which the treatment with HBOT is based. Marx describes 
the irradiation-induced hypoxic, hypocellular and hypovascular (3H) environment 
caused by endarteritis as the basis for the development of ORN29. This underscores 
the potential of HBOT as a treatment for ORN since it could overcome the hypoxic 
environment30. Another theory describes radiation-induced fibrosis as the key event 
in the development of ORN, where a dysregulation of the fibroblastic activity leads 
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to atrophy of the tissue31. Furthermore, the direct effect of radiation on osteoclasts, 
resulting in higher bone resorption, has been suggested as an important factor32. 
The latter two theories do not substantiate the use of HBOT, since it is suggested 
that HBOT might not have an effect on these processes31, 33. Our study however 
shows that HBOT is able to reduce the amount of osteoclasts in irradiated tissue, 
corresponding to a recent study that reported suppressed osteoclast formation due 
to HBOT34. The mechanism behind the suppression of osteoclasts by HBOT is not 
elucidated and needs further research. 
 Green and colleagues report that bone loss is not solely dependent on the 
activity of osteoclasts, but that irradiation-induced effects on the stem cell pools 
in bone marrow are also of importance24. They showed radiation-induced stem cell 
depletion and compromised bone marrow at 2 and 10 days after irradiation, which 
recovered at 8 weeks after irradiation. Hyperbaric oxygen therapy has been shown 
to promote proliferation of neural stem cells35, stimulate growth and differentiation 
of vasculogenic stem cells36 and mobilize bone marrow-derived stem cells37. The 
improved bone quality by HBOT in terms of microstructure and viability seen in our 
study could therefore be caused by its effect on bone marrow stem cells that takes 
place shortly after RT and prevents bone damage on the long term.
HBOT ANd RGTA ANd IRRAdIATEd SALIVARy GLANdS
 The measurement of salivary flow rate is an important tool in animal experimental 
studies regarding injury of salivary glands. Whole saliva measurements following 
pilocarpine injections are fairly easy to perform and reflect the functionality of 
salivary glands. The resulting stimulated salivary flow rate measured, which is also 
used in our study, is primarily indicative of parotid gland function, as the majority 
of stimulated saliva production takes place in this gland. Unstimulated salivary flow 
rates, predominantly the result of submandibular saliva production, are important 
as well since xerostomia complaints are also expressed in the unstimulated state (i.e. 
sleeping, speaking), but they are not easy measurable. Our morphological analysis 
showed a comparable pattern of radiation-induced damage to both parotid- and 
submandibular glands (chapters 5 and 6) suggesting that the stimulated salivary 
flow rate can be used as an indicative measurement for overall salivary gland 
damage.
 While in our study salivary flow rates were significantly lower in irradiated mice at 
6 weeks post-RT, no clear effect on the overall morphology of the glands was visible 
at this time-point. At ten weeks after irradiation, only a slight disorganization of the 
acinar cells was shown, which was severed at 24 weeks and accompanied with a 
reduction in the amount of acinar cells. This dissociation between structural and 
functional changes has been shown by others38-40 and confirms the theory that in 
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salivary glands radiation does not cause a direct severe reduction of acinar cells by 
apoptosis. Instead, it is proposed that radiation-induced damage to the membrane 
of cells causes the early drop in saliva production by affecting signaling pathways 
that use cell surface receptors to facilitate excretion and by causing a dysfunction of 
the water channels in the membrane26, 41. 
 
Hyperbaric oxygen therapy
 Salivary flow rates of irradiated mice were not influenced by HBOT in our study 
(chapter 5), which indicates that HBOT is not able to prevent or restore damage 
to the acinar cells and that it thus may not reduce xerostomia. In line with this 
finding, Schoen and colleagues reported no effect of HBOT on oral dryness in their 
prospective clinical study regarding prosthodontic rehabilitation in radiated head 
and neck cancer patients9. However, Bui et al would considerate the use of HBOT in 
xerostomia patients based on their study16, and even more, clinical (pilot) studies 
regarding oral dryness have advocated a positive effect of HBOT42-45.
 In some clinical studies stimulated salivary flow rates were measured, but more 
often questionnaires were used to assess patient-scored xerostomia. Salivary flow 
rate and patient-scored xerostomia do not always correlate43, 46, 47, indicating that 
other factors such as saliva composition may also contribute to the feeling of dry 
mouth.
 In our study, cell proliferation in the salivary glands increased in response to HBOT. 
This has been shown in other tissues like pancreas, brain and liver48-52. An enhanced 
proliferation rate was primarily visible in acinar cells, and not in duct cells where 
stem cells reside53. This indicates that HBOT did not have a significant effect on the 
proliferation of salivary gland stem cells, but did affect homeostasis mechanisms in 
the acinar cells, that retain the ability to replicate, resulting in increased proliferation 
that potentially could overcome the radiation-induced damage. Other studies have 
proposed the recruitment of bone marrow derived stem/progenitor cells by HBOT36, 
37, 54, 55.
Regenerating Agent
 RGTA-OTR4120 is designed to mimic the function of heparan sulfate at sites of 
injury. Heparan sulfate is normally present in the extracellular matrix, but degraded 
upon tissue damage. It is able to bind growth factors thereby stimulating tissue 
repair and regeneration. The administration of RGTA-OTR4120 to irradiated mice 
(chapter 6) positively influenced salivary flow rate on the short term, two weeks 
after irradiation, but not on the long term. Overall morphology was not influenced 
although the amount of PAS-positive, mucin producing acinar cells was increased at 
ten weeks post-RT. This suggests that some regeneration of the impaired functionality 
of the acinar salivary glands had taken place, albeit it was not translated in a higher 
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salivary flow rate. RGTA may be useful to ameliorate salivation shortly after RT, but 
more evidence of its efficacy will be needed. Whether RGTA is able to treat salivary 
gland damage on the longer term needs further investigation. The combination of 
RGTA with other therapies, like HBOT, might possibly increase functionality of acinar 
cells and thereby restore salivary flow rates. 
HBOT ANd MOLECULAR PATHWAyS IN IRRAdIATEd SALIVARy GLANdS
 Little is known about the influence of HBOT on gene expression, and thereby on 
molecular pathways, in irradiated tissue. Some in vitro studies analyzed the effect 
of a single HBO treatment on different cell types such as neurons, osteoblasts and 
endothelial cells49, 56, 57. Results showed a great variety of responses between cell 
types, except for a shared upregulation of the oxidative stress response. An in vivo 
rat ischemic brain-model showed an influence on the neurotrophin system and 
inflammatory immune response after five consecutive HBO treatments58. HBOT 
effects seem to be highly cell type specific and dependent on the environment in 
which the cells reside. For a better understanding of the cellular and molecular 
processes that are affected by HBOT in irradiated tissue, analysis of the gene 
expression profiles can be of great significance. In our study whole genome gene 
expression was measured in salivary glands by microarray analysis two weeks after 
irradiation, and thus after two weeks of HBO-treatment (chapter 7). Subsequent 
functional pathway analysis gave more insight in pathways and processes influenced 
by HBOT.  
Angiogenesis
 The main action by which HBOT is believed to exert its positive effects is by 
promoting angiogenesis. In 1990, Marx demonstrated an eight- to nine fold 
increase in blood vessel density of irradiated rabbit tissue due to hyperbaric oxygen, 
compared to normobaric oxygen and air-breathing controls59. Later, more studies 
confirmed the angiogenic potential of HBOT52, 60-63. This angiogenic potential may be 
counterintuitive, since it is known that hypoxia triggers angiogenesis by increasing 
hypoxia inducible factor (HIF1α) which in turn increases the expression of vascular 
endothelial growth factor (VEGF), the main growth factor involved in angiogenesis64. 
Nevertheless, it has been shown that hyperoxia is also able to increase HIF1α and/
or VEGF levels52, 60-62, 65-67. Hyperbaric oxygen increases tissue oxygen levels that 
reduce to normal within a few hours after a hyperbaric oxygen session. The tissue 
will repeatedly experience relative hypoxia, which may be the cause for HIF1α 
accumulation and VEGF production52.
 In our model, we observed an increased blood vessel density in salivary glands 
of hyperbaric oxygen-treated irradiated mice, confirming the angiogenic potential 
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of HBOT (chapter 5). However, from our microarray data, obtained two weeks after 
irradiation and after ten HBO sessions, no clear difference in the expression of 
angiogenic factors could be detected. Possibly the expression of these factors is 
transient and since the salivary gland tissue used for the microarray was obtained 
approximately twenty-four hours after HBO treatment, the increased expression 
could have been missed in our experiment. It is also possible that the two-week 
time-point is still too early to see effects. The blood vessel density measured 
immunohistochemically did not show an HBOT-induced difference at the two week 
time-point. 
 Finally, from our experiments it cannot be excluded that the increased blood 
vessel density observed after HBOT was a consequence of protection of the blood 
vessels from radiation-induced damage rather than of induced angiogenesis.
The TGFβ-pathway
 Although HBOT not clearly altered the expression of angiogenic factors, our 
microarray data showed a remarkable HBOT-induced inhibition of genes and 
regulators that are activated by RT. We focused particularly on the TGFβ-pathway, 
which was attenuated by HBOT according to the differential expression of genes 
involved in this pathway. The TGFβ-pathway is involved in many biological processes, 
such as cell proliferation, epithelial-mesenchymal transition (EMT), extracellular 
matrix (ECM) regulation and immune-suppression and inflammation68. The TGFβ- 
affected extracellular matrix regulation is of particular interest regarding radiation-
induced damage. It has been shown that radiation causes overexpression of TGFβ 
and stimulation of its pathway in various tissues68-71. Via different pathways and 
the consecutive expression of target genes, radiation-induced TGFβ activation 
leads to excessive matrix formation (by activated fibroblasts) and preservation. 
This ultimately leads to fibrosis of the tissue in which functional cells are replaced 
by ECM and thereby loss of tissue function. Indeed, Hall and colleagues showed 
induction of fibrosis in salivary glands of mice that conditionally overexpress TGFβ72. 
Although fibrosis presents itself as a late effect, it has been proposed that a cascade 
of cytokines, including TGFβ, is initiated early after irradiation and persists for a long 
time leading to the development of late damage. Early overexpression of TGFβ after 
RT has been shown in various tissues, such as skin, intestine, mammary gland and 
lung71. Our study showed that also in salivary glands radiation caused an activated 
TGFβ response two weeks after RT, which was suppressed by HBOT. Therefore, 
HBOT could have a potential to inhibit radiation-induced fibrosis. In our model 
however, fibrosis was not seen in irradiated salivary glands. Probably the endpoint 
of 24 weeks after RT was not long enough to reveal fibrosis, taken into account 
that fibrosis can take 30 weeks to develop and is highly strain dependent (the c3h 
mice used in our experiments are relatively radioresistant)73. Therefore, we cannot 
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conclude whether HBOT indeed is able to inhibit fibrosis. The lower expression of 
the profibrotic factor α smooth muscle actin-protein at 24 weeks after RT in HBO-
treated salivary glands could indicate a reduced onset of fibrosis, but no conclusive 
evidence on the effect of HBOT on fibrosis was obtained. Despite the fact that 
fibrosis was not evident, salivary flow rates and thus salivary gland functionality, 
was greatly impaired. Radiation-induced fibrosis did therefore not play a major role 
in the damage to salivary glands in the timeframe used in our study. It is however 
interesting to elucidate the precise effect of HBOT on the TGFβ-pathway and the 
potential of HBOT to prevent radiation fibrosis in other tissues, in which radiation-
induced fibrosis has a big impact on tissue functionality such as lung, kidney, heart 
and intestine. 
HBOT ANd TUMOR GROWTH ANd dEVELOPMENT
 Since patients that receive HBOT in order to prevent or treat radiation-induced 
tissue damage have a history of cancer, the effects of HBOT on tumor cells are 
important to decipher. Concerns have been raised on the potential stimulatory 
effect of HBOT on tumor tissue. While solid tumors are poorly oxygenated with a 
reduced ability of cells to divide, the pro-angiogenic effect of HBOT could stimulate 
cancer growth74-76. On the other hand, tumor hypoxia is a feature of aggressive 
tumors with a bad prognosis. HBOT could prove to be beneficial by overcoming 
hypoxia and thereby could lead to less aggressive tumor behaviour77, 78.
 Using an orthotopic mouse model for squamous cells carcinoma, effects of 
HBOT on irradiated and non-irradiated tumors were investigated (chapter 8). HBOT 
slightly stimulated the growth of non-irradiated tumors but not of irradiated tumors. 
Fluorescent imaging remarkably showed that HBOT did not normalize blood vessels 
in terms of leakiness, but even seems to deteriorate tumor vascular quality, and that 
HBOT increased tumor hypoxia. It has been shown previously that HBOT increases 
the oxygen concentration in tumor tissue during and shortly after treatment79, 80. 
The drop in oxygen level following a HBOT session may lead to the induction of a 
hypoxic response which was measured in our study by the fluorescent probe that 
detects carbonic anhydrase IX on the tumor cell surface. 
 Furthermore, animal survival was increased by HBOT, but there were no effects 
on metastatic incidence, histological grade, malignancy markers or blood vessel 
density. Altogether, our results suggest that there is no increased risk for negative 
effects of HBOT in patients previously subjected to RT with a history of squamous 
cell carcinoma. While in salivary glands HBOT positively affected proliferation and 
blood vessel density, no effects on these parameters were seen in tumor tissue. The 
complex and very different microenvironment of (irradiated) tumors, with divers 
oxygen concentrations, pH and distribution of nutrients amongst others81, 82, is 
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possibly accountable for the difference in effect of HBOT.
CONCLUSIONS ANd FUTURE PERSPECTIVES
 In this thesis, the main question is whether HBOT has the ability to protect head 
and neck tissues from radiation-induced damage, when given in a preventative 
manner directly after RT. 
 Mandibular bone tissue appeared to be positively affected by HBOT, although 
the clinical relevance of these results needs to be elucidated. It is of importance 
to know if the observed changes can result in stronger bone, if regeneration is 
improved when trauma is inflicted, and if ORN can thus be prevented. This could 
first be investigated using an animal model in which trauma, for example drilling 
a small hole in the mandibular bone, is inflicted and the subsequent regeneration 
monitored. Bone strength tests can be performed to see whether HBO-treated bone 
is indeed stronger and less likely to experience microfractures. For this purpose, the 
use of rats would be preferred, since the mandibles of mice are too small.
 Salivary flow rates were not improved by HBO-treatment, implying that HBOT 
does not ameliorate xerostomia. However, proliferation and blood vessel density 
were positively affected, suggesting an effect on the regeneration of salivary 
glands. It is discussed that the radiation dose may have been too high to translate 
these cellular effects into functional difference. The use of fractionated radiation, 
as applied clinically, may lead to different results. Adapted timing of the HBO 
treatment may also improve the effects on salivary gland function. Maybe the 
cellular changes that are induced by HBOT are more desirable at later time-points 
after RT and thus have more impact on the regeneration of the tissue if applied 
then. Varying durations of HBOT, in terms of the total amount of HBOT sessions, 
might also cause different effects and it is clinically relevant to know whether fewer 
HBO treatments can cause the same effect. The most optimal HBOT-protocol should 
be identified in animal models, and subsequently tested in randomized controlled 
clinical trials. The protocols used in practise today are not (fully) evidence-based 
and a reconsideration of these protocols might lead to improved treatment and 
outcome.
 The inhibitory influence that HBOT showed to have on the TGFβ-pathway in 
salivary glands is an interesting factor to further investigate. The TGFβ-pathway 
is activated in many other tissues that suffer from radiation-induced fibrosis, and 
HBOT could prove to be a valuable tool to prevent radiation-induced fibrosis and 
thus impaired functionality of irradiated tissues. For this, the most suitable timing 
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and duration of HBO-treatment needs to be investigated and will probably vary 
between tissues and conditions.
 Lastly, HBOT did not seem to have strong adverse effects on the growth and 
development of irradiated squamous cell carcinomas located in the floor of the 
mouth of mice. This suggests that HBOT is safe to use in patients that previously 
received radiation therapy as treatment for cancer. However, literature reports 
various effects of HBOT in various types of cancer76, 83. Further investigation of the 
circumstances and conditions in which HBOT can be safely used in cancer patients 
is necessary. The animal model and imaging techniques used in our study can 
contribute herein.
 
 This thesis has shown that HBOT does affect molecular pathways, cells and 
tissues in irradiated mice. Effects are cell type- and tissue dependent. For example, 
proliferation rate and blood vessel density were increased in irradiated salivary gland 
tissue, but not in irradiated tumor tissue. Additional experimental research with 
adapted animal models will be necessary to further unravel the working mechanism 
of HBOT for different conditions. Furthermore, it is of importance to investigate 
whether the molecular and cellular effects of HBOT are clinically relevant. 
 Currently, too many patients might receive HBOT while there is only little 
evidence for its effectivity. On the other hand, other patient groups might exist that 
potentially could benefit from HBOT. Preclinical- as well as clinical research, in the 
form of randomized controlled trials, is necessary to obtain a more evidence-based 
referral of patients to HBOT.
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SUMMARy
 For the treatment of tumors in the head and neck region, radiation therapy (RT) is 
often used. Apart from the irradiation of tumor cells, it is inevitable that surrounding 
normal tissues will also receive radiation. Salivary glands and bone frequently lie 
in the radiation portal and their functionality can be impaired after RT, leading to 
serious health problems like chronic hyposalivation and osteoradionecrosis (ORN; 
bone death due to radiation). Quality of life is highly impacted in these patients, 
since they experience trouble with eating, speaking and swallowing, suffer from 
taste loss, and moreover ORN proves to be a very painful condition. The effects are 
irreversible and definite treatment or prevention options are scarce.
 Hyperbaric oxygen therapy (HBOT) has been used to treat delayed radiation 
injury since the 1970s. Patients take place in a chamber that is pressurized to 2.4 
atmospheres absolute (normal pressure at sea level is 1.0 ATA) and breath 100% 
oxygen during 1,5 hour, with a total of approximately 20-30 daily sessions. This will 
raise the oxygen tension in the tissues, which is supposed to facilitate repair of the 
hypoxic irradiated tissues, especially by means of the induction of angiogenesis. 
Although ORN is treated in this way, the efficacy of HBOT remains a matter of 
debate. In addition, the working mechanism is not fully understood.
 This thesis aims to give more insight in the effects of hyperbaric oxygen therapy 
on irradiated head and neck tissues and on tumor tissue. For this purpose we used 
a mouse model and analysed the different tissues at a cellular and molecular level 
(Chapter 1).
 In chapter 2, the existing literature regarding HBOT in the irradiated head and 
neck region is discussed. Animal experimental studies were especially scarce, and 
clinical studies lacked randomized controlled trials. Research outcomes varied, but 
in general beneficial effects of HBOT were suggested although strong conclusions 
could not be made.
 Chapter 3 describes the development of a custom-built hyperbaric oxygen 
chamber that allowed us to perform HBOT experimentation with small laboratory 
animals, in a clinically relevant manner.
 In chapter 4 the effects of HBOT on irradiated murine mandibles are investigated. 
Mice were irradiated with a single dose of 15 Gy aimed at the head and neck region. 
HBOT started the day after RT and followed clinical protocols with 20 daily sessions 
(excluding weekends). At 10 and 24 weeks after RT, mice were sacrificed and 
mandibles were examined by microCT and histology. Radiation-induced changes 
were mostly apparent after 24 weeks. MicroCT data proved that the negative effect 
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of RT on different microstructural parameters (i.e. reduction of bone volume and 
trabecular thickness and increase of trabecular separation) was positively affected 
if HBOT had been administered directly after RT. Furthermore, HBOT decreased 
the amount of empty lacunae and bone resorbing osteoclasts in irradiated tissue, 
indicating increased bone viability.
 Chapter 5 focusses on immunohistochemical changes due to HBOT in irradiated 
salivary glands at different time-points (i.e. 2, 6, 10 and 24 weeks after RT) using the 
same mouse model as mentioned in chapter 4. An enhanced proliferation rate and 
blood vessel density was observed in mice that received HBOT after RT, at ten weeks 
post-RT. Salivary flow rates, which dropped soon after RT, were not recovered by 
HBOT. The results indicate that although HBOT in our experimental setting was not 
capable to improve the overall functionality of the salivary glands,  it positively 
influenced regenerative processes.
 In chapter 6 we made a small detour and addressed the effects of the heparan 
sulfate mimetic RGTA (ReGeneraTing Agent) on the regeneration of irradiated 
salivary glands. RGTAs are designed to mimic the effect of heparan sulfates that are 
normally present in the extracellular matrix, but are degraded upon tissue injury. 
RGTAs can bind growth factors and are thereby believed to facilitate regeneration. 
In the mouse model used, with weekly RGTA injections in irradiated mice, RGTA 
was able to increase the salivary flow rate, but only at two weeks after RT and not 
at later time-points. Although histology showed an increase of mucin production 
activity of acinar cells at ten weeks post-RT, the salivary flow rate was decreased. 
It was concluded that RGTA may be useful to ameliorate salivation shortly after RT 
and that further research into its application, alone or in combination with other 
therapies like HBOT, is needed.
 In chapter 7, the molecular pathways that are influenced by HBOT in irradiated 
salivary glands are investigated by means of whole genome microarrays, which 
were performed two weeks after RT. We showed that HBOT was able to significantly 
attenuate the radiation-induced expression of a set of genes and upstream regulators 
including mostly immediate early response genes like Fos, Jun and members of the 
Egr- and Ier family. This indicates a counteraction of HBOT on certain RT-induced 
mechanisms. Functional analysis revealed that stimulation of the TGFβ-pathway 
by RT was attenuated by HBOT. This pathway plays, amongst others, a crucial role 
in radiation-induced fibrosis. Fibrosis did not develop in our mouse model in the 
used time frame, so we were not able to establish effects of HBOT on radiation-
induced fibrosis. However, the potential of HBOT to inhibit the TGFβ-pathway is a 
very interesting finding, not only regarding tissue regeneration of salivary glands, 
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but also of other tissues that suffer from radiation-induced injury.
 Finally, in chapter 8 the effects of HBOT on the growth and development of 
tumor tissue is investigated, since there is concern whether HBOT can promote 
tumor growth. For this purpose, a mouse model was set-up in which a luciferase 
expressing human squamous cell carcinoma cell line was injected into the floor of 
the mouth of nude mice. In vivo monitoring by bioluminescence imaging revealed 
that the growth of non-irradiated tumors was slightly accelerated by HBOT, whereas 
the growth of irradiated tumors was not influenced. Fluorescent imaging with a 
blood pool agent and a hypoxia probe showed increased leakiness of blood vessels 
and increased hypoxia due to HBOT, respectively. Furthermore, no effect of HBOT 
was seen on metastatic incidence, histological grade, malignancy markers and blood 
vessel density and -diameter. The results suggest that there is no increased risk of 
HBOT for previously irradiated patients with a history of squamous cell carcinoma.
 In conclusion, it was shown that HBOT has the ability to induce cellular and 
molecular changes in irradiated tissues that are cell type and tissue dependent. 
Proliferation rate and blood vessel density in salivary glands were increased and 
it was suggested that induction of the TGFβ-pathway was attenuated by HBOT. 
Despite these auspicious signs, improvement of salivary gland function, by means 
of a measurable increase in salivary flow rate, could not be established in our 
experiments. In mandibular bone, certain radiation-induced microstructural and 
histological deteriorations were prevented by HBOT. Squamous cell carcinoma 
tissue responded to HBOT to some extent, but the results do not lead to concern for 
the application of this therapy in irradiated cancer patients. The clinical relevance of 
these results remains to be elucidated in order to achieve a better implementation 
of the therapy.
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SAMENVATTING
 Bij de behandeling van tumoren in het hoofd-halsgebied wordt vaak gebruik 
gemaakt van radiotherapie (RT). De bestraling is erop gericht de tumorcellen te 
doden, maar het is onvermijdelijk dat ook omliggende gezonde weefsels straling 
ontvangen. Speekselklieren en kaakbot liggen dikwijls in het bestralingsgebied 
waardoor de functie kan verminderen, wat kan leiden tot chronische hyposalivatie 
en osteoradionecrosis (ORN; het doodgaan van bot door bestraling). Dit heeft een 
grote impact op de kwaliteit van leven van deze patiënten; ze krijgen moeite met 
eten, praten en slikken, ervaren een vermindering van smaak en daarbij is ORN een 
erg pijnlijke aandoening. De effecten zijn irreversibel en opties voor behandeling of 
preventie zijn schaars.
 Hyperbare zuurstoftherapie (HBOT) wordt al sinds de jaren ’70 gebruikt bij de 
behandeling van late radiatieschade. Patiënten nemen plaats in een cabine die 
op druk wordt gebracht tot 2.4 atmosfeer (normale druk op zeeniveau bedraagt 
1.0 atmosfeer) en ademen 100% zuurstof in gedurende 1,5 uur. In totaal worden 
op deze manier ongeveer 20-30 dagelijkse sessies ondergaan. Dit zorgt ervoor 
dat de zuurstofdruk in de weefsels toeneemt, wat het herstel van het bestraalde, 
hypoxische weefsels zou bevorderen, vooral door de inductie van angiogenese. 
ORN wordt op deze manier behandeld, maar de effectiviteit van de therapie blijft 
onderwerp van discussie. Daarnaast is het precieze werkingsmechanisme nog niet 
volledig doorgrond. 
 Dit proefschrift heeft als doel een beter inzicht te geven in de effecten van 
hyperbare zuurstoftherapie op bestraalde weefsels van het hoofd-halsgebied 
alsmede op tumorweefsel. Hiervoor is een muismodel gebruikt en zijn weefsels op 
cellulair en moleculair niveau geanalyseerd. 
 In hoofdstuk 2 wordt de bestaande literatuur over HBOT in eerder bestraald hoofd-
halsgebied bediscussieerd. Vooral proefdierexperimenten op dit gebied zijn schaars 
en bij de klinische studies is er een gebrek aan gerandomiseerde gecontroleerde 
onderzoeken. De resultaten varieërden, maar in het algemeen werden er gunstige 
effecten van HBOT gesuggereerd, hoewel harde conclusies niet getrokken konden 
worden.
 Hoofdstuk 3 beschrijft de ontwikkeling van een hyperbare zuurstoftank waarmee 
HBOT experimenten met kleine proefdieren gedaan konden worden in een klinisch 
relevante setting.
 In hoofdstuk 4 worden de effecten van HBOT op bestraalde onderkaken van 
de muis onderzocht. Muizen werden bestraald met een éénmalige dosis van 15 
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Gy, gericht op het gehele hoofd-halsgebied. HBOT startte de dag na bestraling en 
was gelijk aan de klinische protocollen met 20 dagelijkse sessies (met uitzondering 
van het weekend). Tien en 24 weken na bestraling werden de muizen geofferd, 
het kaakbot geoogst en door middel van microCT en histologie onderzocht. 
Stralingsgeïnduceerde schade werd vooral waargenomen na 24 weken. MicroCT 
data toonde aan dat de negatieve effecten van RT op verschillende microstructurele 
parameters (reductie in botvolume en dikte van botbalkjes en een vergrote afstand 
tussen botbalkjes) positief beïnvloed werden als HBOT direct na RT gegeven 
werd. Tevens verlaagde HBOT de hoeveelheid lege holtes en osteoclasten (die bot 
resorberen) in bestraald weefsel, wat duidt op een verhoogde levensvatbaarheid 
van het bot.
 Hoofdstuk 5 is gericht op de immunohistochemische veranderingen ten gevolge 
van HBOT in bestraalde speekselklieren op verschillende tijdspunten (2, 6, 10 en 
24 weken na RT). Er werd gebruik gemaakt van het muismodel zoals uitgelegd in 
hoofdstuk 4. Verhoogde proliferatie en bloedvatdichtheid werd waargenomen 
in speekselklieren van muizen die na bestraling HBOT kregen, op tien weken na 
bestraling. De speekselpoductie, die al snel na RT drastisch daalde, werd niet hersteld 
door HBOT. Deze resultaten duiden erop dat hoewel HBOT in onze experimentele 
setting de algemene functionaliteit van de speekselklieren niet kon verbeteren, 
regeneratieve processen weldegelijk positief beïnvloed kunnen worden.
 In hoofdstuk 6  wordt kort uitgeweid en worden de effecten van het heparan 
sulfaat mimeticum RGTA (ReGeneraTing Agent) op de regeneratie van bestraalde 
speekselklieren onderzocht. RGTAs zijn ontworpen om de effecten van heparan 
sulfaten na te boosten. Normaal gesproken zijn deze aanwezig in de extracelullaire 
matrix, maar ze worden afgebroken wanneer het weefsel schade ondervindt. 
RGTAs kunnen groeifactoren binden, waardoor ze mogelijk regeneratie kunnen 
bevorderen. In het muismodel dat in deze studie werd gebruikt bevorderde de 
wekelijkse toediening van RGTA de speekselproductie in bestraalde muizen. Dit 
effect werd alleen twee weken na bestraling gezien. De histologie liet wel een 
verhoging van de activiteit van de mucine productie in de acinaire cellen zien op 
tien weken na bestraling, terwijl op dat tijdspunt de speekselproductie niet werd 
bevorderd. Concluderend kan RGTA bruikbaar zijn om de speekselproductie kort na 
RT te verbeteren en is verder onderzoek naar de mogelijkheden van RGTA, alleen of 
juist in combinatie met andere therapieën zoals HBOT, nodig.
 In hoofdstuk 7 wordt gekeken naar de moleculaire pathways die door HBOT 
beïnvloed kunnen worden in bestraalde speekselklieren, door middel van 
microarrays die twee weken na RT werden uitgevoerd. HBOT kon de expressie 
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van een set genen en regulatoren die door bestraling geïnduceerd werden, vooral 
early response genen als Fos, Jun en leden van de Egr- en Ier familie, significant 
verzwakken. Dit duidt op een tegengestelde actie van HBOT op bepaalde 
stralingsgeïnduceerde mechanismen. Functionele analyse liet zien dat de stimulatie 
van de TGFβ-pathway door RT kon worden verzwakt door HBOT. Deze pathway speelt 
onder andere een belangrijke rol bij stralingsgeïnduceerde fibrose. In het gebruikte 
muismodel werd geen fibrose waargenomen, waardoor we de effecten van HBOT 
op stralingsgeïnduceerde fibrose niet konden vaststellen. Echter, het vermogen van 
HBOT om de TGFβ-pathway te remmen is een zeer interessante bevinding, niet 
alleen als het gaat om weefselregeneratie van speekselklieren, maar zeker ook voor 
andere weefsels die stralingsschade ondervinden.
 Tot slot worden in hoofdstuk 8 de effecten van HBOT op de groei en ontwikkeling 
van tumorweefsel onderzocht. Er bestaat enigszins bezorgdheid over het gebruik 
van HBOT bij patiënten die kanker hebben gehad, omdat het tumorgroei zou 
kunnen bevorderen. Hiertoe werd een muismodel opgezet waarbij humane 
plaveiselcarcinoomcellen die luciferase tot expressie brengen, werden ingespoten 
in de mondbodem van naakte muizen. Met behulp van bioluminiscente 
beeldvorming konden de cellen in vivo gevolgd worden en werd gezien dat de groei 
van niet-bestraalde tumoren lichtelijk werd versneld door HBOT, terwijl de groei 
van bestraalde tumoren niet werd beïnvloed. Fluorescente beeldvorming met een 
middel om de bloedpoel in beeld te brengen en een probe voor hypoxie lieten 
respectievelijk meer lekkende vaten en verhoogde hypoxie in de tumoren onder 
invloed van HBOT zien. Verder was er geen effect van HBOT op de metastase index, 
de histologische stadiëring, maligniteitmarkers en bloedvatdichtheid en -diameter. 
Er werd derhalve geconcludeerd dat op basis van deze studie geen verhoogd risico 
voor HBOT bestaat bij patiënten die bestraald zijn en een voorgeschiedenis met 
plaveiselcelcarcinoom hebben.
 Concluderend hebben we aangetoond dat HBOT cellulaire en moleculaire 
veranderingen kan bewerkstelligen in bestraalde weefsels, die celtype- en weefsel-
afhankelijk zijn.  Proliferatie en bloedvatdichtheid werden in speekselklieren 
verhoogd  na bestraling en er werd gesuggereerd dat de activiteit van de TGFβ-
pathway verzwakt kon worden door HBOT. Ondanks deze veelbelovende bevindingen, 
kon er geen verbetering van de speekselklierfunctie, gemeten aan de hand van 
speekselproductie, vastgesteld worden. In het bot van de onderkaak werden 
bepaalde stralingsgeïnduceerde microstructurele en histologische veranderingen 
voorkomen door HBOT. Plaveiselcelcarcinoom reageerde in enige mate op HBOT, 
maar de resultaten leiden niet tot bezorgdheid als het gaat om het gebruik van 
HBOT bij patiënten met hoofd-halskanker die bestraald zijn. De klinische relevantie 
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van deze resultaten zal onderzocht moeten worden zodat de therapie uiteindelijk 
beter geïmplementeerd kan worden.
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    Care
PhD period:   April 2009 - April 2014
Promotors:   Prof.dr. EB Wolvius
    Prof.dr. KGH van der Wal
Co-promotor:   dr. JAM Braks
Phd training                        year   Workload
            (ECTS)
Courses
•	 Biomedical Research Techniques
•	 Handelingen met dieren gehuisvest in IVCs
•	 Introduction to Adobe Photoshop and Illustrator
•	 Introduction to Adobe Indesign
Conferences – poster presentations
•	 Effects of hyperbaric oxygen therapy on the regeneration 
of irradiated murine salivary glands. 2nd symposium of the 
Dutch Society for Radiobiology (NVRB), Noordwijkerhout.
•	 Effects of hyperbaric oxygen therapy on radiation-induced 
damage in the salivary glands of mice. 18th Molecular 
Medicine Day, Rotterdam.
Conferences – podium presentations
•	 Hyperbaric oxygen therapy in the management of radiation-
induced injury in the head and neck region. 13th European 
Congres of Scientists and Plastic Surgeons (ECSAPS), 
Rotterdam.
•	 Hyperbaric oxygen therapy in the management of radiation-
induced injury in the head and neck region. Vergadering 
Rotterdamse Werkgroep Hoofd-Hals tumoren (RWHHT), 
Rotterdam.
•	 Exploration of the efficacy of hyperbaric oxygen therapy 
on the repair and regeneration of irradiated head and 
neck tissues in a murine model. Vergadering Rotterdamse 
Werkgroep Hoofd-Hals Tumoren (RWHHT), Rotterdam.
2009 1.5
2013
2013
2013
0.15
0.3
0.15
2012 1.0
2014 1.0
2009 1.5
2010 1.5
2011 1.5
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•	 Het effect van hyperbare zuurstoftherapie op de regeneratie 
van bestraalde speekselklieren. Wetenschappelijke 
vergadering van de Nederlandse Werkgroep Hoofd-Hals 
Tumoren (NWHHT), Nijmegen.
•	 Hyperbare zuurstoftherapie in de regeneratie van bestraalde 
speekselklieren van de muis. 55e Najaarsvergadering van 
de Nederlandse Vereniging voor Mondziekten, Kaak- en 
Aangezichtschirurgie (NVMKA), Leiden.
•	 Hyperbare zuurstoftherapie in de regeneratie van bestraald 
weefsel in het hoofd-halsgebied. 3e Jonge Onderzoeksdag 
van de Nederlandse Werkgroep Hoofd-Hals Tumoren 
(NWHHT), Utrecht.
Conferences – attendance
•	 53e Najaarsvergadering Nederlandse Vereniging voor 
Mondziekten, Kaak- en Aangezichtschirurgie (NVMKA), 
Groenekan.
•	 Congress of the European Association for Cranio-Maxillo-
Facial Surgery(EACMFS), Brugge.
•	 Symposium van de Nederlandse Vereniging voor 
Radiobiologie (NVRB) en de Nederlandse Vereniging voor 
Radiotherapie en Oncologie (NVRO), Utrecht.
•	 Scientific Meeting Nederlandse Vereniging voor Radiobiologie 
(NVRB), Utrecht. 
Grant
•	 BOOA Research Grant (5000,-) van de Stichting BOOA van 
de Nederlandse Vereniging voor Mondziekten, Kaak- en 
Aangezichtchirurgie (NVMKA).
Teaching activities
•	 Supervision Master student Molecular Medicine
2011 1.5
2011 1.5
2013 1.5
2009 0.6
2010 0.3
2010 0.3
2014 0.3
2009 3.0
2012 3.0
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dANkWOORd
Mijn proefschrift is af! En dan is het nu tijd om iedereen te bedanken die in welke 
mate dan ook hieraan heeft bijgedragen.
Ten eerste mijn promotoren, 
Prof.dr. E.B. Wolvius, beste Eppo, bedankt voor de supervisie over mijn promotie. 
Ondanks je vaak overvolle agenda was er altijd wel een gaatje te vinden om de 
voortgang van mijn promotie te bespreken en kwamen al mijn artikelen snel weer 
van commentaar voorzien terug.
Prof.dr K.G.H van der Wal, beste Karel, onder jouw leiding ben ik begonnen aan mijn 
promotieonderzoek. Hoewel ik zeer zenuwachtig was voor de sollicitatie, werd dat 
een leuk gesprek. Bedankt voor de interesse in mijn onderzoek en de suggesties die 
je altijd bent blijven geven.
Dr J.A.M Braks, beste Anneke, hoewel je niet vanaf het begin bij mijn onderzoek 
betrokken bent geweest, ben ik blij dat jij mijn co-promotor bent. Jij bent vooral 
de drijvende kracht geweest achter hoofdstuk 7 en 8. Het uitpluizen van de micro-
array data was zonder jou een heel stuk moeilijker geweest.  Ook ben ik trots op het 
tumormodel dat we opgezet hebben; beiden hadden we er geen enkele ervaring 
mee, maar uiteindelijk is het toch maar mooi gelukt! Ook dank voor de kritische 
blik op mijn artikelen, ze zijn er zonder meer veel beter door geworden. Ik wilde 
misschien af en toe een beetje tè snel gaan, maar dat doet promotie-druk nu 
eenmaal met je.
Dr. Urville Djasim, onder jouw supervisie ben ik begonnen aan mijn 
promotieonderzoek. Ik kan me de sollicitatie-gesprekken, en vooral het bevrijdende 
telefoontje toen ik in de trein terug naar Eindhoven zat na het laatste gesprek, 
nog goed herinneren. Je rustige manier van doen vond ik aangenaam en ik heb 
bij jou geen moment een spoortje van stress kunnen ontdekken. Ook al zat het 
één en ander tegen, vooral met betrekking tot het aanschaffen van de hyperbare 
zuurstoftank, jij bleef er altijd rustig onder. Daar kan ik nog wat van leren!
Het labwerk van mijn onderzoek vond plaats op het lab van de plastische chirurgie, 
waar ik als verstekeling van de kaakchirurgie ook altijd mijn werkplek heb gehad. 
Dr. Han van Neck, dank voor deze gastvrijheid. Je bent ook betrokken geweest bij 
de eerste artikelen, waarbij ik je constructieve opmerkingen zeer goed heb kunnen 
gebruiken. Ook later kon ik altijd even binnenlopen voor advies. 
Dr. Soledad Perez-Amodio en Antoinette van Driel, kamergenootjes van het eerste 
uur, bedankt voor de gezelligheid en de toch ook serieuze gesprekken. 
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Shoista Kambiz, ik vond het erg gezellig dat je de laatste 2 jaar bij ons op de kamer 
zat. We hebben wat afgelachen, maar ook hard gewerkt natuurlijk. Heel veel succes 
met het afronden van je proefschrift en in je verdere loopbaan. Ik weet zeker dat jij 
alles kan bereiken wat je voor ogen hebt!
Dr. Femke Verseijden, hoewel kort, heb ik met plezier met je samengewerkt en van je 
geleerd, met name als het gaat om het hebben van een kritische onderzoekersblik. 
Dr. Miao Tong, it was an honour for me to be your paranymph and I enjoyed working 
with you.
Ineke Hekking-Weijma en Esther Fijneman, bedankt voor de gastvrijheid in het 
skills-lab en het eindeloos uitlenen van spullen. Ik vond het altijd prettig om bij 
jullie aan het werk te zijn. 
Ook wil ik alle collega’s van de afdeling Mondziekten, Kaak- en Aangezichtschirurgie 
en Bijzondere Tandheelkunde bedanken. Hoewel mijn pré-klinische onderzoek toch 
altijd een beetje een vreemde eend in de bijt was, vond ik het prettig ook contact te 
houden met de klinische kant van de afdeling. Dank voor jullie interesse en vragen 
tijdens de besprekingen. Linda Caron en Manouk van Lieshout; veel succes met jullie 
promotie-onderzoek. Speciale dank ook aan Ton Dumans en dr. Maarten Koudstaal 
voor de oprechte interesse in het hyperbare zuurstofonderzoek. Dr. Eric Farrell, 
bedankt dat je me geïntroduceerd hebt bij de maandagochtendbesprekingen van 
de orthopedie en voor de commentaren op hoofdstuk 5. Ook kon ik altijd bij je 
terecht voor vragen of advies. Jouw positieve instelling is aanstekelijk!
Dr. Senada Koljenovic, bedankt voor het beoordelen van mijn coupes.
Lisanne Groeneveldt, hoewel ik je kort begeleid heb, is mede door jouw inzet en het 
snijden van honderden coupes hoofdstuk 4 tot stand gekomen. Dank daarvoor en 
succes met je verdere loopbaan.
Graag wil ik ook alle dierverzorgers van het EDC bedanken voor de goede zorgen 
voor mijn muizen, zeker ook wanneer ze wekenlang in het weekend een speciaal 
dieet moesten hebben.
In de laatste twee jaar van mijn onderzoek hebben we voorzichtig aansluiting 
gevonden bij de afdeling Genetica. Prof.dr. Kanaar, bedankt voor het mogelijk 
maken hiervan. Dr. Jeroen Essers, bedankt voor je frisse kijk op ons onderzoek en de 
waardevolle tips, die hebben geleid tot twee mooie artikelen. Paula van Heijningen, 
bedankt voor je hulp en uitleg op het lab en Yanto Ridwan voor het leren omgaan 
met de imaging-apparatuur.
Ook wil ik graag alle collega’s van het lab van de KNO/orthopedie, onder 
leiding van Prof.dr. Gerjo van Osch, bedanken dat ik mocht aansluiten bij de 
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maandagochtendbesprekingen en voor het geven van feedback op mijn presentaties.
De laatste collega’s die ik wil bedanken zijn zeker niet de minste. Daarom zijn ze ook 
mijn paranimfen en alleen dat is al een bedankje waard.
Wendy (of ik moet inmiddels zeggen dr. Wendy!), toen ik in 2009 begon kwam ik 
bij jou op de kamer terecht en we konden het meteen goed vinden. Altijd fijn om 
in dat verre Rotterdam gewoon lekker Brabants met iemand te kunnen praten. We 
hebben allebei, zoals dat hoort tijdens een promotie, genoeg tegenslagen gehad, 
maar het was fijn om dat met een lotgenoot te kunnen bespreken. Maar bovenal 
hebben we veel lol gehad. Een dubbelpromotie is er niet van gekomen; je was me 
net voor. Zo is het schuitje toch maar mooi blijven drijven! Ik wens je veel geluk met 
jullie gezin, wat binnenkort wordt uitgebreid.
Bas, ook met jou heb ik het grootste gedeelte van mijn promotie op een kamer 
gezeten. Je bent altijd heel hulpvaardig geweest, ook als ik voor de zoveelste keer 
met een mislukte immuno-kleuring aan kwam zetten en weer om advies vroeg. 
Ik heb veel geleerd van je precieze manier van werken, hoewel je me alsnog wel 
eens ‘lui’ noemde omdat ik niet alle tientallen opties om een kleuring te laten 
werken tegelijk wilde doen. Mede dankzij jouw humor en positieve instelling, ook 
in moeilijke tijden, kwam ik altijd graag naar het werk. Ik wens je alle geluk van de 
wereld, en geniet met volle teugen van Joris!
Naast collega’s zijn er meer mensen die het maken van een proefschrift mogelijk 
maken, zij het op een minder directe manier. Allereerst wil ik Wendy, Linda en 
Malou, vriendinnen van de middelbare school, bedanken.  Ondanks dat we elkaar 
niet zo veel meer zien, vooral omdat we zo ver van elkaar wonen, vind ik het altijd 
supergezellig als het weer eens lukt om af te spreken. We zijn allevier toch in de 
medische wereld terechtgekomen en daarom kon ik met jullie ook goed praten over 
mijn onderzoek en de stress die daar af en toe bij komt kijken.
Dat laatste geldt ook voor Judith, Monique en Eric, studiegenootjes van Biomedische 
Wetenschappen. Onze etentjes zijn altijd zeer gezellig, en ik hoop dat we deze 
traditie nog lang vol zullen houden!
Ontspanning naast je werk is erg belangrijk, vandaar ook een bedankje naar mijn 
voetbalteam, Wodan dames 1. Heerlijk om op donderdag en zondag even stoom af 
te blazen. Het is altijd een dolle boel in de kleedkamer en het kampioenschap van 
afgelopen jaar was er één om niet te vergeten!
Celina en Marieke, jullie verdienen natuurlijk ook een speciaal plaatsje van dank. 
We hebben bijna 20 jaar samen gevoetbald en gaan ook al jaren samen naar PSV, 
een perfecte plaats om even alle werkgerelateerde dingen te vergeten en je zorgen 
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te maken om heel iets anders. Maar het meest bijzondere wat we samen hebben 
gedaan is het maken van onze wereldreis, vlak voordat ik aan deze promotie begon. 
Nog altijd denk ik met veel plezier en dankbaarheid daaraan terug; wat was het gaaf 
om dat samen met jullie te doen. Net zoals de reizen die ik daarna nog met jullie 
gemaakt heb tijdens mijn promotie. Bedankt voor de jarenlange vriendschap!
Pap en mam, jullie zijn er altijd voor me. Dankzij jullie harde werken en goede zorgen 
heb ik een heerlijke en onbezorgde jeugd gehad en kon ik later gaan studeren. Jullie 
hebben me altijd overal in gesteund en zonder jullie zou ik niet staan waar ik nu sta. 
Bedankt en ik hou van jullie.
Ben, als jongere zus kijk je toch altijd een beetje op tegen je oudere broer. En je hebt 
altijd het goede voorbeeld gegeven. Ook sta je altijd voor me klaar en vind ik het 
gezellig dat we nu zo dichtbij elkaar wonen.
Ook mijn schoonfamilie wil ik bedanken, Broer en José, Roel en Linda, en Ben; wat 
heb ik het met jullie getroffen. En niet te vergeten mijn nichtje en neefje, Silke en 
Tuur; wat een genot om jullie op te zien groeien en wat ben ik trots dat ik peettante 
van Tuur mag zijn.
De allerlaatste plaats is voorbehouden aan de belangrijkste persoon. Joost, ik 
leerde je kennen tijdens mijn promotieonderzoek. En ik was best wel een beetje 
zenuwachtig toen ik bij onze eerste date aan een principieel vegetariër moest 
gaan vertellen dat ik met proefdieren werkte. Gelukkig zie je het nut van medisch 
onderzoek in en werd dat geen breekpunt. 
Ondertussen zijn we drie jaar samen en kan ik me geen leven zonder jou meer 
voorstellen. Je bent er altijd om me op te vrolijken als het even tegenzit en ik kan 
met je over de meest uiteenlopende dingen praten en lachen. We hebben al wat 
mooie reizen gemaakt en avonturen beleefd, en ik ben je dankbaar dat je je hierin 
mee liet slepen door mij. 
Maar bovenal ben je de allerliefste!


